format-version: 1.4 data-version: 2026-08-02 ontology: bemo default-namespace: bemo remark: DRAFT BEMO 0.1.0; provisional namespace and license; not yet an OBO Foundry ontology. import: http://purl.obolibrary.org/obo/bfo.owl import: http://purl.obolibrary.org/obo/iao.owl import: http://purl.obolibrary.org/obo/obi.owl import: http://purl.obolibrary.org/obo/eco.owl [Term] id: BEMO:0000001 name: biomedical evidence metric def: "An information content entity that specifies a scientifically interpretable quantity, category, rubric, or assessment construct used to evaluate biomedical evidence." [BEMO:source] is_a: IAO:0000030 [Term] id: BEMO:1000001 name: Evidence Synthesis and Certainty metric def: "Metrics assessing the completeness, certainty, consistency, precision, and synthesis of biomedical evidence." [BEMO:source] is_a: BEMO:0000001 [Term] id: BEMO:1000002 name: Study Design, Statistical Validity, and Causal Inference metric def: "Metrics assessing internal validity, statistical inference, causal identification, bias, and study design." [BEMO:source] is_a: BEMO:0000001 [Term] id: BEMO:1000003 name: Measurement, Assay, and Biospecimen Quality metric def: "Metrics assessing analytical measurement performance, assay validity, biospecimen handling, and preanalytical quality." [BEMO:source] is_a: BEMO:0000001 [Term] id: BEMO:1000004 name: Reproducibility, Replication, and Research Transparency metric def: "Metrics assessing reproducibility, independent replication, reporting completeness, and research transparency." [BEMO:source] is_a: BEMO:0000001 [Term] id: BEMO:1000005 name: External Validity, Biomarkers, and Clinical Evidence metric def: "Metrics assessing generalizability, diagnostic or prognostic evidence, biomarkers, endpoints, and clinical applicability." [BEMO:source] is_a: BEMO:0000001 [Term] id: BEMO:1000006 name: Biological Mechanism and Experimental Evidence metric def: "Metrics assessing biological plausibility, mechanistic evidence, experimental biology, and model-system evidence." [BEMO:source] is_a: BEMO:0000001 [Term] id: BEMO:1000007 name: Genetics, Omics, and Systems Biology metric def: "Metrics assessing genetic, genomic, transcriptomic, proteomic, metabolomic, multi-omic, and systems-level evidence." [BEMO:source] is_a: BEMO:0000001 [Term] id: BEMO:1000008 name: Pharmacology and Toxicology metric def: "Metrics assessing pharmacologic activity, exposure, efficacy, selectivity, and toxicologic evidence." [BEMO:source] is_a: BEMO:0000001 [Term] id: BEMO:1100001 name: Biological Plausibility and Mechanism metric def: "Category of biomedical evidence metrics concerned with biological plausibility and mechanism." [BEMO:source] is_a: BEMO:1000006 [Term] id: BEMO:1100002 name: Biomarker and Endpoint Validation metric def: "Category of biomedical evidence metrics concerned with biomarker and endpoint validation." [BEMO:source] is_a: BEMO:1000005 [Term] id: BEMO:1100003 name: Biospecimen and Preanalytical Quality metric def: "Category of biomedical evidence metrics concerned with biospecimen and preanalytical quality." [BEMO:source] is_a: BEMO:1000003 [Term] id: BEMO:1100004 name: Causal Inference metric def: "Category of biomedical evidence metrics concerned with causal inference." [BEMO:source] is_a: BEMO:1000002 [Term] id: BEMO:1100005 name: Diagnostic and Prognostic Evidence metric def: "Category of biomedical evidence metrics concerned with diagnostic and prognostic evidence." [BEMO:source] is_a: BEMO:1000005 [Term] id: BEMO:1100006 name: Evidence Certainty and Synthesis metric def: "Category of biomedical evidence metrics concerned with evidence certainty and synthesis." [BEMO:source] is_a: BEMO:1000001 [Term] id: BEMO:1100007 name: Experimental Biology and Animal Research metric def: "Category of biomedical evidence metrics concerned with experimental biology and animal research." [BEMO:source] is_a: BEMO:1000006 [Term] id: BEMO:1100008 name: External Validity and Applicability metric def: "Category of biomedical evidence metrics concerned with external validity and applicability." [BEMO:source] is_a: BEMO:1000005 [Term] id: BEMO:1100009 name: Genetics and Variant Evidence metric def: "Category of biomedical evidence metrics concerned with genetics and variant evidence." [BEMO:source] is_a: BEMO:1000007 [Term] id: BEMO:1100010 name: Genomics and Transcriptomics metric def: "Category of biomedical evidence metrics concerned with genomics and transcriptomics." [BEMO:source] is_a: BEMO:1000007 [Term] id: BEMO:1100011 name: Measurement and Assay Analytical Validity metric def: "Category of biomedical evidence metrics concerned with measurement and assay analytical validity." [BEMO:source] is_a: BEMO:1000003 [Term] id: BEMO:1100012 name: Multi-omics and Systems Biology metric def: "Category of biomedical evidence metrics concerned with multi-omics and systems biology." [BEMO:source] is_a: BEMO:1000007 [Term] id: BEMO:1100013 name: Pharmacology and Toxicology metric def: "Category of biomedical evidence metrics concerned with pharmacology and toxicology." [BEMO:source] is_a: BEMO:1000008 [Term] id: BEMO:1100014 name: Proteomics and Metabolomics metric def: "Category of biomedical evidence metrics concerned with proteomics and metabolomics." [BEMO:source] is_a: BEMO:1000007 [Term] id: BEMO:1100015 name: Reproducibility and Replication metric def: "Category of biomedical evidence metrics concerned with reproducibility and replication." [BEMO:source] is_a: BEMO:1000004 [Term] id: BEMO:1100016 name: Research Transparency and Reporting Completeness metric def: "Category of biomedical evidence metrics concerned with research transparency and reporting completeness." [BEMO:source] is_a: BEMO:1000004 [Term] id: BEMO:1100017 name: Statistical Validity and Inference metric def: "Category of biomedical evidence metrics concerned with statistical validity and inference." [BEMO:source] is_a: BEMO:1000002 [Term] id: BEMO:1100018 name: Study Design and Internal Validity metric def: "Category of biomedical evidence metrics concerned with study design and internal validity." [BEMO:source] is_a: BEMO:1000002 [Term] id: BEMO:2000001 name: Biological Gradient def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of biological gradient." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses biological gradient using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in biological gradient can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating biological gradient as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000001" xsd:string property_value: BEMO:3100022 "8" xsd:string property_value: BEMO:3100023 "6471dcf670c9dd05424f4606389decf6b51812d07c0a0680842d77bda957b0f3" xsd:string [Term] id: BEMO:2000002 name: Biological Plausibility def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of biological plausibility." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses biological plausibility using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in biological plausibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating biological plausibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000002" xsd:string property_value: BEMO:3100022 "9" xsd:string property_value: BEMO:3100023 "6cbc5f525d668cebb0928b8428848a625103a7b6492d0a2a618adb116f200bd3" xsd:string [Term] id: BEMO:2000003 name: Cell-Type Specificity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of cell-type specificity." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses cell-type specificity using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in cell-type specificity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating cell-type specificity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000003" xsd:string property_value: BEMO:3100022 "10" xsd:string property_value: BEMO:3100023 "8fcb10135485d0dff26bef51519f2178a09a543c766f354a728ca79b2c39c582" xsd:string [Term] id: BEMO:2000004 name: Cross-Species Biological Concordance def: "The degree of agreement in cross-species biological across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses cross-species biological concordance using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in cross-species biological concordance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating cross-species biological concordance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000004" xsd:string property_value: BEMO:3100022 "11" xsd:string property_value: BEMO:3100023 "6f883b8ebe7aa3d7407688c8b2390b245a894c21f5c21ffef99fe634674c5fd3" xsd:string [Term] id: BEMO:2000005 name: Epistasis Support def: "The magnitude and credibility of independent evidence supporting epistasis." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses epistasis support using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in epistasis support can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating epistasis support as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000005" xsd:string property_value: BEMO:3100022 "12" xsd:string property_value: BEMO:3100023 "cd57f610728234561644257a8387987f0aa8934688593c5fbd817b3779032054" xsd:string [Term] id: BEMO:2000006 name: Gain-of-Function Validation def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of gain-of-function validation." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses gain-of-function validation using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in gain-of-function validation can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating gain-of-function validation as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000006" xsd:string property_value: BEMO:3100022 "13" xsd:string property_value: BEMO:3100023 "5c02cfac370a9d2c1514479546d6e291e60bffe1758412ceec02bbf8edaab2dc" xsd:string [Term] id: BEMO:2000007 name: Homeostatic Compensation Assessment def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of homeostatic compensation assessment." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses homeostatic compensation assessment using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in homeostatic compensation assessment can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating homeostatic compensation assessment as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000007" xsd:string property_value: BEMO:3100022 "14" xsd:string property_value: BEMO:3100023 "61aaa3d7ba71760f01fcbbb79304031b61f416940944ef459f48b6d07dc0628d" xsd:string [Term] id: BEMO:2000008 name: Loss-of-Function Validation def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of loss-of-function validation." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses loss-of-function validation using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in loss-of-function validation can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating loss-of-function validation as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000008" xsd:string property_value: BEMO:3100022 "15" xsd:string property_value: BEMO:3100023 "7b09e166eefa32f832c89264de2b3521f93b540fbc674d78fc625fd792779d09" xsd:string [Term] id: BEMO:2000009 name: Mechanistic Causality Strength def: "The magnitude and credibility of independent evidence supporting mechanistic causality." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses mechanistic causality strength using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in mechanistic causality strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Directed acyclic graphs; design emulation; balance diagnostics; negative controls; quantitative bias analysis; sensitivity and falsification analyses." xsd:string property_value: BEMO:3200006 "Treating mechanistic causality strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000009" xsd:string property_value: BEMO:3100022 "16" xsd:string property_value: BEMO:3100023 "114851a566f6667271761fd50b701ab810f623c4ee0ecdabe88d5bbacc5941db" xsd:string [Term] id: BEMO:2000010 name: Mechanistic Coherence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of mechanistic coherence." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses mechanistic coherence using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in mechanistic coherence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating mechanistic coherence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000010" xsd:string property_value: BEMO:3100022 "17" xsd:string property_value: BEMO:3100023 "dc1b3b375698d0aec42693d5a0b2f87405e7e7bf90759105797ad714ab4e9ab2" xsd:string [Term] id: BEMO:2000011 name: Mechanistic Completeness def: "The extent to which all scientifically necessary components of mechanistic are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses mechanistic completeness using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in mechanistic completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating mechanistic completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000011" xsd:string property_value: BEMO:3100022 "18" xsd:string property_value: BEMO:3100023 "70dc43fe10f07fb6cf3546a825ad424f5db2e21cc1b19a9f92b47d758bf660bd" xsd:string [Term] id: BEMO:2000012 name: Mechanistic Coverage def: "The proportion and representativeness of the relevant mechanistic captured by the evidence or measurement process." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses mechanistic coverage using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in mechanistic coverage can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating mechanistic coverage as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000012" xsd:string property_value: BEMO:3100022 "19" xsd:string property_value: BEMO:3100023 "8582aac321a237f1dd1db68f0893021d3bc987b71b373d1879cc2dfb098adbdb" xsd:string [Term] id: BEMO:2000013 name: Mechanistic Specificity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of mechanistic specificity." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses mechanistic specificity using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in mechanistic specificity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating mechanistic specificity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000013" xsd:string property_value: BEMO:3100022 "20" xsd:string property_value: BEMO:3100023 "29074cf2dac765628d0a639b922f2e3313846aa414af9c4ef760ea93c86819ca" xsd:string [Term] id: BEMO:2000014 name: Mechanistic Support def: "The magnitude and credibility of independent evidence supporting mechanistic." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses mechanistic support using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in mechanistic support can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating mechanistic support as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000014" xsd:string property_value: BEMO:3100022 "21" xsd:string property_value: BEMO:3100023 "d05eb179325de1077bb0eedc4d22a5f8c9cc2049d4ca5a5830b380984606cc90" xsd:string [Term] id: BEMO:2000015 name: Molecular-Phenotypic Concordance def: "The degree of agreement in molecular-phenotypic across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses molecular-phenotypic concordance using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in molecular-phenotypic concordance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating molecular-phenotypic concordance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000015" xsd:string property_value: BEMO:3100022 "22" xsd:string property_value: BEMO:3100023 "81a78e88eaa62f6e2bb0ae947aba28fe819150032abcf9264f9205803cc7dfd1" xsd:string [Term] id: BEMO:2000016 name: Network Context Support def: "The magnitude and credibility of independent evidence supporting network context." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses network context support using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in network context support can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating network context support as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000016" xsd:string property_value: BEMO:3100022 "23" xsd:string property_value: BEMO:3100023 "d14cae7a1ae4e812a18da95395619423ade3837794dc32beea80cb11af0003f0" xsd:string [Term] id: BEMO:2000017 name: Off-Target Liability Evidence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of off-target liability evidence." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses off-target liability evidence using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in off-target liability evidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating off-target liability evidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000017" xsd:string property_value: BEMO:3100022 "24" xsd:string property_value: BEMO:3100023 "688a2bdbd29ad4b59eca6350cf3462f2bc158ee3d70ef4de59f338b6e6c797a6" xsd:string [Term] id: BEMO:2000018 name: On-Target Specificity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of on-target specificity." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses on-target specificity using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in on-target specificity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating on-target specificity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000018" xsd:string property_value: BEMO:3100022 "25" xsd:string property_value: BEMO:3100023 "5b75004715c78ae57eb0dfbf1a6fe3b6212289ca6b06f39e35b36270d16b13e5" xsd:string [Term] id: BEMO:2000019 name: Pathway-Level Support def: "The magnitude and credibility of independent evidence supporting pathway-level." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses pathway-level support using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in pathway-level support can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating pathway-level support as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000019" xsd:string property_value: BEMO:3100022 "26" xsd:string property_value: BEMO:3100023 "a1a0e0a377d9f949a45a0ad0a040b0443e29f24bfe701f3b015420b52cd21ab2" xsd:string [Term] id: BEMO:2000020 name: Perturbational Validation def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of perturbational validation." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses perturbational validation using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in perturbational validation can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating perturbational validation as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000020" xsd:string property_value: BEMO:3100022 "27" xsd:string property_value: BEMO:3100023 "e56c259480c9a3f5c7efe467a62a9721824469292b9aeb900d1804f2bbfb7983" xsd:string [Term] id: BEMO:2000021 name: Phenotypic Concordance def: "The degree of agreement in phenotypic across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses phenotypic concordance using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in phenotypic concordance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating phenotypic concordance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000021" xsd:string property_value: BEMO:3100022 "28" xsd:string property_value: BEMO:3100023 "d6b2622e1418a4a4c75dd4e74edee6d3fe7ea5ecac7eb6c453c614421e29173a" xsd:string [Term] id: BEMO:2000022 name: Rescue Experiment Support def: "The magnitude and credibility of independent evidence supporting rescue experiment." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses rescue experiment support using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in rescue experiment support can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating rescue experiment support as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000022" xsd:string property_value: BEMO:3100022 "29" xsd:string property_value: BEMO:3100023 "9f3de30fb4252544b664477f26ad879c47cffd18e4a902652a07ca5b9fa59ec2" xsd:string [Term] id: BEMO:2000023 name: Spatial Biological Concordance def: "The degree of agreement in spatial biological across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses spatial biological concordance using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in spatial biological concordance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating spatial biological concordance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000023" xsd:string property_value: BEMO:3100022 "30" xsd:string property_value: BEMO:3100023 "6c08ba26b1257f37b62212d7633a9e83166a0f74706ae3ffbb9de90cd98613f7" xsd:string [Term] id: BEMO:2000024 name: Systems-Level Emergence Support def: "The magnitude and credibility of independent evidence supporting systems-level emergence." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses systems-level emergence support using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in systems-level emergence support can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating systems-level emergence support as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000024" xsd:string property_value: BEMO:3100022 "31" xsd:string property_value: BEMO:3100023 "07df8f6070c405006e36806e8ccb515126dc2c7269ea9cf3934662d28e9264c6" xsd:string [Term] id: BEMO:2000025 name: Target Engagement Evidence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of target engagement evidence." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses target engagement evidence using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in target engagement evidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating target engagement evidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000025" xsd:string property_value: BEMO:3100022 "32" xsd:string property_value: BEMO:3100023 "a51c69d24f2bf9ef711f1d3b54d2086032245754bf1992c1b5999a88e3ca185f" xsd:string [Term] id: BEMO:2000026 name: Temporal Biological Concordance def: "The degree of agreement in temporal biological across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses temporal biological concordance using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in temporal biological concordance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating temporal biological concordance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000026" xsd:string property_value: BEMO:3100022 "33" xsd:string property_value: BEMO:3100023 "57d68c3c49543e85a4a6ee1a26a1705e9e0e05df169673d5a8f0a00632bfa39b" xsd:string [Term] id: BEMO:2000027 name: Tissue Specificity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of tissue specificity." [BEMO:source] is_a: BEMO:1100001 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://www.gradeworkinggroup.org/ xref: https://www.fda.gov/media/119271/download xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses tissue specificity using evidence appropriate to biological plausibility and mechanism, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in tissue specificity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating tissue specificity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Molecular, cellular, animal, translational, pharmacologic, and human studies" xsd:string property_value: BEMO:3200010 "GRADE; FDA Biomarker; ClinGen; OHAT; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000027" xsd:string property_value: BEMO:3100022 "34" xsd:string property_value: BEMO:3100023 "e3cc6b49f3bcbfabd500e6222a7c3cc053aca55c824a6afddd04a9b448378651" xsd:string [Term] id: BEMO:2000028 name: Biomarker Clinical Relevance def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of biomarker clinical relevance." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses biomarker clinical relevance using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in biomarker clinical relevance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating biomarker clinical relevance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000028" xsd:string property_value: BEMO:3100022 "35" xsd:string property_value: BEMO:3100023 "70bbbca5f05350dbfed193659c18ff0eef66a6552528618a931911c0bbfe7878" xsd:string [Term] id: BEMO:2000029 name: Biomarker Qualification Strength def: "The magnitude and credibility of independent evidence supporting biomarker qualification." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses biomarker qualification strength using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in biomarker qualification strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating biomarker qualification strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000029" xsd:string property_value: BEMO:3100022 "36" xsd:string property_value: BEMO:3100023 "35003a5d4be2844c7914597bb95d8d44ce388ce934a6b5067c8e498ac9e8de35" xsd:string [Term] id: BEMO:2000030 name: Biomarker Reliability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of biomarker reliability." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses biomarker reliability using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in biomarker reliability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating biomarker reliability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000030" xsd:string property_value: BEMO:3100022 "37" xsd:string property_value: BEMO:3100023 "74c0c7f33ecc210cbe2fa1dd5ddc15c31273005f3e5caaa4afc370a3f6c94a4e" xsd:string [Term] id: BEMO:2000031 name: Biomarker Responsiveness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of biomarker responsiveness." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses biomarker responsiveness using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in biomarker responsiveness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating biomarker responsiveness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000031" xsd:string property_value: BEMO:3100022 "38" xsd:string property_value: BEMO:3100023 "19a54854b5dfb7168eddad304da95ddbab2e1ad34992146fcedfd650dfe09548" xsd:string [Term] id: BEMO:2000032 name: Biomarker Sensitivity to Change def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of biomarker sensitivity to change." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses biomarker sensitivity to change using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in biomarker sensitivity to change can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating biomarker sensitivity to change as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000032" xsd:string property_value: BEMO:3100022 "39" xsd:string property_value: BEMO:3100023 "80beed232e03f65da1843b394120d8baef7fb4428401374caac926260837e2b2" xsd:string [Term] id: BEMO:2000033 name: Biomarker-Outcome Association Strength def: "The magnitude and credibility of independent evidence supporting biomarker-outcome association." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses biomarker-outcome association strength using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in biomarker-outcome association strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating biomarker-outcome association strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000033" xsd:string property_value: BEMO:3100022 "40" xsd:string property_value: BEMO:3100023 "d54499df144e3534026302c035690746b731c0abf25107f5fccdd8bada0bd79a" xsd:string [Term] id: BEMO:2000034 name: Clinical Validity def: "The degree to which clinical supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses clinical validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in clinical validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating clinical validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000034" xsd:string property_value: BEMO:3100022 "41" xsd:string property_value: BEMO:3100023 "628005d99d3e18a7b100ce400c64fc5218e46beeaa2cfec80dbac2445270cead" xsd:string [Term] id: BEMO:2000035 name: Construct Validity def: "The degree to which construct supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses construct validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in construct validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating construct validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000035" xsd:string property_value: BEMO:3100022 "42" xsd:string property_value: BEMO:3100023 "5bd558ed006f260bde44545e9ab38951fc6c2e450b4d3cb07f929d1fcb479f4e" xsd:string [Term] id: BEMO:2000036 name: Content Validity def: "The degree to which content supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses content validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in content validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating content validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000036" xsd:string property_value: BEMO:3100022 "43" xsd:string property_value: BEMO:3100023 "1ceb580fd3a672a7c14d44163bda2886dd03d14b99ce004f1db40aa485bb3e1b" xsd:string [Term] id: BEMO:2000037 name: Context-of-Use Validity def: "The degree to which context-of-use supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses context-of-use validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in context-of-use validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating context-of-use validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000037" xsd:string property_value: BEMO:3100022 "44" xsd:string property_value: BEMO:3100023 "170c4bee423f9901b11abd5c6c7203f1253da40dbd46a33c459bac07471058e8" xsd:string [Term] id: BEMO:2000038 name: Convergent Validity def: "The degree to which convergent supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses convergent validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in convergent validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating convergent validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000038" xsd:string property_value: BEMO:3100022 "45" xsd:string property_value: BEMO:3100023 "4ad4866845885f677cad74042f65b0303f2d26597ea694b76dfed4bc71fedd68" xsd:string [Term] id: BEMO:2000039 name: Criterion Validity def: "The degree to which criterion supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses criterion validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in criterion validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating criterion validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000039" xsd:string property_value: BEMO:3100022 "46" xsd:string property_value: BEMO:3100023 "04af58cc2d88f851cf92e0d1960d29a74b3d8a5cf3525dda9579101a813732b2" xsd:string [Term] id: BEMO:2000040 name: Diagnostic Biomarker Validity def: "The degree to which diagnostic biomarker supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses diagnostic biomarker validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in diagnostic biomarker validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating diagnostic biomarker validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000040" xsd:string property_value: BEMO:3100022 "47" xsd:string property_value: BEMO:3100023 "b87f6768315d9d24a6505cd78867a8b0dc9310fbd10aa04b46856994c12562e5" xsd:string [Term] id: BEMO:2000041 name: Discriminant Validity def: "The degree to which discriminant supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses discriminant validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in discriminant validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating discriminant validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000041" xsd:string property_value: BEMO:3100022 "48" xsd:string property_value: BEMO:3100023 "c0e22c7d45b8b17a4c9f1de5c7c7bb4e085d98eb667da8d43e452ea31955900b" xsd:string [Term] id: BEMO:2000042 name: Endpoint Reliability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of endpoint reliability." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses endpoint reliability using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in endpoint reliability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating endpoint reliability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000042" xsd:string property_value: BEMO:3100022 "49" xsd:string property_value: BEMO:3100023 "e147bf4116de09d3c1bd6b5fb8081223589d31f54f697b6e869790830619757d" xsd:string [Term] id: BEMO:2000043 name: Endpoint Responsiveness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of endpoint responsiveness." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses endpoint responsiveness using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in endpoint responsiveness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating endpoint responsiveness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000043" xsd:string property_value: BEMO:3100022 "50" xsd:string property_value: BEMO:3100023 "3cb1f45a15a5daa5f6b98c2d745a57440f42e5840e757c82a744e9f010f76df0" xsd:string [Term] id: BEMO:2000044 name: Endpoint Validity def: "The degree to which endpoint supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses endpoint validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in endpoint validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating endpoint validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000044" xsd:string property_value: BEMO:3100022 "51" xsd:string property_value: BEMO:3100023 "f79c486fa1f56b17619593da318c44a3704cbd1294be41ae30a2b38ceb9410d1" xsd:string [Term] id: BEMO:2000045 name: Individual-Level Surrogacy def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of individual-level surrogacy." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses individual-level surrogacy using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in individual-level surrogacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating individual-level surrogacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000045" xsd:string property_value: BEMO:3100022 "52" xsd:string property_value: BEMO:3100023 "4d46697f970727d741077ee1e1f9eeeaed4beee8d6ef96a339ca927181b91ef5" xsd:string [Term] id: BEMO:2000046 name: Known-Groups Validity def: "The degree to which known-groups supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses known-groups validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in known-groups validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating known-groups validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000046" xsd:string property_value: BEMO:3100022 "53" xsd:string property_value: BEMO:3100023 "8e195ef346deba393b7a3adaf4c77bfbd949dbf0f057cd9af26312568cb85421" xsd:string [Term] id: BEMO:2000047 name: Minimal Clinically Important Difference Validity def: "The degree to which minimal clinically important difference supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses minimal clinically important difference validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in minimal clinically important difference validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating minimal clinically important difference validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000047" xsd:string property_value: BEMO:3100022 "54" xsd:string property_value: BEMO:3100023 "604e83a95f413c6c8ddc8abe7ad03f24c441ede8e65d506baef0410866c23fa7" xsd:string [Term] id: BEMO:2000048 name: Monitoring Biomarker Validity def: "The degree to which monitoring biomarker supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses monitoring biomarker validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in monitoring biomarker validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating monitoring biomarker validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000048" xsd:string property_value: BEMO:3100022 "55" xsd:string property_value: BEMO:3100023 "cc605972d7119b4dabf5e0bc927d29fa05979e706703654bb3ea93c2ebe95461" xsd:string [Term] id: BEMO:2000049 name: Outcome Relevance def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of outcome relevance." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses outcome relevance using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in outcome relevance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating outcome relevance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000049" xsd:string property_value: BEMO:3100022 "56" xsd:string property_value: BEMO:3100023 "1adca583ee04c245cdae3428bd050f3ed8796d29bf4b214b5880769da8977172" xsd:string [Term] id: BEMO:2000050 name: Pharmacodynamic Biomarker Validity def: "The degree to which pharmacodynamic biomarker supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses pharmacodynamic biomarker validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in pharmacodynamic biomarker validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating pharmacodynamic biomarker validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000050" xsd:string property_value: BEMO:3100022 "57" xsd:string property_value: BEMO:3100023 "4eb497c772907b7927e32ee929fba9a804b1c75888594041caa61dfab977440a" xsd:string [Term] id: BEMO:2000051 name: Predictive Biomarker Validity def: "The degree to which predictive biomarker supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses predictive biomarker validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in predictive biomarker validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating predictive biomarker validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000051" xsd:string property_value: BEMO:3100022 "58" xsd:string property_value: BEMO:3100023 "c5c7cbb5b7738940f61731df207186f05f8ae71ecab7ca3c5588c823af8d00eb" xsd:string [Term] id: BEMO:2000052 name: Prognostic Biomarker Validity def: "The degree to which prognostic biomarker supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses prognostic biomarker validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in prognostic biomarker validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating prognostic biomarker validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000052" xsd:string property_value: BEMO:3100022 "59" xsd:string property_value: BEMO:3100023 "2dd804ff14e01e089d83a5d2d6ef790d24cf90ca54d3426049116e4e7aeb095f" xsd:string [Term] id: BEMO:2000053 name: Response Biomarker Validity def: "The degree to which response biomarker supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses response biomarker validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in response biomarker validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating response biomarker validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000053" xsd:string property_value: BEMO:3100022 "60" xsd:string property_value: BEMO:3100023 "a8e8ef21a701fbb547c028557e4678bc79ebeda610eb6926bf0061b6e9a016c4" xsd:string [Term] id: BEMO:2000054 name: Safety Biomarker Validity def: "The degree to which safety biomarker supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses safety biomarker validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in safety biomarker validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating safety biomarker validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000054" xsd:string property_value: BEMO:3100022 "61" xsd:string property_value: BEMO:3100023 "a6b6c6cf8ada87a1112583df9bc78595f4f0975ec0e8bbfc01ca6f00c2c0adf1" xsd:string [Term] id: BEMO:2000055 name: Surrogate Endpoint Validity def: "The degree to which surrogate endpoint supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses surrogate endpoint validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in surrogate endpoint validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating surrogate endpoint validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000055" xsd:string property_value: BEMO:3100022 "62" xsd:string property_value: BEMO:3100023 "880b1c4a9fa2a25e2876679a2a7e759365591c8d0d0ae431e9a6e89a9d327bd9" xsd:string [Term] id: BEMO:2000056 name: Susceptibility/Risk Biomarker Validity def: "The probability or degree that susceptibility/risk biomarker validity introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses susceptibility/risk biomarker validity using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in susceptibility/risk biomarker validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating susceptibility/risk biomarker validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000056" xsd:string property_value: BEMO:3100022 "63" xsd:string property_value: BEMO:3100023 "596927f557190db71a0b686158bde6134cafa9cdb9c1876784270d91a80452f5" xsd:string [Term] id: BEMO:2000057 name: Trial-Level Surrogacy def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of trial-level surrogacy." [BEMO:source] is_a: BEMO:1100002 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.fda.gov/media/119271/download xref: https://www.ncbi.nlm.nih.gov/books/NBK326791/ xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses trial-level surrogacy using evidence appropriate to biomarker and endpoint validation, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in trial-level surrogacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating trial-level surrogacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Biomarker development, qualification, endpoint and surrogate validation studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; BEST; EMA E16; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000057" xsd:string property_value: BEMO:3100022 "64" xsd:string property_value: BEMO:3100023 "977d5f2b7e02b5e90f442ea4e8788e2fe539316cddda3ae61da29b0fa71c5325" xsd:string [Term] id: BEMO:2000058 name: Anatomical Site Fidelity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of anatomical site fidelity." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses anatomical site fidelity using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in anatomical site fidelity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating anatomical site fidelity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000058" xsd:string property_value: BEMO:3100022 "65" xsd:string property_value: BEMO:3100023 "8fa3b411fb892fff8cc31c078e25770eb74980a525cbc8e76d63bcb0f15bdaf8" xsd:string [Term] id: BEMO:2000059 name: Biospecimen Integrity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of biospecimen integrity." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses biospecimen integrity using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in biospecimen integrity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating biospecimen integrity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000059" xsd:string property_value: BEMO:3100022 "66" xsd:string property_value: BEMO:3100023 "b89a21b15f8ca110af0a2e2a28ae4ce7939819f7d62769c459c1cd5dc9b712cc" xsd:string [Term] id: BEMO:2000060 name: Biospecimen Provenance Completeness def: "The extent to which all scientifically necessary components of biospecimen provenance are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses biospecimen provenance completeness using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in biospecimen provenance completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating biospecimen provenance completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000060" xsd:string property_value: BEMO:3100022 "67" xsd:string property_value: BEMO:3100023 "c859051c1fe5f3cb60cda0bb4dcf804459be135ee18bb1bb44d89345dea50253" xsd:string [Term] id: BEMO:2000061 name: Cellularity Adequacy def: "The extent to which cellularity is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses cellularity adequacy using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in cellularity adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating cellularity adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000061" xsd:string property_value: BEMO:3100022 "68" xsd:string property_value: BEMO:3100023 "de5efa73121b798bb0e1a53bddae9ef743d4a522e6df52007a5b7569bc63e020" xsd:string [Term] id: BEMO:2000062 name: Chain-of-Custody Integrity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of chain-of-custody integrity." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses chain-of-custody integrity using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in chain-of-custody integrity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating chain-of-custody integrity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000062" xsd:string property_value: BEMO:3100022 "69" xsd:string property_value: BEMO:3100023 "38ecb99023f4b12b1bfca7d66221917ae384546ef170c868cd32fb2eb70f3f40" xsd:string [Term] id: BEMO:2000063 name: Cold Ischemia Control def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of cold ischemia control." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses cold ischemia control using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in cold ischemia control can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating cold ischemia control as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000063" xsd:string property_value: BEMO:3100022 "70" xsd:string property_value: BEMO:3100023 "450f9e94b009036abe7a13fe3055116e7c4959857a7291ed7e337a746d7bf722" xsd:string [Term] id: BEMO:2000064 name: Collection Procedure Consistency def: "The degree of agreement in collection procedure across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses collection procedure consistency using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in collection procedure consistency can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating collection procedure consistency as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000064" xsd:string property_value: BEMO:3100022 "71" xsd:string property_value: BEMO:3100023 "c748a49d52923f74e8e31a0f69a4e91ee50970289d8b43c903a638e0573cc828" xsd:string [Term] id: BEMO:2000065 name: DNA Integrity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of dna integrity." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses dna integrity using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in dna integrity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating dna integrity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000065" xsd:string property_value: BEMO:3100022 "72" xsd:string property_value: BEMO:3100023 "494036e6478a34bfe608bc3b1267e04a777d16e96430109ab2ba9b01e99c6693" xsd:string [Term] id: BEMO:2000066 name: Fixation Adequacy def: "The extent to which fixation is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses fixation adequacy using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in fixation adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating fixation adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000066" xsd:string property_value: BEMO:3100022 "73" xsd:string property_value: BEMO:3100023 "c08e61688a36fec680e9073fc8888dbfd98852919e3f7ccf7c3180ed49d1e921" xsd:string [Term] id: BEMO:2000067 name: Freeze–Thaw Burden def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of freeze–thaw burden." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses freeze–thaw burden using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in freeze–thaw burden can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating freeze–thaw burden as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000067" xsd:string property_value: BEMO:3100022 "74" xsd:string property_value: BEMO:3100023 "40c5c886eacc67a9addeaa92c47d69bf9fbd4b1d2a0042a2efd3611fd5cebb4b" xsd:string [Term] id: BEMO:2000068 name: Hemolysis Burden def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of hemolysis burden." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses hemolysis burden using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in hemolysis burden can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating hemolysis burden as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000068" xsd:string property_value: BEMO:3100022 "75" xsd:string property_value: BEMO:3100023 "1b0946c6b109834d9e6fa6dc5ae7dde1ce95bc65f999a58a3c5a88bc66c6a47c" xsd:string [Term] id: BEMO:2000069 name: Icterus Interference def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of icterus interference." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses icterus interference using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in icterus interference can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Replicate dilution series; blank and spiked samples; reference materials; method-comparison studies; predefined CLSI/ISO acceptance criteria." xsd:string property_value: BEMO:3200006 "Treating icterus interference as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000069" xsd:string property_value: BEMO:3100022 "76" xsd:string property_value: BEMO:3100023 "d0f3346c9caa8abb9b49bded0ab6e26e5f13d5a8fb5a20971f64067dd82054ea" xsd:string [Term] id: BEMO:2000070 name: Lipemia Burden def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of lipemia burden." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses lipemia burden using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in lipemia burden can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating lipemia burden as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000070" xsd:string property_value: BEMO:3100022 "77" xsd:string property_value: BEMO:3100023 "572ca1cf50802a5447be4c1286cdad2930a7ec08e97e7b9af663a3cb66e1d788" xsd:string [Term] id: BEMO:2000071 name: Matched-Sample Integrity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of matched-sample integrity." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses matched-sample integrity using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in matched-sample integrity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating matched-sample integrity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000071" xsd:string property_value: BEMO:3100022 "78" xsd:string property_value: BEMO:3100023 "daf35eaf7e6632e499a494b9ba629171cde4aa96d4d637ad7669da2f69668fd5" xsd:string [Term] id: BEMO:2000072 name: Microbial Contamination def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of microbial contamination." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses microbial contamination using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in microbial contamination can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating microbial contamination as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000072" xsd:string property_value: BEMO:3100022 "79" xsd:string property_value: BEMO:3100023 "a7e7bf9a47cefd808a5ba122413c735b8b095ffc84592451f9857f4fe080e389" xsd:string [Term] id: BEMO:2000073 name: Necrosis Burden def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of necrosis burden." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses necrosis burden using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in necrosis burden can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating necrosis burden as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000073" xsd:string property_value: BEMO:3100022 "80" xsd:string property_value: BEMO:3100023 "33466881e023e8dc75d5f189be9da266f95f3bf8283fa46f9f4cff10e5af6f95" xsd:string [Term] id: BEMO:2000074 name: Pathology Confirmation def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of pathology confirmation." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses pathology confirmation using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in pathology confirmation can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating pathology confirmation as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000074" xsd:string property_value: BEMO:3100022 "81" xsd:string property_value: BEMO:3100023 "e470a75855d7bb24a7f3957922ccdf78961ef4c923b6f754c0006ebb46c0367e" xsd:string [Term] id: BEMO:2000075 name: Preservation Adequacy def: "The extent to which preservation is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses preservation adequacy using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in preservation adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating preservation adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000075" xsd:string property_value: BEMO:3100022 "82" xsd:string property_value: BEMO:3100023 "de3923232eba7ea0cab4f8eddc6a1539eac9f06416d7c31e6d2ce8fbf8492ba5" xsd:string [Term] id: BEMO:2000076 name: Processing Delay Control def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of processing delay control." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses processing delay control using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in processing delay control can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating processing delay control as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000076" xsd:string property_value: BEMO:3100022 "83" xsd:string property_value: BEMO:3100023 "575df935e8ca0edd1975c05772eaa99f38b63f196b0ee598cef40ebcb4554aaf" xsd:string [Term] id: BEMO:2000077 name: Protein Integrity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of protein integrity." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses protein integrity using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in protein integrity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Target-decoy analysis; spectral scoring; reference standards; replicate injections; retention-time and mass-error monitoring; orthogonal confirmation." xsd:string property_value: BEMO:3200006 "Treating protein integrity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000077" xsd:string property_value: BEMO:3100022 "84" xsd:string property_value: BEMO:3100023 "f776649240f851879898d488bb90516491936e0936f6f03ac5946be6c8b62a20" xsd:string [Term] id: BEMO:2000078 name: RNA Integrity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of rna integrity." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses rna integrity using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in rna integrity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating rna integrity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000078" xsd:string property_value: BEMO:3100022 "85" xsd:string property_value: BEMO:3100023 "98ac509f170b3163d862e8e08cc16dad8b915df5508f4e7394a8627d881f7350" xsd:string [Term] id: BEMO:2000079 name: Storage Temperature Control def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of storage temperature control." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses storage temperature control using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in storage temperature control can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating storage temperature control as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000079" xsd:string property_value: BEMO:3100022 "86" xsd:string property_value: BEMO:3100023 "b39a92acfa55bd840331823c88476d9d65ca0179f68f0f37ed8d7677a63d2193" xsd:string [Term] id: BEMO:2000080 name: Time-to-Fixation Adequacy def: "The extent to which time-to-fixation is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses time-to-fixation adequacy using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in time-to-fixation adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating time-to-fixation adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000080" xsd:string property_value: BEMO:3100022 "87" xsd:string property_value: BEMO:3100023 "49559a7ae628351af963a27a55893cf501098be34876ce35bdc2d4969fd4f94b" xsd:string [Term] id: BEMO:2000081 name: Transport Condition Integrity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of transport condition integrity." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses transport condition integrity using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in transport condition integrity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating transport condition integrity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000081" xsd:string property_value: BEMO:3100022 "88" xsd:string property_value: BEMO:3100023 "81f1c97831f3ffbcc8b4e89c16604f987d3fa2baac750496d710981c68a60598" xsd:string [Term] id: BEMO:2000082 name: Tumor Purity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of tumor purity." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses tumor purity using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in tumor purity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating tumor purity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000082" xsd:string property_value: BEMO:3100022 "89" xsd:string property_value: BEMO:3100023 "e7836bb1f6728d199c8634dbdbf560dae6243a3932920cc82164935a37c9180e" xsd:string [Term] id: BEMO:2000083 name: Warm Ischemia Control def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of warm ischemia control." [BEMO:source] is_a: BEMO:1100003 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.equator-network.org/reporting-guidelines/brisq/ xref: https://www.iso.org/standard/76677.html xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses warm ischemia control using evidence appropriate to biospecimen and preanalytical quality, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in warm ischemia control can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating warm ischemia control as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "All studies using human or animal biospecimens" xsd:string property_value: BEMO:3200010 "BRISQ; ISO 15189; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000083" xsd:string property_value: BEMO:3100022 "90" xsd:string property_value: BEMO:3100023 "293c5ebda3d3695852f06644549a5b920266b83358bf49b383b5d90078fcdde6" xsd:string [Term] id: BEMO:2000084 name: Assumption Sensitivity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of assumption sensitivity." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses assumption sensitivity using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in assumption sensitivity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating assumption sensitivity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000084" xsd:string property_value: BEMO:3100022 "91" xsd:string property_value: BEMO:3100023 "b75d62759fbd8f126f27997543f0f46dde1cb8c2484d156a08c9925c9476aa63" xsd:string [Term] id: BEMO:2000085 name: Causal Contrast Clarity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of causal contrast clarity." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses causal contrast clarity using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in causal contrast clarity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Directed acyclic graphs; design emulation; balance diagnostics; negative controls; quantitative bias analysis; sensitivity and falsification analyses." xsd:string property_value: BEMO:3200006 "Treating causal contrast clarity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000085" xsd:string property_value: BEMO:3100022 "92" xsd:string property_value: BEMO:3100023 "d81e7f98cb339c656ef93d3243144295a2c872dc2bcb50f64863414984f27993" xsd:string [Term] id: BEMO:2000086 name: Causal Identifiability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of causal identifiability." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses causal identifiability using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in causal identifiability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Directed acyclic graphs; design emulation; balance diagnostics; negative controls; quantitative bias analysis; sensitivity and falsification analyses." xsd:string property_value: BEMO:3200006 "Treating causal identifiability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000086" xsd:string property_value: BEMO:3100022 "93" xsd:string property_value: BEMO:3100023 "a6559bfe5ff78dd7455ed538b35cec6508c7c5507441bc614a71e2140188258e" xsd:string [Term] id: BEMO:2000087 name: Collider Bias Risk def: "The probability or degree that collider bias introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses collider bias risk using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in collider bias risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating collider bias risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000087" xsd:string property_value: BEMO:3100022 "94" xsd:string property_value: BEMO:3100023 "0d0ee23715a02b538d00c3772dc0b2a1a64aba9fb6a21ecd62845d74c88b63ca" xsd:string [Term] id: BEMO:2000088 name: Confounding Risk def: "The probability or degree that confounding introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses confounding risk using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in confounding risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Directed acyclic graphs; design emulation; balance diagnostics; negative controls; quantitative bias analysis; sensitivity and falsification analyses." xsd:string property_value: BEMO:3200006 "Treating confounding risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000088" xsd:string property_value: BEMO:3100022 "95" xsd:string property_value: BEMO:3100023 "cebd58c93ed86b363870e131c5d23217522d15af0abb7eac8956ec81e8515565" xsd:string [Term] id: BEMO:2000089 name: Consistency Assumption Plausibility def: "The degree of agreement in consistency assumption plausibility across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses consistency assumption plausibility using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in consistency assumption plausibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating consistency assumption plausibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000089" xsd:string property_value: BEMO:3100022 "96" xsd:string property_value: BEMO:3100023 "1bec3d5308662b9b5fad28978574efe7573d32766cf45ac34286863d2d2267a8" xsd:string [Term] id: BEMO:2000090 name: Correct Temporal Ordering def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of correct temporal ordering." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses correct temporal ordering using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in correct temporal ordering can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating correct temporal ordering as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000090" xsd:string property_value: BEMO:3100022 "97" xsd:string property_value: BEMO:3100023 "b11d505f3985b03d1ab78fe50a79558d187aeacc3fabbc39b5dc3da61a0cfbe2" xsd:string [Term] id: BEMO:2000091 name: Dechallenge–Rechallenge Support def: "The magnitude and credibility of independent evidence supporting dechallenge–rechallenge." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses dechallenge–rechallenge support using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in dechallenge–rechallenge support can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating dechallenge–rechallenge support as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000091" xsd:string property_value: BEMO:3100022 "98" xsd:string property_value: BEMO:3100023 "9e166f37b12b35c895b18fc7e56e04526e22004c0b70dee562c1cf80c5d17e69" xsd:string [Term] id: BEMO:2000092 name: Dose–Response Support def: "The magnitude and credibility of independent evidence supporting dose–response." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses dose–response support using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in dose–response support can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating dose–response support as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000092" xsd:string property_value: BEMO:3100022 "99" xsd:string property_value: BEMO:3100023 "75f662d9e2ee059c317733c8704b2f0f1f234146f1b2920ed572ec892b5a2d41" xsd:string [Term] id: BEMO:2000093 name: E-value Strength def: "The magnitude and credibility of independent evidence supporting e-value." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses e-value strength using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in e-value strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating e-value strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000093" xsd:string property_value: BEMO:3100022 "100" xsd:string property_value: BEMO:3100023 "8587ae49790e995db7d3bf84506f3bebdce4263532f6e5dcbd136229f5da442f" xsd:string [Term] id: BEMO:2000094 name: Effect-Modification Credibility def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of effect-modification credibility." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses effect-modification credibility using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in effect-modification credibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating effect-modification credibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000094" xsd:string property_value: BEMO:3100022 "101" xsd:string property_value: BEMO:3100023 "f66521085db07e7bd17f7b93b07cf74e57b1c85461a2555c1146f672069098b2" xsd:string [Term] id: BEMO:2000095 name: Exchangeability Plausibility def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of exchangeability plausibility." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses exchangeability plausibility using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in exchangeability plausibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Directed acyclic graphs; design emulation; balance diagnostics; negative controls; quantitative bias analysis; sensitivity and falsification analyses." xsd:string property_value: BEMO:3200006 "Treating exchangeability plausibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000095" xsd:string property_value: BEMO:3100022 "102" xsd:string property_value: BEMO:3100023 "7f4004986e0cd5fd0b8462346aec167d3be6e60fe67bb8a5838de7a005fd58d1" xsd:string [Term] id: BEMO:2000096 name: Falsification Test Support def: "The magnitude and credibility of independent evidence supporting falsification test." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses falsification test support using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in falsification test support can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating falsification test support as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000096" xsd:string property_value: BEMO:3100022 "103" xsd:string property_value: BEMO:3100023 "280760fd65dbda26ef711b182bed36c1b7e3679af41be52e50dfca26f92b3400" xsd:string [Term] id: BEMO:2000097 name: Immortal-Time Bias Risk def: "The probability or degree that immortal-time bias introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses immortal-time bias risk using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in immortal-time bias risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating immortal-time bias risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000097" xsd:string property_value: BEMO:3100022 "104" xsd:string property_value: BEMO:3100023 "21a510319cb99a940f9fc99111522f80932b8a874f1ea984fb332f8f218483c8" xsd:string [Term] id: BEMO:2000098 name: Instrument Validity def: "The degree to which instrument supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses instrument validity using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in instrument validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating instrument validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000098" xsd:string property_value: BEMO:3100022 "105" xsd:string property_value: BEMO:3100023 "e7033f91a59f115f9fba748b04cab66664ac151f4c8d653ea61aa823a8c6cce4" xsd:string [Term] id: BEMO:2000099 name: Mediation Evidence Strength def: "The magnitude and credibility of independent evidence supporting mediation evidence." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses mediation evidence strength using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in mediation evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating mediation evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000099" xsd:string property_value: BEMO:3100022 "106" xsd:string property_value: BEMO:3100023 "b7abd5f34cd2addb34f26d923a9c80b402d8914f57510a7f5fe8c4ed41659c58" xsd:string [Term] id: BEMO:2000100 name: Negative-Control Validation def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of negative-control validation." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses negative-control validation using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in negative-control validation can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating negative-control validation as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000100" xsd:string property_value: BEMO:3100022 "107" xsd:string property_value: BEMO:3100023 "63bedc3fc09ef48160a8d522d76618e50e47197d3d502ae109f1015d0fbcb67e" xsd:string [Term] id: BEMO:2000101 name: No-Interference Plausibility def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of no-interference plausibility." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses no-interference plausibility using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in no-interference plausibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Replicate dilution series; blank and spiked samples; reference materials; method-comparison studies; predefined CLSI/ISO acceptance criteria." xsd:string property_value: BEMO:3200006 "Treating no-interference plausibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000101" xsd:string property_value: BEMO:3100022 "108" xsd:string property_value: BEMO:3100023 "8aa9a1ba76fa5fd8217fff1b4352656d262602a1040dc8618b138b2e37a93d9a" xsd:string [Term] id: BEMO:2000102 name: Positivity Adequacy def: "The extent to which positivity is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses positivity adequacy using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in positivity adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Directed acyclic graphs; design emulation; balance diagnostics; negative controls; quantitative bias analysis; sensitivity and falsification analyses." xsd:string property_value: BEMO:3200006 "Treating positivity adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000102" xsd:string property_value: BEMO:3100022 "109" xsd:string property_value: BEMO:3100023 "be2ac5c0345d954f0ccc1ce41f05b792425f3fb9c158083a6db1928102b69608" xsd:string [Term] id: BEMO:2000103 name: Quantitative Bias Analysis Robustness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of quantitative bias analysis robustness." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses quantitative bias analysis robustness using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in quantitative bias analysis robustness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating quantitative bias analysis robustness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000103" xsd:string property_value: BEMO:3100022 "110" xsd:string property_value: BEMO:3100023 "7ee1bd197cfd8211ed7ac785b0e49ec8e73324814e415213789e479477f73c74" xsd:string [Term] id: BEMO:2000104 name: Residual Confounding Risk def: "The probability or degree that residual confounding introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses residual confounding risk using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in residual confounding risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Directed acyclic graphs; design emulation; balance diagnostics; negative controls; quantitative bias analysis; sensitivity and falsification analyses." xsd:string property_value: BEMO:3200006 "Treating residual confounding risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000104" xsd:string property_value: BEMO:3100022 "111" xsd:string property_value: BEMO:3100023 "fef3c7d8a6ff0d0d4088a08abb2cfe7420127e6170b4998b7b5ce06d44124e81" xsd:string [Term] id: BEMO:2000105 name: Reverse-Causation Risk def: "The probability or degree that reverse-causation introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses reverse-causation risk using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in reverse-causation risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating reverse-causation risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000105" xsd:string property_value: BEMO:3100022 "112" xsd:string property_value: BEMO:3100023 "17fc4b74f3434a4ae22f908b09530b9a1be33f82af499c89239235d78d7e1375" xsd:string [Term] id: BEMO:2000106 name: Selection-on-Survival Bias Risk def: "The probability or degree that selection-on-survival bias introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses selection-on-survival bias risk using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in selection-on-survival bias risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating selection-on-survival bias risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000106" xsd:string property_value: BEMO:3100022 "113" xsd:string property_value: BEMO:3100023 "ba5e2bde29a386ccb9cae3afe1f1c9476a350f65371bc1aebd58a3579e6e702c" xsd:string [Term] id: BEMO:2000107 name: Target Trial Emulation Fidelity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of target trial emulation fidelity." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses target trial emulation fidelity using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in target trial emulation fidelity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating target trial emulation fidelity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000107" xsd:string property_value: BEMO:3100022 "114" xsd:string property_value: BEMO:3100023 "7a907a8dc4fe2c40df0aa3c333c85c8e7231c1e33d26321171335bcd3464b6a6" xsd:string [Term] id: BEMO:2000108 name: Time-Varying Confounding Control def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of time-varying confounding control." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses time-varying confounding control using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in time-varying confounding control can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Directed acyclic graphs; design emulation; balance diagnostics; negative controls; quantitative bias analysis; sensitivity and falsification analyses." xsd:string property_value: BEMO:3200006 "Treating time-varying confounding control as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000108" xsd:string property_value: BEMO:3100022 "115" xsd:string property_value: BEMO:3100023 "f46690f0cea7611ea5bb0e9a0e5c1b90d25ecad9c8f28f3083cc2a71b53ce7f0" xsd:string [Term] id: BEMO:2000109 name: Unmeasured Confounding Sensitivity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of unmeasured confounding sensitivity." [BEMO:source] is_a: BEMO:1100004 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.gradeworkinggroup.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses unmeasured confounding sensitivity using evidence appropriate to causal inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in unmeasured confounding sensitivity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Directed acyclic graphs; design emulation; balance diagnostics; negative controls; quantitative bias analysis; sensitivity and falsification analyses." xsd:string property_value: BEMO:3200006 "Treating unmeasured confounding sensitivity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized and observational etiologic studies, natural experiments, target-trial emulations" xsd:string property_value: BEMO:3200010 "ROBINS-I; ROBINS-E; GRADE; STROBE; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000109" xsd:string property_value: BEMO:3100022 "116" xsd:string property_value: BEMO:3100023 "50677da95ed69c14f1f1ec5786cb5c4d590d6e339c1a13fdedfd18d811ffc8f4" xsd:string [Term] id: BEMO:2000110 name: Area Under the Receiver Operating Characteristic Curve def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of area under the receiver operating characteristic curve." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses area under the receiver operating characteristic curve using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in area under the receiver operating characteristic curve can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating area under the receiver operating characteristic curve as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000110" xsd:string property_value: BEMO:3100022 "117" xsd:string property_value: BEMO:3100023 "5c4feaae4c2a565042108ac4cb807678f9be09f3e84e62f596afd3338e3ceec6" xsd:string [Term] id: BEMO:2000111 name: Calibration Slope def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of calibration slope." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses calibration slope using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in calibration slope can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating calibration slope as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000111" xsd:string property_value: BEMO:3100022 "118" xsd:string property_value: BEMO:3100023 "44bfcfec74d2b98de3507998b5e63f6506912c93210fea4df7a678aed4417a75" xsd:string [Term] id: BEMO:2000112 name: Calibration-in-the-Large def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of calibration-in-the-large." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses calibration-in-the-large using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in calibration-in-the-large can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating calibration-in-the-large as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000112" xsd:string property_value: BEMO:3100022 "119" xsd:string property_value: BEMO:3100023 "4a117ceb82993be69cf387d42f6626e25d4ff682e98eb458d01d55a60ca6f29d" xsd:string [Term] id: BEMO:2000113 name: Comparative Test Accuracy def: "The closeness of comparative test to the accepted reference or true value." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses comparative test accuracy using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in comparative test accuracy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating comparative test accuracy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000113" xsd:string property_value: BEMO:3100022 "120" xsd:string property_value: BEMO:3100023 "01f4b65430acfaca391e550bb1550450d424a1dd47aebe4ed0f6dd9d60fe28ab" xsd:string [Term] id: BEMO:2000114 name: Competing-Risk Model Validity def: "The probability or degree that competing-risk model validity introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses competing-risk model validity using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in competing-risk model validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating competing-risk model validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000114" xsd:string property_value: BEMO:3100022 "121" xsd:string property_value: BEMO:3100023 "6f322698057cc9561b413498181b8f2503720420a935d144d2173ae5298a3b2f" xsd:string [Term] id: BEMO:2000115 name: Diagnostic Odds Ratio def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of diagnostic odds ratio." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses diagnostic odds ratio using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in diagnostic odds ratio can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Two-by-two tables; binomial confidence intervals; hierarchical diagnostic meta-analysis; threshold and prevalence analyses." xsd:string property_value: BEMO:3200006 "Treating diagnostic odds ratio as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000115" xsd:string property_value: BEMO:3100022 "122" xsd:string property_value: BEMO:3100023 "a903f03627bce43e756f3c1d10c27c552a53bce0346a40196ea1cd72afe63de0" xsd:string [Term] id: BEMO:2000116 name: Diagnostic Sensitivity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of diagnostic sensitivity." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses diagnostic sensitivity using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in diagnostic sensitivity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Two-by-two tables; binomial confidence intervals; hierarchical diagnostic meta-analysis; threshold and prevalence analyses." xsd:string property_value: BEMO:3200006 "Treating diagnostic sensitivity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000116" xsd:string property_value: BEMO:3100022 "123" xsd:string property_value: BEMO:3100023 "4ea75714eea731a1e4644a00db0476f8628bf028934f92bd9e4029ee31ddf173" xsd:string [Term] id: BEMO:2000117 name: Diagnostic Specificity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of diagnostic specificity." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses diagnostic specificity using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in diagnostic specificity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Two-by-two tables; binomial confidence intervals; hierarchical diagnostic meta-analysis; threshold and prevalence analyses." xsd:string property_value: BEMO:3200006 "Treating diagnostic specificity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000117" xsd:string property_value: BEMO:3100022 "124" xsd:string property_value: BEMO:3100023 "14be8f0b88f11902e6b1562a38b9cb710840858fc59f748048f96b74c8f6c2b2" xsd:string [Term] id: BEMO:2000118 name: Differential Verification Bias Risk def: "The probability or degree that differential verification bias introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses differential verification bias risk using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in differential verification bias risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating differential verification bias risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000118" xsd:string property_value: BEMO:3100022 "125" xsd:string property_value: BEMO:3100023 "2805e0d0838d99254f4675a5517e72c35cb3e1cb875fbc214edb03376568c858" xsd:string [Term] id: BEMO:2000119 name: Incorporation Bias Risk def: "The probability or degree that incorporation bias introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses incorporation bias risk using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in incorporation bias risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating incorporation bias risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000119" xsd:string property_value: BEMO:3100022 "126" xsd:string property_value: BEMO:3100023 "00ceeb2a9486ba76c68ad0f07ad3fe11fadf573e3b3b3fb37898281142b34a91" xsd:string [Term] id: BEMO:2000120 name: Incremental Diagnostic Value def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of incremental diagnostic value." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses incremental diagnostic value using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in incremental diagnostic value can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating incremental diagnostic value as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000120" xsd:string property_value: BEMO:3100022 "127" xsd:string property_value: BEMO:3100023 "8c0d8dc6983b3100a525f45a2c3c327af7d21cf2d155dc05a19b99e0d7f43578" xsd:string [Term] id: BEMO:2000121 name: Index-Test Blinding def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of index-test blinding." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses index-test blinding using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in index-test blinding can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating index-test blinding as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000121" xsd:string property_value: BEMO:3100022 "128" xsd:string property_value: BEMO:3100023 "3bc623a30f8cb3956f6d71196888c1021137e72c87604513c9fc1e352f98bb4c" xsd:string [Term] id: BEMO:2000122 name: Negative Likelihood Ratio def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of negative likelihood ratio." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses negative likelihood ratio using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in negative likelihood ratio can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Two-by-two tables; binomial confidence intervals; hierarchical diagnostic meta-analysis; threshold and prevalence analyses." xsd:string property_value: BEMO:3200006 "Treating negative likelihood ratio as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000122" xsd:string property_value: BEMO:3100022 "129" xsd:string property_value: BEMO:3100023 "6dc29889e79017542636c8b841aff4c0f5947b19dec51307e00a9c51cdc593cc" xsd:string [Term] id: BEMO:2000123 name: Negative Predictive Value def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of negative predictive value." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses negative predictive value using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in negative predictive value can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Two-by-two tables; binomial confidence intervals; hierarchical diagnostic meta-analysis; threshold and prevalence analyses." xsd:string property_value: BEMO:3200006 "Treating negative predictive value as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000123" xsd:string property_value: BEMO:3100022 "130" xsd:string property_value: BEMO:3100023 "9f42e5362ad2e55445a028ec6d3cc9c062886d8c9272f983b0c1acec345502f7" xsd:string [Term] id: BEMO:2000124 name: Observed-to-Expected Ratio def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of observed-to-expected ratio." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses observed-to-expected ratio using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in observed-to-expected ratio can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating observed-to-expected ratio as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000124" xsd:string property_value: BEMO:3100022 "131" xsd:string property_value: BEMO:3100023 "cdf33871a90f7426da799fbf8148672bff9e925c7981ff58372c39511bd4050e" xsd:string [Term] id: BEMO:2000125 name: Partial Area Under the Receiver Operating Characteristic Curve def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of partial area under the receiver operating characteristic curve." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses partial area under the receiver operating characteristic curve using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in partial area under the receiver operating characteristic curve can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating partial area under the receiver operating characteristic curve as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000125" xsd:string property_value: BEMO:3100022 "132" xsd:string property_value: BEMO:3100023 "79f6b607e0d7504f46e1d3842fa8966ae929db7058236a6b4ed553277ad444b5" xsd:string [Term] id: BEMO:2000126 name: Patient Flow Integrity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of patient flow integrity." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses patient flow integrity using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in patient flow integrity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating patient flow integrity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000126" xsd:string property_value: BEMO:3100022 "133" xsd:string property_value: BEMO:3100023 "67544e05c38d184f5e9fa9830136b1408e7835e115b1fa9c54147ad65e14b99c" xsd:string [Term] id: BEMO:2000127 name: Positive Likelihood Ratio def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of positive likelihood ratio." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses positive likelihood ratio using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in positive likelihood ratio can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Two-by-two tables; binomial confidence intervals; hierarchical diagnostic meta-analysis; threshold and prevalence analyses." xsd:string property_value: BEMO:3200006 "Treating positive likelihood ratio as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000127" xsd:string property_value: BEMO:3100022 "134" xsd:string property_value: BEMO:3100023 "65ab6bc3c7bfa89dbab942e4977888e1ec5d3ea554c360ceffa76f4daab1fd7e" xsd:string [Term] id: BEMO:2000128 name: Positive Predictive Value def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of positive predictive value." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses positive predictive value using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in positive predictive value can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Two-by-two tables; binomial confidence intervals; hierarchical diagnostic meta-analysis; threshold and prevalence analyses." xsd:string property_value: BEMO:3200006 "Treating positive predictive value as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000128" xsd:string property_value: BEMO:3100022 "135" xsd:string property_value: BEMO:3100023 "89034784369de0142956f172eb3ca87ccad9b4cc69ac8a45b8a92adf9cc1731f" xsd:string [Term] id: BEMO:2000129 name: Prognostic Added Value def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of prognostic added value." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses prognostic added value using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in prognostic added value can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating prognostic added value as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000129" xsd:string property_value: BEMO:3100022 "136" xsd:string property_value: BEMO:3100023 "6a8e54c8d71bbaa2bc8361d6fc19eb1f50b8f4acd2b6d09e2b648f2337fa9298" xsd:string [Term] id: BEMO:2000130 name: Prognostic Calibration def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of prognostic calibration." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses prognostic calibration using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in prognostic calibration can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating prognostic calibration as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000130" xsd:string property_value: BEMO:3100022 "137" xsd:string property_value: BEMO:3100023 "bddeb4ff61529649f6f5d81ae9a9ab5588a6f6aed10ca70d0d400119d6c2e940" xsd:string [Term] id: BEMO:2000131 name: Prognostic Discrimination def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of prognostic discrimination." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses prognostic discrimination using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in prognostic discrimination can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating prognostic discrimination as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000131" xsd:string property_value: BEMO:3100022 "138" xsd:string property_value: BEMO:3100023 "b58deaf6b24f17f45025c2e10bd742dcb00a937cc0410366fbe092bfbfd13882" xsd:string [Term] id: BEMO:2000132 name: Prognostic Transportability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of prognostic transportability." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses prognostic transportability using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in prognostic transportability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating prognostic transportability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000132" xsd:string property_value: BEMO:3100022 "139" xsd:string property_value: BEMO:3100023 "c2720768cdf2be8ed6a3b935c205e9cb522ea1c958d036e680eee5e7cba4038e" xsd:string [Term] id: BEMO:2000133 name: Reclassification Improvement def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of reclassification improvement." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses reclassification improvement using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in reclassification improvement can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating reclassification improvement as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000133" xsd:string property_value: BEMO:3100022 "140" xsd:string property_value: BEMO:3100023 "74d83029c18dff3247c8fb9baae1d6aba52c9b7328d218dd0210458cbd5ad7d5" xsd:string [Term] id: BEMO:2000134 name: Reference Standard Validity def: "The degree to which reference standard supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses reference standard validity using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in reference standard validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating reference standard validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000134" xsd:string property_value: BEMO:3100022 "141" xsd:string property_value: BEMO:3100023 "3bd12b9aed8e6e227ec8b1e5082fc9060b988babbc4204f8a360bb7503e6ad49" xsd:string [Term] id: BEMO:2000135 name: Test-Timing Appropriateness def: "The extent to which test-timing is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses test-timing appropriateness using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in test-timing appropriateness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating test-timing appropriateness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000135" xsd:string property_value: BEMO:3100022 "142" xsd:string property_value: BEMO:3100023 "ffb2707e3bed89aca5f5c790dc5a9b0312e89c5a1dba27ebac908e4597a355bd" xsd:string [Term] id: BEMO:2000136 name: Threshold Validity def: "The degree to which threshold supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses threshold validity using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in threshold validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating threshold validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000136" xsd:string property_value: BEMO:3100022 "143" xsd:string property_value: BEMO:3100023 "c27bfe6217acf4b748aeb85aa4e9c4176c8256e12b7c61ff84a201b6fd374c82" xsd:string [Term] id: BEMO:2000137 name: Time-Dependent Discrimination def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of time-dependent discrimination." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses time-dependent discrimination using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in time-dependent discrimination can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating time-dependent discrimination as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000137" xsd:string property_value: BEMO:3100022 "144" xsd:string property_value: BEMO:3100023 "5232bfe9f1dc1ddd88662ddb65a550d0d1fc5338bb4a530ed1072ed6078116bf" xsd:string [Term] id: BEMO:2000138 name: Verification Bias Risk def: "The probability or degree that verification bias introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100005 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ property_value: BEMO:3200002 "Assesses verification bias risk using evidence appropriate to diagnostic and prognostic evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in verification bias risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating verification bias risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Diagnostic accuracy, screening, prognostic-factor, and prediction-model studies" xsd:string property_value: BEMO:3200010 "QUADAS-2; STARD; TRIPOD; REMARK" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000138" xsd:string property_value: BEMO:3100022 "145" xsd:string property_value: BEMO:3100023 "2f165758b70b1e482bfb8517e1a69a7d4e05ba84cd41dc36c2f346f991371034" xsd:string [Term] id: BEMO:2000139 name: Between-Study Variance def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of between-study variance." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses between-study variance using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in between-study variance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Forest plots; heterogeneity statistics; tau-squared; prediction intervals; funnel plots; regression or selection models; sensitivity analyses." xsd:string property_value: BEMO:3200006 "Treating between-study variance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000139" xsd:string property_value: BEMO:3100022 "146" xsd:string property_value: BEMO:3100023 "167d33dabeef5837833710d7e97d42ff17e46ede74b98e0e88db46e921ff811e" xsd:string [Term] id: BEMO:2000140 name: Counterevidence Strength def: "The magnitude and credibility of independent evidence supporting counterevidence." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses counterevidence strength using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in counterevidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating counterevidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000140" xsd:string property_value: BEMO:3100022 "147" xsd:string property_value: BEMO:3100023 "d4c1d3bbceb7e86e058c678a7bbc386dd5980f93dcbc9a60ebc6c6d39231fcdb" xsd:string [Term] id: BEMO:2000141 name: Cumulative Evidence Stability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of cumulative evidence stability." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses cumulative evidence stability using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in cumulative evidence stability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating cumulative evidence stability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000141" xsd:string property_value: BEMO:3100022 "148" xsd:string property_value: BEMO:3100023 "e87943e84aae44a1eeb6300f5a52416f0528fe0f3bf76f40f0a2a4486c87ea6a" xsd:string [Term] id: BEMO:2000142 name: Evidence Coherence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of evidence coherence." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses evidence coherence using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in evidence coherence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating evidence coherence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000142" xsd:string property_value: BEMO:3100022 "149" xsd:string property_value: BEMO:3100023 "573628981de9da600edff4f13001018973ec4403d9ad58179a02f6958d0404dd" xsd:string [Term] id: BEMO:2000143 name: Evidence Completeness def: "The extent to which all scientifically necessary components of evidence are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses evidence completeness using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in evidence completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating evidence completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000143" xsd:string property_value: BEMO:3100022 "150" xsd:string property_value: BEMO:3100023 "263bd485141b0cc75ee285fb1989c667b83eb378666886a960ed5bd2a610f232" xsd:string [Term] id: BEMO:2000144 name: Evidence Confidence def: "The justified degree of certainty assigned to evidence given the quantity, quality, consistency, and limitations of supporting evidence." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses evidence confidence using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in evidence confidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating evidence confidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000144" xsd:string property_value: BEMO:3100022 "151" xsd:string property_value: BEMO:3100023 "a6abc5b380d07d44d4ec1e48b63cf0e3bf7299ab7264d6edcc898627f3bd0952" xsd:string [Term] id: BEMO:2000145 name: Evidence Consensus Strength def: "The magnitude and credibility of independent evidence supporting evidence consensus." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses evidence consensus strength using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in evidence consensus strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating evidence consensus strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000145" xsd:string property_value: BEMO:3100022 "152" xsd:string property_value: BEMO:3100023 "f207ed4da0508b76cb7e86f43fc62efc4861d327760c860608fc73ff3f4a6da8" xsd:string [Term] id: BEMO:2000146 name: Evidence Consistency def: "The degree of agreement in evidence across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses evidence consistency using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in evidence consistency can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating evidence consistency as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000146" xsd:string property_value: BEMO:3100022 "153" xsd:string property_value: BEMO:3100023 "f74a279906eee7e4453803727494ade321b94fc1d6196fb1882daae7f1abcf75" xsd:string [Term] id: BEMO:2000147 name: Evidence Coverage def: "The proportion and representativeness of the relevant evidence captured by the evidence or measurement process." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses evidence coverage using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in evidence coverage can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating evidence coverage as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000147" xsd:string property_value: BEMO:3100022 "154" xsd:string property_value: BEMO:3100023 "a64cee9a2114ea7d5580ea8d59eaef0691fce1d63dd3e4fd9f3d63e0dac86a3d" xsd:string [Term] id: BEMO:2000148 name: Evidence Directness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of evidence directness." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses evidence directness using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in evidence directness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating evidence directness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000148" xsd:string property_value: BEMO:3100022 "155" xsd:string property_value: BEMO:3100023 "880de5f192c9dc60c14576e428f1c46fbdcda3180afe950bcde297920e65c6df" xsd:string [Term] id: BEMO:2000149 name: Evidence Freshness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of evidence freshness." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses evidence freshness using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in evidence freshness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating evidence freshness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000149" xsd:string property_value: BEMO:3100022 "156" xsd:string property_value: BEMO:3100023 "2dc879dd1ad8ed3ebf228b83983e7de95e06b9c72131b584ccaa785f551eea2b" xsd:string [Term] id: BEMO:2000150 name: Evidence Precision def: "The closeness of repeated estimates or measurements and the narrowness of uncertainty around evidence." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses evidence precision using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in evidence precision can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating evidence precision as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000150" xsd:string property_value: BEMO:3100022 "157" xsd:string property_value: BEMO:3100023 "fed12d9ff25f08fc6db399dc5bed2e8d719fc0db8bcefb33987a3ef3db40f55c" xsd:string [Term] id: BEMO:2000151 name: Evidence Quality def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of evidence quality." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses evidence quality using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in evidence quality can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating evidence quality as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000151" xsd:string property_value: BEMO:3100022 "158" xsd:string property_value: BEMO:3100023 "f4e08b1965ce7d1832ff4c5191f1e7298781d9bec3cb9a96c09198d6faaa1339" xsd:string [Term] id: BEMO:2000152 name: Evidence Robustness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of evidence robustness." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses evidence robustness using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in evidence robustness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating evidence robustness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000152" xsd:string property_value: BEMO:3100022 "159" xsd:string property_value: BEMO:3100023 "59315ce160586081fc3fd71f96646716829d26fde9e0a21aa0afec923b5083d6" xsd:string [Term] id: BEMO:2000153 name: Evidence Stability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of evidence stability." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses evidence stability using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in evidence stability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating evidence stability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000153" xsd:string property_value: BEMO:3100022 "160" xsd:string property_value: BEMO:3100023 "1f9ca5bc5be56489e2caf9d2f3eaaf37b12ae4271716853fb373d2db6aa8d657" xsd:string [Term] id: BEMO:2000154 name: Evidence Strength def: "The magnitude and credibility of independent evidence supporting evidence." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses evidence strength using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000154" xsd:string property_value: BEMO:3100022 "161" xsd:string property_value: BEMO:3100023 "d0050ec2d0692a0a792ec941fce4c076cf8613142effd9ef06a03cab99fa82fe" xsd:string [Term] id: BEMO:2000155 name: Evidence Sufficiency def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of evidence sufficiency." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses evidence sufficiency using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in evidence sufficiency can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating evidence sufficiency as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000155" xsd:string property_value: BEMO:3100022 "162" xsd:string property_value: BEMO:3100023 "516f7f59fc37d19455d99f12f79cf9f0baf5cd671807c3364f013a016d7ec68a" xsd:string [Term] id: BEMO:2000156 name: Evidence Triangulation Strength def: "The magnitude and credibility of independent evidence supporting evidence triangulation." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses evidence triangulation strength using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in evidence triangulation strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating evidence triangulation strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000156" xsd:string property_value: BEMO:3100022 "163" xsd:string property_value: BEMO:3100023 "b9d887ba211f3aea4699afd087a0aa12fb8ca924209ee34ccda2bfd968c02a4a" xsd:string [Term] id: BEMO:2000157 name: Information Size Adequacy def: "The extent to which information size is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses information size adequacy using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in information size adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating information size adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000157" xsd:string property_value: BEMO:3100022 "164" xsd:string property_value: BEMO:3100023 "1349313eaf86ad90454f8dbf26aa9cb5389132fc9ac2e44b703024851df5136c" xsd:string [Term] id: BEMO:2000158 name: Missing Evidence Risk def: "The probability or degree that missing evidence introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses missing evidence risk using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in missing evidence risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating missing evidence risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000158" xsd:string property_value: BEMO:3100022 "165" xsd:string property_value: BEMO:3100023 "ffec67315125f9639a3601d51e352906c34b1c9847a274942f934888c1188977" xsd:string [Term] id: BEMO:2000159 name: Multiplicity-Adjusted Credibility def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of multiplicity-adjusted credibility." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses multiplicity-adjusted credibility using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in multiplicity-adjusted credibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating multiplicity-adjusted credibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000159" xsd:string property_value: BEMO:3100022 "166" xsd:string property_value: BEMO:3100023 "40900cc3965adf1a4a61ca1880158e0ed27ede5d1a6163f63eb4f6d38b99a3b8" xsd:string [Term] id: BEMO:2000160 name: Overall Evidence Certainty def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of overall evidence certainty." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses overall evidence certainty using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in overall evidence certainty can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating overall evidence certainty as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000160" xsd:string property_value: BEMO:3100022 "167" xsd:string property_value: BEMO:3100023 "31b48110148a1ebdd1379016bfff93898087ec61573fac3b850ccada3e1f7ae5" xsd:string [Term] id: BEMO:2000161 name: Prediction Interval Adequacy def: "The extent to which prediction interval is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses prediction interval adequacy using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in prediction interval adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating prediction interval adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000161" xsd:string property_value: BEMO:3100022 "168" xsd:string property_value: BEMO:3100023 "0acc1464b5d065a6f38744191dff4d933036cf918aeac3f16274b9cdb9dd1059" xsd:string [Term] id: BEMO:2000162 name: Publication Bias Risk def: "The probability or degree that publication bias introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses publication bias risk using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in publication bias risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Forest plots; heterogeneity statistics; tau-squared; prediction intervals; funnel plots; regression or selection models; sensitivity analyses." xsd:string property_value: BEMO:3200006 "Treating publication bias risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000162" xsd:string property_value: BEMO:3100022 "169" xsd:string property_value: BEMO:3100023 "ae14a6a3126f2ecd31144006a017263d5e10df0fcde0e6bd8cc0872e93853a7a" xsd:string [Term] id: BEMO:2000163 name: Selective Nonreporting Risk def: "The probability or degree that selective nonreporting introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses selective nonreporting risk using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in selective nonreporting risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating selective nonreporting risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000163" xsd:string property_value: BEMO:3100022 "170" xsd:string property_value: BEMO:3100023 "8c42609174eeba28064b2f75bd158a40f97b17f9cdaa32aed81219eddf87ef89" xsd:string [Term] id: BEMO:2000164 name: Small-Study Effects def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of small-study effects." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses small-study effects using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in small-study effects can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Forest plots; heterogeneity statistics; tau-squared; prediction intervals; funnel plots; regression or selection models; sensitivity analyses." xsd:string property_value: BEMO:3200006 "Treating small-study effects as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000164" xsd:string property_value: BEMO:3100022 "171" xsd:string property_value: BEMO:3100023 "ec5ee159f748d5035209ae456b71092c6724bc73af9b720bf70afe3ffc41f242" xsd:string [Term] id: BEMO:2000165 name: Study Heterogeneity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of study heterogeneity." [BEMO:source] is_a: BEMO:1100006 subset: bemo_evidence_synthesis_and_certainty xref: https://www.gradeworkinggroup.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.bmj.com/content/358/bmj.j4008 xref: https://www.riskofbias.info/ property_value: BEMO:3200002 "Assesses study heterogeneity using evidence appropriate to evidence certainty and synthesis, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in study heterogeneity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Forest plots; heterogeneity statistics; tau-squared; prediction intervals; funnel plots; regression or selection models; sensitivity analyses." xsd:string property_value: BEMO:3200006 "Treating study heterogeneity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Systematic reviews, meta-analyses, evidence profiles, guidelines" xsd:string property_value: BEMO:3200010 "GRADE; PRISMA; AMSTAR 2; RoB" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000165" xsd:string property_value: BEMO:3100022 "172" xsd:string property_value: BEMO:3100023 "93fce0e52f596e9f5e6b6636a82da697803846e686e6144faa894115a270196a" xsd:string [Term] id: BEMO:2000166 name: Age Appropriateness def: "The extent to which age is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses age appropriateness using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in age appropriateness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating age appropriateness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000166" xsd:string property_value: BEMO:3100022 "173" xsd:string property_value: BEMO:3100023 "6f50922de3489bf44a56c621fcc8933973821a524b4c3ba13cb746276b4a9bea" xsd:string [Term] id: BEMO:2000167 name: Animal Model Construct Validity def: "The degree to which animal model construct supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses animal model construct validity using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in animal model construct validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating animal model construct validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000167" xsd:string property_value: BEMO:3100022 "174" xsd:string property_value: BEMO:3100023 "f8c928bcc279a4856d6377104c402fb4a00d102300c3c3fa14181f174b53f974" xsd:string [Term] id: BEMO:2000168 name: Animal Model Face Validity def: "The degree to which animal model face supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses animal model face validity using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in animal model face validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating animal model face validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000168" xsd:string property_value: BEMO:3100022 "175" xsd:string property_value: BEMO:3100023 "1bc9d94635678f728d2a96fd7016f3d61e24c78d9e33c5093213c9d715511534" xsd:string [Term] id: BEMO:2000169 name: Animal Model Predictive Validity def: "The degree to which animal model predictive supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses animal model predictive validity using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in animal model predictive validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating animal model predictive validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000169" xsd:string property_value: BEMO:3100022 "176" xsd:string property_value: BEMO:3100023 "ae7f68af5b958c01b88066cf76664c77d333abaff4414b63760b817bf19359d0" xsd:string [Term] id: BEMO:2000170 name: Attrition Accounting in Animal Studies def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of attrition accounting in animal studies." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses attrition accounting in animal studies using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in attrition accounting in animal studies can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating attrition accounting in animal studies as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000170" xsd:string property_value: BEMO:3100022 "177" xsd:string property_value: BEMO:3100023 "bfb6735bf1e0494f94802ec087edc274ccdaea50558f3ea043f6f21ae9210505" xsd:string [Term] id: BEMO:2000171 name: Biological Replicate Adequacy def: "The extent to which biological replicate is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses biological replicate adequacy using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in biological replicate adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating biological replicate adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000171" xsd:string property_value: BEMO:3100022 "178" xsd:string property_value: BEMO:3100023 "74976e4cf57f53c444f4721c04fc26fb7298cad4ac743db45feeb9a0be34587a" xsd:string [Term] id: BEMO:2000172 name: Blinding in Experimental Assessment def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of blinding in experimental assessment." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses blinding in experimental assessment using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in blinding in experimental assessment can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating blinding in experimental assessment as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000172" xsd:string property_value: BEMO:3100022 "179" xsd:string property_value: BEMO:3100023 "2a7451a420224db55e7f75f4a33818fc20cbc59d2bbc81f21fd652f7ea1a7931" xsd:string [Term] id: BEMO:2000173 name: Environmental Standardization def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of environmental standardization." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses environmental standardization using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in environmental standardization can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating environmental standardization as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000173" xsd:string property_value: BEMO:3100022 "180" xsd:string property_value: BEMO:3100023 "432e96e9d5c02fcda1a353b0ddb2e18d1019ff594f33c248eedfbe337bf31fae" xsd:string [Term] id: BEMO:2000174 name: Exclusion-Criteria Prespecification def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of exclusion-criteria prespecification." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses exclusion-criteria prespecification using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in exclusion-criteria prespecification can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating exclusion-criteria prespecification as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000174" xsd:string property_value: BEMO:3100022 "181" xsd:string property_value: BEMO:3100023 "9718ea523adf00e3cd776b8e22423abc28cf080bd659786c7568ddd524ab9208" xsd:string [Term] id: BEMO:2000175 name: Experimental Batch Randomization def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of experimental batch randomization." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses experimental batch randomization using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in experimental batch randomization can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating experimental batch randomization as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000175" xsd:string property_value: BEMO:3100022 "182" xsd:string property_value: BEMO:3100023 "1291027c6f53e5902a86a2cf22b3cca02564dbc940590bb8b8bcfd5004b998b7" xsd:string [Term] id: BEMO:2000176 name: Experimental Unit Validity def: "The degree to which experimental unit supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses experimental unit validity using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in experimental unit validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating experimental unit validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000176" xsd:string property_value: BEMO:3100022 "183" xsd:string property_value: BEMO:3100023 "3d08eaaab51eb4d1095b9fb5e884110ba36de86e61615acc1661c581f985a6b1" xsd:string [Term] id: BEMO:2000177 name: Genetic Background Control def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of genetic background control." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses genetic background control using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in genetic background control can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating genetic background control as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000177" xsd:string property_value: BEMO:3100022 "184" xsd:string property_value: BEMO:3100023 "3f6791503c2895971802b5fb5573311999fc32cde51839dc771c56e4855ceb83" xsd:string [Term] id: BEMO:2000178 name: Housing and Husbandry Control def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of housing and husbandry control." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses housing and husbandry control using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in housing and husbandry control can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating housing and husbandry control as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000178" xsd:string property_value: BEMO:3100022 "185" xsd:string property_value: BEMO:3100023 "d4c26e56573de7f55de0caafd1e2880580fe66b8b4d599787ebf0b2bb3808344" xsd:string [Term] id: BEMO:2000179 name: Humane Endpoint Appropriateness def: "The extent to which humane endpoint is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses humane endpoint appropriateness using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in humane endpoint appropriateness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating humane endpoint appropriateness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000179" xsd:string property_value: BEMO:3100022 "186" xsd:string property_value: BEMO:3100023 "efafe26c06dac15c0d485bfb264933c40fe9cf7ca97c5195ea92c9cfeb3f7a98" xsd:string [Term] id: BEMO:2000180 name: Intervention Fidelity in Animal Studies def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of intervention fidelity in animal studies." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses intervention fidelity in animal studies using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in intervention fidelity in animal studies can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating intervention fidelity in animal studies as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000180" xsd:string property_value: BEMO:3100022 "187" xsd:string property_value: BEMO:3100023 "f4ebc6af400b7084f27d64f43d25beed78acdab6caf4a03c3179cab231054034" xsd:string [Term] id: BEMO:2000181 name: Negative-Control Performance def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of negative-control performance." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses negative-control performance using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in negative-control performance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating negative-control performance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000181" xsd:string property_value: BEMO:3100022 "188" xsd:string property_value: BEMO:3100023 "0095c2122f8f2e2a2aa6070b8c33f6576321db691574400350300c93ce956830" xsd:string [Term] id: BEMO:2000182 name: Orthogonal Validation def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of orthogonal validation." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses orthogonal validation using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in orthogonal validation can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating orthogonal validation as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000182" xsd:string property_value: BEMO:3100022 "189" xsd:string property_value: BEMO:3100023 "86d52a57d493edc61e94352ed7d2d8f4feaaa492b37b0afb047315bb8706c00e" xsd:string [Term] id: BEMO:2000183 name: Positive-Control Performance def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of positive-control performance." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses positive-control performance using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in positive-control performance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating positive-control performance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000183" xsd:string property_value: BEMO:3100022 "190" xsd:string property_value: BEMO:3100023 "98f43a472c5bc9ced611ad7ff89ac485c18a5c20ba0a8428164700738b649f75" xsd:string [Term] id: BEMO:2000184 name: Randomization in Experimental Allocation def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of randomization in experimental allocation." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses randomization in experimental allocation using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in randomization in experimental allocation can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating randomization in experimental allocation as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000184" xsd:string property_value: BEMO:3100022 "191" xsd:string property_value: BEMO:3100023 "5cc94b6085b9c596d4f74c18712e9f8177db4335ab703b2218b9c3a63209c113" xsd:string [Term] id: BEMO:2000185 name: Sample Size Justification def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of sample size justification." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses sample size justification using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in sample size justification can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating sample size justification as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000185" xsd:string property_value: BEMO:3100022 "192" xsd:string property_value: BEMO:3100023 "9c4289123cb7c0f9d87fa9453151e360a9b6781cd9fbb6f6b26a09f4543b0dab" xsd:string [Term] id: BEMO:2000186 name: Sex as a Biological Variable Adequacy def: "The extent to which sex as a biological variable is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses sex as a biological variable adequacy using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in sex as a biological variable adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating sex as a biological variable adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000186" xsd:string property_value: BEMO:3100022 "193" xsd:string property_value: BEMO:3100023 "67d1bc84f2c2d0324ee734ed3d2df1c72cd4820b21290b5a8b136d75863a4866" xsd:string [Term] id: BEMO:2000187 name: Species Appropriateness def: "The extent to which species is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses species appropriateness using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in species appropriateness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating species appropriateness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000187" xsd:string property_value: BEMO:3100022 "194" xsd:string property_value: BEMO:3100023 "93f7de14ca784e8a47e3c6ab351c1e75c21a4c3e26305cfe63e0d4fef2122575" xsd:string [Term] id: BEMO:2000188 name: Technical Artifact Exclusion def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of technical artifact exclusion." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses technical artifact exclusion using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in technical artifact exclusion can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating technical artifact exclusion as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000188" xsd:string property_value: BEMO:3100022 "195" xsd:string property_value: BEMO:3100023 "8d21017136fa388d87b531d9b552fc3f6787a0b2615866e0c0a1ca9ae2fb0bbf" xsd:string [Term] id: BEMO:2000189 name: Technical Replicate Adequacy def: "The extent to which technical replicate is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses technical replicate adequacy using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in technical replicate adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating technical replicate adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000189" xsd:string property_value: BEMO:3100022 "196" xsd:string property_value: BEMO:3100023 "8f5bd5eed372632eafdff28f1c8035067d4634c207012fb089ff55a67d705176" xsd:string [Term] id: BEMO:2000190 name: Vehicle-Control Validity def: "The degree to which vehicle-control supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100007 subset: bemo_biological_mechanism_and_experimental_evidence xref: https://arriveguidelines.org/arrive-guidelines xref: https://www.radboudumc.nl/en/research/departments/health-evidence/systematic-review-center-for-laboratory-animal-experimentation xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm property_value: BEMO:3200002 "Assesses vehicle-control validity using evidence appropriate to experimental biology and animal research, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in vehicle-control validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating vehicle-control validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "In vitro, ex vivo, organoid, animal, and preclinical experiments" xsd:string property_value: BEMO:3200010 "ARRIVE 2.0; SYRCLE; OECD" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000190" xsd:string property_value: BEMO:3100022 "197" xsd:string property_value: BEMO:3100023 "b1aee501d417f186bec79f011141586c66408c5b9c272dd6db3a4fa3a34f419d" xsd:string [Term] id: BEMO:2000191 name: Care-Pathway Independence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of care-pathway independence." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses care-pathway independence using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in care-pathway independence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating care-pathway independence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000191" xsd:string property_value: BEMO:3100022 "198" xsd:string property_value: BEMO:3100023 "e39c9004563f895f591d754f0c2c01d5cfe45a0e26d44584ecb91c07d72c494a" xsd:string [Term] id: BEMO:2000192 name: Comparator Applicability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of comparator applicability." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses comparator applicability using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in comparator applicability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating comparator applicability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000192" xsd:string property_value: BEMO:3100022 "199" xsd:string property_value: BEMO:3100023 "607cceee390b7cb8ce577becf5db87c7c9a4643da6c8fbe5bd44948e1b9e3853" xsd:string [Term] id: BEMO:2000193 name: Context Sensitivity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of context sensitivity." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses context sensitivity using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in context sensitivity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating context sensitivity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000193" xsd:string property_value: BEMO:3100022 "200" xsd:string property_value: BEMO:3100023 "84e49bfba34c254503c96b181528bf2beab33e58bfa3d6d711b6afaa740ea566" xsd:string [Term] id: BEMO:2000194 name: Demographic Generalizability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of demographic generalizability." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses demographic generalizability using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in demographic generalizability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating demographic generalizability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000194" xsd:string property_value: BEMO:3100022 "201" xsd:string property_value: BEMO:3100023 "e22341c32d6f7aad19740ed4b08e7f5ffc168107f1e04a79ba4ec60f6b92c463" xsd:string [Term] id: BEMO:2000195 name: Disease-Severity Generalizability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of disease-severity generalizability." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses disease-severity generalizability using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in disease-severity generalizability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating disease-severity generalizability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000195" xsd:string property_value: BEMO:3100022 "202" xsd:string property_value: BEMO:3100023 "867ff07055e7596b98039def11c9ce9ca056af7a3a11134bb8f46a0bd5adc97a" xsd:string [Term] id: BEMO:2000196 name: Ecological Validity def: "The degree to which ecological supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses ecological validity using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in ecological validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating ecological validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000196" xsd:string property_value: BEMO:3100022 "203" xsd:string property_value: BEMO:3100023 "04e73707dc619457f6718e0be03029ef6e99208f68cbcad30d9f5bb20b2cd94b" xsd:string [Term] id: BEMO:2000197 name: External Validity def: "The degree to which external supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses external validity using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in external validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating external validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000197" xsd:string property_value: BEMO:3100022 "204" xsd:string property_value: BEMO:3100023 "291600cbcf719af0c4e82629e00cccabf1b55b19eff672c1fb6c5c7fe2ec4338" xsd:string [Term] id: BEMO:2000198 name: Generalizability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of generalizability." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses generalizability using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in generalizability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating generalizability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000198" xsd:string property_value: BEMO:3100022 "205" xsd:string property_value: BEMO:3100023 "27f8a61447192cbdeaaa7e84078183a3604b2e6ac6c0df13be6cfe9e4a09224a" xsd:string [Term] id: BEMO:2000199 name: Geographic Consistency def: "The degree of agreement in geographic across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses geographic consistency using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in geographic consistency can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating geographic consistency as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000199" xsd:string property_value: BEMO:3100022 "206" xsd:string property_value: BEMO:3100023 "22cb03e816656f6f9ad7a2acb4c32a01ffbc6b40d04a48011cef0a52134d504e" xsd:string [Term] id: BEMO:2000200 name: Intervention Applicability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of intervention applicability." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses intervention applicability using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in intervention applicability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating intervention applicability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000200" xsd:string property_value: BEMO:3100022 "207" xsd:string property_value: BEMO:3100023 "d1cb3929ecc9b0976fba4823cb5a09ca13a634dd6efaa3ee43969eafe3250a95" xsd:string [Term] id: BEMO:2000201 name: Outcome Applicability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of outcome applicability." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses outcome applicability using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in outcome applicability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating outcome applicability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000201" xsd:string property_value: BEMO:3100022 "208" xsd:string property_value: BEMO:3100023 "5c0db0a0257f7b171655d97624fdf4764d1fabad77716300abc92c2debe71f7d" xsd:string [Term] id: BEMO:2000202 name: Population Applicability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of population applicability." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses population applicability using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in population applicability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating population applicability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000202" xsd:string property_value: BEMO:3100022 "209" xsd:string property_value: BEMO:3100023 "9073b7f8b73fc788aa084d5c4ac174d69482c2a1439b22f86a39e465503328bc" xsd:string [Term] id: BEMO:2000203 name: Population Representativeness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of population representativeness." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses population representativeness using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in population representativeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating population representativeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000203" xsd:string property_value: BEMO:3100022 "210" xsd:string property_value: BEMO:3100023 "efa730876069251ed2dde336a59f381b8c109c4ee429da0b68bf8bae61b0ba48" xsd:string [Term] id: BEMO:2000204 name: Real-World Evidence Alignment def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of real-world evidence alignment." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses real-world evidence alignment using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in real-world evidence alignment can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating real-world evidence alignment as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000204" xsd:string property_value: BEMO:3100022 "211" xsd:string property_value: BEMO:3100023 "2bcc973aa3f12efded260e2aef1541636262ee110856a34255ce0823d91dfb20" xsd:string [Term] id: BEMO:2000205 name: Sampling Frame Adequacy def: "The extent to which sampling frame is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses sampling frame adequacy using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in sampling frame adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating sampling frame adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000205" xsd:string property_value: BEMO:3100022 "212" xsd:string property_value: BEMO:3100023 "39b818e971de479787fde11a4523a1b0d31f5dcbc88f645b968cff60fa6bf381" xsd:string [Term] id: BEMO:2000206 name: Setting Applicability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of setting applicability." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses setting applicability using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in setting applicability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating setting applicability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000206" xsd:string property_value: BEMO:3100022 "213" xsd:string property_value: BEMO:3100023 "323f595d53815c626b380456c55c73f7ff5e2e10beb1e0ffc44edb8067c37e86" xsd:string [Term] id: BEMO:2000207 name: Spectrum Representativeness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of spectrum representativeness." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses spectrum representativeness using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in spectrum representativeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Target-decoy analysis; spectral scoring; reference standards; replicate injections; retention-time and mass-error monitoring; orthogonal confirmation." xsd:string property_value: BEMO:3200006 "Treating spectrum representativeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000207" xsd:string property_value: BEMO:3100022 "214" xsd:string property_value: BEMO:3100023 "771c727a328004aa438f83d20410cd3600ce67ac5affa57fc6e9aaee55cb7ed9" xsd:string [Term] id: BEMO:2000208 name: Subgroup Consistency def: "The degree of agreement in subgroup across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses subgroup consistency using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in subgroup consistency can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating subgroup consistency as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000208" xsd:string property_value: BEMO:3100022 "215" xsd:string property_value: BEMO:3100023 "26cabc1a909ce4ef7d5d54dc609f85f9fea3829985a8f8573b3da07a3e225f5b" xsd:string [Term] id: BEMO:2000209 name: Temporal Generalizability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of temporal generalizability." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses temporal generalizability using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in temporal generalizability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating temporal generalizability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000209" xsd:string property_value: BEMO:3100022 "216" xsd:string property_value: BEMO:3100023 "dc35bc0fc74498ddd3acc1a47faf52ec96fba459b80f9800025d1a3d1e674317" xsd:string [Term] id: BEMO:2000210 name: Transportability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of transportability." [BEMO:source] is_a: BEMO:1100008 subset: bemo_external_validity_biomarkers_and_clinical_evidence xref: https://www.gradeworkinggroup.org/ xref: https://pubmed.ncbi.nlm.nih.gov/22007046/ xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ property_value: BEMO:3200002 "Assesses transportability using evidence appropriate to external validity and applicability, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in transportability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating transportability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Body of evidence / synthesis / outcome" xsd:string property_value: BEMO:3200009 "Clinical, epidemiologic, diagnostic, translational, and population studies" xsd:string property_value: BEMO:3200010 "GRADE; QUADAS-2; CONSORT; STROBE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000210" xsd:string property_value: BEMO:3100022 "217" xsd:string property_value: BEMO:3100023 "ef0b46b07942a1780f9e2e890b09b7edc3579f016762848aa46c4d956da3075d" xsd:string [Term] id: BEMO:2000211 name: Allelic Evidence Strength def: "The magnitude and credibility of independent evidence supporting allelic evidence." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses allelic evidence strength using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in allelic evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "ClinGen/ACMG evidence scoring; pedigree analysis; population databases; case-control data; functional assays; expert-panel review." xsd:string property_value: BEMO:3200006 "Treating allelic evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000211" xsd:string property_value: BEMO:3100022 "218" xsd:string property_value: BEMO:3100023 "2dd4a685750034c6175101f0128d889784cf621fed0cf93a74098e6b4879332b" xsd:string [Term] id: BEMO:2000212 name: Case-Control Evidence Strength def: "The magnitude and credibility of independent evidence supporting case-control evidence." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses case-control evidence strength using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in case-control evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating case-control evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000212" xsd:string property_value: BEMO:3100022 "219" xsd:string property_value: BEMO:3100023 "a2868c878aff5e68e6f9aeb87fd5a98fd776f1ca106d2e9dbad34a8cc81ecfd8" xsd:string [Term] id: BEMO:2000213 name: Case-Level Evidence Strength def: "The magnitude and credibility of independent evidence supporting case-level evidence." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses case-level evidence strength using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in case-level evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating case-level evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000213" xsd:string property_value: BEMO:3100022 "220" xsd:string property_value: BEMO:3100023 "e9e681d8a3c5b4ca82348a6cd8fe70f3f48bd8351d482c3aa492a6712873c3db" xsd:string [Term] id: BEMO:2000214 name: Co-segregation Likelihood def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of co-segregation likelihood." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses co-segregation likelihood using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in co-segregation likelihood can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "ClinGen/ACMG evidence scoring; pedigree analysis; population databases; case-control data; functional assays; expert-panel review." xsd:string property_value: BEMO:3200006 "Treating co-segregation likelihood as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000214" xsd:string property_value: BEMO:3100022 "221" xsd:string property_value: BEMO:3100023 "965b0273f9a305e64b50437dcad85ab39818fad51d561d0ac4da1daaf7d204f2" xsd:string [Term] id: BEMO:2000215 name: Computational Variant Evidence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of computational variant evidence." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses computational variant evidence using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in computational variant evidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "ClinGen/ACMG evidence scoring; pedigree analysis; population databases; case-control data; functional assays; expert-panel review." xsd:string property_value: BEMO:3200006 "Treating computational variant evidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000215" xsd:string property_value: BEMO:3100022 "222" xsd:string property_value: BEMO:3100023 "1f84faa3d8c87f3b1ed44b62077d2c489782ab72b149d6009c127395a0070a10" xsd:string [Term] id: BEMO:2000216 name: Conflicting Interpretation Burden def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of conflicting interpretation burden." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses conflicting interpretation burden using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in conflicting interpretation burden can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating conflicting interpretation burden as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000216" xsd:string property_value: BEMO:3100022 "223" xsd:string property_value: BEMO:3100023 "54567aec6ae0bbdadfae015005c07328ab45d161c0cc6d36f9e5198150b2b29e" xsd:string [Term] id: BEMO:2000217 name: De Novo Evidence Strength def: "The magnitude and credibility of independent evidence supporting de novo evidence." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses de novo evidence strength using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in de novo evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "ClinGen/ACMG evidence scoring; pedigree analysis; population databases; case-control data; functional assays; expert-panel review." xsd:string property_value: BEMO:3200006 "Treating de novo evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000217" xsd:string property_value: BEMO:3100022 "224" xsd:string property_value: BEMO:3100023 "e1a17a41d450c91691b405a890d0fa9af7ecd8fed12385f8124d85b912c16860" xsd:string [Term] id: BEMO:2000218 name: Expressivity Consistency def: "The degree of agreement in expressivity across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses expressivity consistency using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in expressivity consistency can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating expressivity consistency as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000218" xsd:string property_value: BEMO:3100022 "225" xsd:string property_value: BEMO:3100023 "d100842d4d2c367ecd1122df00784975aa0a773a92bbb5c68a8ff23fbbd4dfc4" xsd:string [Term] id: BEMO:2000219 name: Founder-Effect Assessment def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of founder-effect assessment." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses founder-effect assessment using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in founder-effect assessment can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating founder-effect assessment as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000219" xsd:string property_value: BEMO:3100022 "226" xsd:string property_value: BEMO:3100023 "6530e53b02059e4bfd6465ae64ac385198a560d8a80df4ba701894a8c5cb0975" xsd:string [Term] id: BEMO:2000220 name: Functional Variant Evidence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of functional variant evidence." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses functional variant evidence using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in functional variant evidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "ClinGen/ACMG evidence scoring; pedigree analysis; population databases; case-control data; functional assays; expert-panel review." xsd:string property_value: BEMO:3200006 "Treating functional variant evidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000220" xsd:string property_value: BEMO:3100022 "227" xsd:string property_value: BEMO:3100023 "7a71bec12dfb580d6d32593ad450868d51a755f2a8b35e7eee350ad98d24c73e" xsd:string [Term] id: BEMO:2000221 name: Gene–Disease Validity def: "The degree to which gene–disease supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses gene–disease validity using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in gene–disease validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "ClinGen/ACMG evidence scoring; pedigree analysis; population databases; case-control data; functional assays; expert-panel review." xsd:string property_value: BEMO:3200006 "Treating gene–disease validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000221" xsd:string property_value: BEMO:3100022 "228" xsd:string property_value: BEMO:3100023 "4501a0d637c0d3d7b3852d3be8f61115b2b1ac442582dd9a3ec88bd21dad9f7c" xsd:string [Term] id: BEMO:2000222 name: Genotype–Phenotype Concordance def: "The degree of agreement in genotype–phenotype across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses genotype–phenotype concordance using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in genotype–phenotype concordance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Read- and variant-level quality-control summaries; replicate concordance; orthogonal confirmation; benchmarking against reference materials." xsd:string property_value: BEMO:3200006 "Treating genotype–phenotype concordance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000222" xsd:string property_value: BEMO:3100022 "229" xsd:string property_value: BEMO:3100023 "baeee8e900a9ffef8f3ddd054b3a12f2233d89fc626f852fd31efc4b84b81685" xsd:string [Term] id: BEMO:2000223 name: Hotspot/Functional-Domain Evidence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of hotspot/functional-domain evidence." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses hotspot/functional-domain evidence using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in hotspot/functional-domain evidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating hotspot/functional-domain evidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000223" xsd:string property_value: BEMO:3100022 "230" xsd:string property_value: BEMO:3100023 "d2e72ca269dc077aef430f8efab1ad3e7adf8db5e6aa339468796f69dfaaee12" xsd:string [Term] id: BEMO:2000224 name: Locus Heterogeneity Assessment def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of locus heterogeneity assessment." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses locus heterogeneity assessment using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in locus heterogeneity assessment can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Forest plots; heterogeneity statistics; tau-squared; prediction intervals; funnel plots; regression or selection models; sensitivity analyses." xsd:string property_value: BEMO:3200006 "Treating locus heterogeneity assessment as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000224" xsd:string property_value: BEMO:3100022 "231" xsd:string property_value: BEMO:3100023 "bd3af304ec15826df5f67db7f079c0ba66a1f5f5a3e852d600550186267f50cb" xsd:string [Term] id: BEMO:2000225 name: Loss-of-Function Mechanism Validity def: "The degree to which loss-of-function mechanism supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses loss-of-function mechanism validity using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in loss-of-function mechanism validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating loss-of-function mechanism validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000225" xsd:string property_value: BEMO:3100022 "232" xsd:string property_value: BEMO:3100023 "a389d5411c414282451fe5495bf2c1c444f06ae12cd17457edf93df2953dc32e" xsd:string [Term] id: BEMO:2000226 name: Null-Variant Quality def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of null-variant quality." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses null-variant quality using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in null-variant quality can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "ClinGen/ACMG evidence scoring; pedigree analysis; population databases; case-control data; functional assays; expert-panel review." xsd:string property_value: BEMO:3200006 "Treating null-variant quality as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000226" xsd:string property_value: BEMO:3100022 "233" xsd:string property_value: BEMO:3100023 "de2f4749e64a7014070a28c9c8587efaf4dbb9b3583c2ab6e78cd6826c00de34" xsd:string [Term] id: BEMO:2000227 name: Penetrance Evidence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of penetrance evidence." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses penetrance evidence using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in penetrance evidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "ClinGen/ACMG evidence scoring; pedigree analysis; population databases; case-control data; functional assays; expert-panel review." xsd:string property_value: BEMO:3200006 "Treating penetrance evidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000227" xsd:string property_value: BEMO:3100022 "234" xsd:string property_value: BEMO:3100023 "83c8ddff797d0831554af5cae66094d559ff9fcf3cefc498edc05f2c18b6ee97" xsd:string [Term] id: BEMO:2000228 name: Phenocopy Risk def: "The probability or degree that phenocopy introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses phenocopy risk using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in phenocopy risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating phenocopy risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000228" xsd:string property_value: BEMO:3100022 "235" xsd:string property_value: BEMO:3100023 "eba377fe2c190b6390cd804f64874ad58540debe287184cfa259e70d97d1fcc8" xsd:string [Term] id: BEMO:2000229 name: Phenotypic Specificity for Variant def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of phenotypic specificity for variant." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses phenotypic specificity for variant using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in phenotypic specificity for variant can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "ClinGen/ACMG evidence scoring; pedigree analysis; population databases; case-control data; functional assays; expert-panel review." xsd:string property_value: BEMO:3200006 "Treating phenotypic specificity for variant as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000229" xsd:string property_value: BEMO:3100022 "236" xsd:string property_value: BEMO:3100023 "ae0b81578c2487ac58cc25c0925e5e5b5580990b17b1391fc512e266a26a2788" xsd:string [Term] id: BEMO:2000230 name: Population Frequency Compatibility def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of population frequency compatibility." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses population frequency compatibility using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in population frequency compatibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating population frequency compatibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000230" xsd:string property_value: BEMO:3100022 "237" xsd:string property_value: BEMO:3100023 "da2b6bc79f60e4e8121c9a5cd9a562fbe0d255feef3ecb78f1de13bffe50a0f4" xsd:string [Term] id: BEMO:2000231 name: RNA Evidence Strength def: "The magnitude and credibility of independent evidence supporting rna evidence." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses rna evidence strength using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in rna evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating rna evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000231" xsd:string property_value: BEMO:3100022 "238" xsd:string property_value: BEMO:3100023 "8e776a34bb92ed3d093c7eb03481f1c61ce724a0995235355586c28e53418e35" xsd:string [Term] id: BEMO:2000232 name: Segregation Evidence Strength def: "The magnitude and credibility of independent evidence supporting segregation evidence." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses segregation evidence strength using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in segregation evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "ClinGen/ACMG evidence scoring; pedigree analysis; population databases; case-control data; functional assays; expert-panel review." xsd:string property_value: BEMO:3200006 "Treating segregation evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000232" xsd:string property_value: BEMO:3100022 "239" xsd:string property_value: BEMO:3100023 "4f9bdcfda63260ced3f40796d43228eea03ead68f517bc87939698d4f5d4faf2" xsd:string [Term] id: BEMO:2000233 name: Splicing Evidence Strength def: "The magnitude and credibility of independent evidence supporting splicing evidence." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses splicing evidence strength using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in splicing evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating splicing evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000233" xsd:string property_value: BEMO:3100022 "240" xsd:string property_value: BEMO:3100023 "50c6384810a1443b5a98f42466fb8ab2489b57dad29ed2dab35ef7acec1960d2" xsd:string [Term] id: BEMO:2000234 name: Variant Classification Stability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of variant classification stability." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses variant classification stability using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in variant classification stability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "ClinGen/ACMG evidence scoring; pedigree analysis; population databases; case-control data; functional assays; expert-panel review." xsd:string property_value: BEMO:3200006 "Treating variant classification stability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000234" xsd:string property_value: BEMO:3100022 "241" xsd:string property_value: BEMO:3100023 "103d1dc365ad36d3caee0208333084352e814015d8cdbebbb9964106d3315f21" xsd:string [Term] id: BEMO:2000235 name: Variant Pathogenicity Evidence Strength def: "The magnitude and credibility of independent evidence supporting variant pathogenicity evidence." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses variant pathogenicity evidence strength using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in variant pathogenicity evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "ClinGen/ACMG evidence scoring; pedigree analysis; population databases; case-control data; functional assays; expert-panel review." xsd:string property_value: BEMO:3200006 "Treating variant pathogenicity evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000235" xsd:string property_value: BEMO:3100022 "242" xsd:string property_value: BEMO:3100023 "ce239eedae0622eb1018ab2bfc52cd2d32ef0a5f6a874008c2d8838deb99bd4a" xsd:string [Term] id: BEMO:2000236 name: Variant Phase Evidence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of variant phase evidence." [BEMO:source] is_a: BEMO:1100009 subset: bemo_genetics_omics_and_systems_biology xref: https://clinicalgenome.org/curation-activities/gene-disease-validity/ xref: https://pubmed.ncbi.nlm.nih.gov/25741868/ xref: https://www.equator-network.org/reporting-guidelines/strega/ xref: https://geneontology.org/docs/guide-go-evidence-codes/ property_value: BEMO:3200002 "Assesses variant phase evidence using evidence appropriate to genetics and variant evidence, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in variant phase evidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "ClinGen/ACMG evidence scoring; pedigree analysis; population databases; case-control data; functional assays; expert-panel review." xsd:string property_value: BEMO:3200006 "Treating variant phase evidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mendelian disease, cancer genetics, association, segregation, and functional studies" xsd:string property_value: BEMO:3200010 "ClinGen; ACMG AMP; STREGA; Gene Ontology" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000236" xsd:string property_value: BEMO:3100022 "243" xsd:string property_value: BEMO:3100023 "e63350cbc225389693f86f1ceb6c24e47930b1a6b522574479bcaf1390376503" xsd:string [Term] id: BEMO:2000237 name: Allelic Balance def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of allelic balance." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses allelic balance using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in allelic balance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "ClinGen/ACMG evidence scoring; pedigree analysis; population databases; case-control data; functional assays; expert-panel review." xsd:string property_value: BEMO:3200006 "Treating allelic balance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000237" xsd:string property_value: BEMO:3100022 "244" xsd:string property_value: BEMO:3100023 "0857b2292263da43e4b892ac8b30335b2a7fd8730d0baae8269f0919f1da549b" xsd:string [Term] id: BEMO:2000238 name: Alternative Splicing Validation def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of alternative splicing validation." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses alternative splicing validation using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in alternative splicing validation can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating alternative splicing validation as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000238" xsd:string property_value: BEMO:3100022 "245" xsd:string property_value: BEMO:3100023 "64b27913521868b5a9491d569eb82729fee0c3cb2133bfc9132e110785fa8847" xsd:string [Term] id: BEMO:2000239 name: Batch-Effect Control def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of batch-effect control." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses batch-effect control using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in batch-effect control can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating batch-effect control as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000239" xsd:string property_value: BEMO:3100022 "246" xsd:string property_value: BEMO:3100023 "0751d3491af658db1257b3b04a366a751c7fd0fdfb5e615ebbae3dab6970c7c9" xsd:string [Term] id: BEMO:2000240 name: Call-Rate Completeness def: "The extent to which all scientifically necessary components of call-rate are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses call-rate completeness using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in call-rate completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Read- and variant-level quality-control summaries; replicate concordance; orthogonal confirmation; benchmarking against reference materials." xsd:string property_value: BEMO:3200006 "Treating call-rate completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000240" xsd:string property_value: BEMO:3100022 "247" xsd:string property_value: BEMO:3100023 "c69a25da4615faa5675944ca32d4c5ec30a0c44f5216034581329797d9a32abc" xsd:string [Term] id: BEMO:2000241 name: Cell-Type Annotation Confidence def: "The justified degree of certainty assigned to cell-type annotation given the quantity, quality, consistency, and limitations of supporting evidence." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses cell-type annotation confidence using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in cell-type annotation confidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating cell-type annotation confidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000241" xsd:string property_value: BEMO:3100022 "248" xsd:string property_value: BEMO:3100023 "f7aebc612affb172059739df32608fb7c4d69384f1ff8c565432595eea6b9937" xsd:string [Term] id: BEMO:2000242 name: Contamination Burden def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of contamination burden." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses contamination burden using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in contamination burden can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating contamination burden as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000242" xsd:string property_value: BEMO:3100022 "249" xsd:string property_value: BEMO:3100023 "fc0cd98bc92235d469bf2bc025f0d327d8170dfb4df97b973710a8d887eff3f4" xsd:string [Term] id: BEMO:2000243 name: Cross-Platform Genomic Concordance def: "The degree of agreement in cross-platform genomic across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses cross-platform genomic concordance using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in cross-platform genomic concordance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating cross-platform genomic concordance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000243" xsd:string property_value: BEMO:3100022 "250" xsd:string property_value: BEMO:3100023 "91130249c6d3c5254de370a79251a5dce82ecc1afbe7b1276235f59ee93b7b5a" xsd:string [Term] id: BEMO:2000244 name: Differential Expression Robustness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of differential expression robustness." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses differential expression robustness using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in differential expression robustness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating differential expression robustness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000244" xsd:string property_value: BEMO:3100022 "251" xsd:string property_value: BEMO:3100023 "e70802b2991914211c0dcd91213c02319dd673fc93963b9e2064b8bca944c528" xsd:string [Term] id: BEMO:2000245 name: Duplicate Read Burden def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of duplicate read burden." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses duplicate read burden using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in duplicate read burden can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Read- and variant-level quality-control summaries; replicate concordance; orthogonal confirmation; benchmarking against reference materials." xsd:string property_value: BEMO:3200006 "Treating duplicate read burden as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000245" xsd:string property_value: BEMO:3100022 "252" xsd:string property_value: BEMO:3100023 "c1d6b63aea87c65750f96b5e3a771c6866843a2e5ba7e8081dd07af03bc0e9c5" xsd:string [Term] id: BEMO:2000246 name: Genome Coverage Uniformity def: "The proportion and representativeness of the relevant genome uniformity captured by the evidence or measurement process." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses genome coverage uniformity using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in genome coverage uniformity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating genome coverage uniformity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000246" xsd:string property_value: BEMO:3100022 "253" xsd:string property_value: BEMO:3100023 "c86e8ba8cbfb79ea4dbc1a9a4cd5da76837e35c7f45f5966b51b9734760bdf1f" xsd:string [Term] id: BEMO:2000247 name: Genotype Quality def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of genotype quality." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses genotype quality using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in genotype quality can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Read- and variant-level quality-control summaries; replicate concordance; orthogonal confirmation; benchmarking against reference materials." xsd:string property_value: BEMO:3200006 "Treating genotype quality as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000247" xsd:string property_value: BEMO:3100022 "254" xsd:string property_value: BEMO:3100023 "6b3ff41c46f655393bf02a8730b778b41b8fad3c6f62302d7543aef197484ea3" xsd:string [Term] id: BEMO:2000248 name: Hardy–Weinberg Equilibrium Compatibility def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of hardy–weinberg equilibrium compatibility." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses hardy–weinberg equilibrium compatibility using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in hardy–weinberg equilibrium compatibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating hardy–weinberg equilibrium compatibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000248" xsd:string property_value: BEMO:3100022 "255" xsd:string property_value: BEMO:3100023 "158d6abc0d325612b86f33eeb0aa8e0dbdfd4460dc9c1934f90601f28ed25284" xsd:string [Term] id: BEMO:2000249 name: Library Complexity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of library complexity." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses library complexity using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in library complexity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating library complexity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000249" xsd:string property_value: BEMO:3100022 "256" xsd:string property_value: BEMO:3100023 "fb650cc4b9fc46d550895b59d1656dada1a7ec625426686e0a708ba75b6fc5f0" xsd:string [Term] id: BEMO:2000250 name: Mapping Quality def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of mapping quality." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses mapping quality using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in mapping quality can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Read- and variant-level quality-control summaries; replicate concordance; orthogonal confirmation; benchmarking against reference materials." xsd:string property_value: BEMO:3200006 "Treating mapping quality as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000250" xsd:string property_value: BEMO:3100022 "257" xsd:string property_value: BEMO:3100023 "aef9eeffa971170a3db3642e806206bdf35806d1d8cc427e16ad9106f7e0207c" xsd:string [Term] id: BEMO:2000251 name: Normalization Adequacy def: "The extent to which normalization is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses normalization adequacy using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in normalization adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating normalization adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000251" xsd:string property_value: BEMO:3100022 "258" xsd:string property_value: BEMO:3100023 "518f55960ed771c22a0c382ff436c097ae34f4481b35b5a64e7f2cf8493778a4" xsd:string [Term] id: BEMO:2000252 name: Population Stratification Control def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of population stratification control." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses population stratification control using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in population stratification control can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating population stratification control as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000252" xsd:string property_value: BEMO:3100022 "259" xsd:string property_value: BEMO:3100023 "c82d16c5b00c0127f5b02c510a48d677f57d7580cba4dcb68dce1141e1686c1d" xsd:string [Term] id: BEMO:2000253 name: Read Quality def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of read quality." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses read quality using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in read quality can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Read- and variant-level quality-control summaries; replicate concordance; orthogonal confirmation; benchmarking against reference materials." xsd:string property_value: BEMO:3200006 "Treating read quality as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000253" xsd:string property_value: BEMO:3100022 "260" xsd:string property_value: BEMO:3100023 "e9483af6db486496b6f4b0c18d333bb38a6c500a6b80dd23beefe82c05de4acc" xsd:string [Term] id: BEMO:2000254 name: Reference Bias def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of reference bias." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses reference bias using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in reference bias can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating reference bias as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000254" xsd:string property_value: BEMO:3100022 "261" xsd:string property_value: BEMO:3100023 "7f170b7ac0b632bb15937074f6f54297bd1374274ba7dd6a71c308a1270c144b" xsd:string [Term] id: BEMO:2000255 name: Relatedness Control def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of relatedness control." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses relatedness control using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in relatedness control can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating relatedness control as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000255" xsd:string property_value: BEMO:3100022 "262" xsd:string property_value: BEMO:3100023 "c66c714b8c2b1fb9da08eabc61ab1b346b5733232f7901baf90ed1206b3491ba" xsd:string [Term] id: BEMO:2000256 name: Sample Identity Concordance def: "The degree of agreement in sample identity across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses sample identity concordance using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in sample identity concordance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating sample identity concordance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000256" xsd:string property_value: BEMO:3100022 "263" xsd:string property_value: BEMO:3100023 "cf22f061ff0a6f0403c89f061c9c86c0fdc0e5186e885958801878829549f2cd" xsd:string [Term] id: BEMO:2000257 name: Sequencing Depth Adequacy def: "The extent to which sequencing depth is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses sequencing depth adequacy using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in sequencing depth adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Read- and variant-level quality-control summaries; replicate concordance; orthogonal confirmation; benchmarking against reference materials." xsd:string property_value: BEMO:3200006 "Treating sequencing depth adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000257" xsd:string property_value: BEMO:3100022 "264" xsd:string property_value: BEMO:3100023 "719d5f0d3157f75114503dd8e8b0e75aa481929ab009d6c25b68024c7b5f71a0" xsd:string [Term] id: BEMO:2000258 name: Sex Concordance def: "The degree of agreement in sex across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses sex concordance using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in sex concordance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating sex concordance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000258" xsd:string property_value: BEMO:3100022 "265" xsd:string property_value: BEMO:3100023 "897b2797d8e6449a88906be71f955c7726607e3b28833aef8661c12a890476a4" xsd:string [Term] id: BEMO:2000259 name: Single-Cell Ambient RNA Burden def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of single-cell ambient rna burden." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses single-cell ambient rna burden using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in single-cell ambient rna burden can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating single-cell ambient rna burden as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000259" xsd:string property_value: BEMO:3100022 "266" xsd:string property_value: BEMO:3100023 "1685a23504d9a42b00cb2ea9bdca0c2daeec5f3be11cc0d479a9acb5349c658a" xsd:string [Term] id: BEMO:2000260 name: Single-Cell Doublet Burden def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of single-cell doublet burden." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses single-cell doublet burden using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in single-cell doublet burden can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating single-cell doublet burden as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000260" xsd:string property_value: BEMO:3100022 "267" xsd:string property_value: BEMO:3100023 "47e6d4bd3f64b35d8abb9925b05e112fbb1356d383dc641a47f78f8e9bbeb676" xsd:string [Term] id: BEMO:2000261 name: Single-Cell Feature Detection Rate def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of single-cell feature detection rate." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses single-cell feature detection rate using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in single-cell feature detection rate can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating single-cell feature detection rate as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000261" xsd:string property_value: BEMO:3100022 "268" xsd:string property_value: BEMO:3100023 "1ce87bfa0e14b3c49cdf26e92f3b39ba4ce32c6192d394a99b4f3b80c80031b2" xsd:string [Term] id: BEMO:2000262 name: Single-Cell Viability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of single-cell viability." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses single-cell viability using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in single-cell viability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating single-cell viability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000262" xsd:string property_value: BEMO:3100022 "269" xsd:string property_value: BEMO:3100023 "faf5bedb35b3c8e6f9b571b29c9788bb087192d600f7d5646da266201f76f5dd" xsd:string [Term] id: BEMO:2000263 name: Spatial Transcriptomic Registration Accuracy def: "The closeness of spatial transcriptomic registration to the accepted reference or true value." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses spatial transcriptomic registration accuracy using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in spatial transcriptomic registration accuracy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating spatial transcriptomic registration accuracy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000263" xsd:string property_value: BEMO:3100022 "270" xsd:string property_value: BEMO:3100023 "e61d8e9d42dcb8b644bc33652bdf4f396f77ace1c2d848fb684d0c722e5a1598" xsd:string [Term] id: BEMO:2000264 name: Strand Bias def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of strand bias." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses strand bias using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in strand bias can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Read- and variant-level quality-control summaries; replicate concordance; orthogonal confirmation; benchmarking against reference materials." xsd:string property_value: BEMO:3200006 "Treating strand bias as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000264" xsd:string property_value: BEMO:3100022 "271" xsd:string property_value: BEMO:3100023 "6ac08afc8cf99d9cd5ee94bc247ff32edf260fc542fd5e27409d9c3b702afd66" xsd:string [Term] id: BEMO:2000265 name: Transcript Quantification Reliability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of transcript quantification reliability." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses transcript quantification reliability using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in transcript quantification reliability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating transcript quantification reliability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000265" xsd:string property_value: BEMO:3100022 "272" xsd:string property_value: BEMO:3100023 "45c762be688f8b3f57f3b563b58fc816d5802e731de9aee9acb732eea429ea1a" xsd:string [Term] id: BEMO:2000266 name: Variant Call Quality def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of variant call quality." [BEMO:source] is_a: BEMO:1100010 subset: bemo_genetics_omics_and_systems_biology xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.equator-network.org/reporting-guidelines/strobe-me/ xref: https://www.ga4gh.org/ xref: https://www.humancellatlas.org/ property_value: BEMO:3200002 "Assesses variant call quality using evidence appropriate to genomics and transcriptomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in variant call quality can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "ClinGen/ACMG evidence scoring; pedigree analysis; population databases; case-control data; functional assays; expert-panel review." xsd:string property_value: BEMO:3200006 "Treating variant call quality as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Whole-genome, exome, panel, bulk/single-cell/spatial transcriptomic studies" xsd:string property_value: BEMO:3200010 "MIAME; MINSEQE; STROBE-ME; GA4GH; HCA" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000266" xsd:string property_value: BEMO:3100022 "273" xsd:string property_value: BEMO:3100023 "45320c5b96fc37b8148ee2721453c92e6bec79491a4ed2d2f6fedbc2cb99cb01" xsd:string [Term] id: BEMO:2000267 name: Accuracy def: "The closeness of accuracy to the accepted reference or true value." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses accuracy using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in accuracy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating accuracy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000267" xsd:string property_value: BEMO:3100022 "274" xsd:string property_value: BEMO:3100023 "35d988975cf78a06cb70788f89a4196551552de36a3cf47e57d2d96fc8cf41fd" xsd:string [Term] id: BEMO:2000268 name: Analytical Measurement Range def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of analytical measurement range." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses analytical measurement range using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in analytical measurement range can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating analytical measurement range as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000268" xsd:string property_value: BEMO:3100022 "275" xsd:string property_value: BEMO:3100023 "40562e2bdf0f0c373312aa0a75941fd6a83f056ba5201b300a46242b3f5457df" xsd:string [Term] id: BEMO:2000269 name: Analytical Precision def: "The closeness of repeated estimates or measurements and the narrowness of uncertainty around analytical." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses analytical precision using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in analytical precision can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating analytical precision as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000269" xsd:string property_value: BEMO:3100022 "276" xsd:string property_value: BEMO:3100023 "7c4987f5f8c3c9cca41bb28896f2392e5c664fc505d3f5db2c63ad7c10e1d04d" xsd:string [Term] id: BEMO:2000270 name: Analytical Sensitivity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of analytical sensitivity." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses analytical sensitivity using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in analytical sensitivity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating analytical sensitivity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000270" xsd:string property_value: BEMO:3100022 "277" xsd:string property_value: BEMO:3100023 "193a9fb566dfa18750368d0657f7d1e8c3de7251eea014f0d99b1b3e73df3afa" xsd:string [Term] id: BEMO:2000271 name: Analytical Specificity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of analytical specificity." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses analytical specificity using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in analytical specificity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating analytical specificity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000271" xsd:string property_value: BEMO:3100022 "278" xsd:string property_value: BEMO:3100023 "f6458dae6787eecc6dbfe775e26236c89d02f80c2f92e3575c7f9ddfa0e84b0e" xsd:string [Term] id: BEMO:2000272 name: Analytical Validity def: "The degree to which analytical supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses analytical validity using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in analytical validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating analytical validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000272" xsd:string property_value: BEMO:3100022 "279" xsd:string property_value: BEMO:3100023 "e4b1deae92fd2c549054f6f19f234dbf0b73ab8ff30ff5741db1c88b5618f6c3" xsd:string [Term] id: BEMO:2000273 name: Batch-Effect Sensitivity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of batch-effect sensitivity." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses batch-effect sensitivity using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in batch-effect sensitivity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating batch-effect sensitivity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000273" xsd:string property_value: BEMO:3100022 "280" xsd:string property_value: BEMO:3100023 "7222c30713cc035f86bae406549aaf0d4751a919d50ae68b917efd9629244d28" xsd:string [Term] id: BEMO:2000274 name: Calibration Traceability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of calibration traceability." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses calibration traceability using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in calibration traceability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating calibration traceability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000274" xsd:string property_value: BEMO:3100022 "281" xsd:string property_value: BEMO:3100023 "7d6efe540a48fdb6c1d86b381d867ad016fd03d3ba3039e34ba0dd8d59bcbf8d" xsd:string [Term] id: BEMO:2000275 name: Carryover def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of carryover." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses carryover using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in carryover can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Replicate dilution series; blank and spiked samples; reference materials; method-comparison studies; predefined CLSI/ISO acceptance criteria." xsd:string property_value: BEMO:3200006 "Treating carryover as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000275" xsd:string property_value: BEMO:3100022 "282" xsd:string property_value: BEMO:3100023 "0e987b7e93f5f6b586140ce3b08eb3d87acd863bc4cb825ee0d1e4b7b1bb3994" xsd:string [Term] id: BEMO:2000276 name: Commutability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of commutability." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses commutability using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in commutability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating commutability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000276" xsd:string property_value: BEMO:3100022 "283" xsd:string property_value: BEMO:3100023 "0d8876821c8ce33e4a6f72fcdd334c759d21fb2784bd7f9f779179758d7849c8" xsd:string [Term] id: BEMO:2000277 name: Cross-Reactivity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of cross-reactivity." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses cross-reactivity using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in cross-reactivity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating cross-reactivity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000277" xsd:string property_value: BEMO:3100022 "284" xsd:string property_value: BEMO:3100023 "1de0ffae2d83059ba1d111ea3bf309f20078d963ac7b7f912a42e8b4e10e5e32" xsd:string [Term] id: BEMO:2000278 name: Cutoff Validity def: "The degree to which cutoff supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses cutoff validity using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in cutoff validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating cutoff validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000278" xsd:string property_value: BEMO:3100022 "285" xsd:string property_value: BEMO:3100023 "f74e484a95fd67b9bd73e0f0c112bc85ddaf01e7476f82b9c24c9382fe2bfe48" xsd:string [Term] id: BEMO:2000279 name: Dilution Integrity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of dilution integrity." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses dilution integrity using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in dilution integrity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating dilution integrity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000279" xsd:string property_value: BEMO:3100022 "286" xsd:string property_value: BEMO:3100023 "a31ef0b724223ebc3d1ad0dbe731b0b7823f6b347840ea43769f01a33866757b" xsd:string [Term] id: BEMO:2000280 name: Dynamic Range def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of dynamic range." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses dynamic range using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in dynamic range can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating dynamic range as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000280" xsd:string property_value: BEMO:3100022 "287" xsd:string property_value: BEMO:3100023 "41309e5f36c397d08d76621c273137352b099c93484f2a2eca025bcf85ccffdc" xsd:string [Term] id: BEMO:2000281 name: Hook Effect Risk def: "The probability or degree that hook effect introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses hook effect risk using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in hook effect risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating hook effect risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000281" xsd:string property_value: BEMO:3100022 "288" xsd:string property_value: BEMO:3100023 "3d6a1547d736b7a958bf1c94a2df8cb5599400f10305a91c657ae1dce184650b" xsd:string [Term] id: BEMO:2000282 name: Instrument Drift def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of instrument drift." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses instrument drift using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in instrument drift can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating instrument drift as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000282" xsd:string property_value: BEMO:3100022 "289" xsd:string property_value: BEMO:3100023 "39eec82dab659b7826d3bea8f3227e8afeb55e0f15214b02955200cb8a59a8ba" xsd:string [Term] id: BEMO:2000283 name: Interference Susceptibility def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of interference susceptibility." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses interference susceptibility using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in interference susceptibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Replicate dilution series; blank and spiked samples; reference materials; method-comparison studies; predefined CLSI/ISO acceptance criteria." xsd:string property_value: BEMO:3200006 "Treating interference susceptibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000283" xsd:string property_value: BEMO:3100022 "290" xsd:string property_value: BEMO:3100023 "af7341a32f2656e5638dc5bce7ac126974e88c78554d2916a696247ebbe11d2b" xsd:string [Term] id: BEMO:2000284 name: Intermediate Precision def: "The closeness of repeated estimates or measurements and the narrowness of uncertainty around intermediate." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses intermediate precision using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in intermediate precision can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating intermediate precision as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000284" xsd:string property_value: BEMO:3100022 "291" xsd:string property_value: BEMO:3100023 "543dc6e95f52dce066f892ad8d141154500ea9d0cf35d11564c84cc551f70c3b" xsd:string [Term] id: BEMO:2000285 name: Limit of Detection def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of limit of detection." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses limit of detection using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in limit of detection can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Replicate dilution series; blank and spiked samples; reference materials; method-comparison studies; predefined CLSI/ISO acceptance criteria." xsd:string property_value: BEMO:3200006 "Treating limit of detection as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000285" xsd:string property_value: BEMO:3100022 "292" xsd:string property_value: BEMO:3100023 "32751f0c3f93a66c901d3c5cea950ee45482dac2a524a6e4ed0ddc20000649d1" xsd:string [Term] id: BEMO:2000286 name: Limit of Quantification def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of limit of quantification." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses limit of quantification using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in limit of quantification can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Replicate dilution series; blank and spiked samples; reference materials; method-comparison studies; predefined CLSI/ISO acceptance criteria." xsd:string property_value: BEMO:3200006 "Treating limit of quantification as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000286" xsd:string property_value: BEMO:3100022 "293" xsd:string property_value: BEMO:3100023 "e110a21f976b308d8a01ff42efac55157e3af426e1182c74cf700e2fb4ce3595" xsd:string [Term] id: BEMO:2000287 name: Linearity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of linearity." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses linearity using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in linearity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Replicate dilution series; blank and spiked samples; reference materials; method-comparison studies; predefined CLSI/ISO acceptance criteria." xsd:string property_value: BEMO:3200006 "Treating linearity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000287" xsd:string property_value: BEMO:3100022 "294" xsd:string property_value: BEMO:3100023 "511e3fb111714ad52a916859d22dfd9a9aa36539d615e5b295fdf52500ac32e5" xsd:string [Term] id: BEMO:2000288 name: Matrix Effect def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of matrix effect." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses matrix effect using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in matrix effect can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Replicate dilution series; blank and spiked samples; reference materials; method-comparison studies; predefined CLSI/ISO acceptance criteria." xsd:string property_value: BEMO:3200006 "Treating matrix effect as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000288" xsd:string property_value: BEMO:3100022 "295" xsd:string property_value: BEMO:3100023 "e901d4ca31939164c2ecbe0d0bed735b156c8e09a3c3f28444f5359947798b49" xsd:string [Term] id: BEMO:2000289 name: Measurement Uncertainty def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of measurement uncertainty." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses measurement uncertainty using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in measurement uncertainty can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating measurement uncertainty as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000289" xsd:string property_value: BEMO:3100022 "296" xsd:string property_value: BEMO:3100023 "02b8d5d020f47fcd1190b0fa52a15a86a5dd04748bbf2908e8c4e87ccdb4670f" xsd:string [Term] id: BEMO:2000290 name: Method Comparison Agreement def: "The degree of agreement in method comparison across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses method comparison agreement using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in method comparison agreement can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating method comparison agreement as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000290" xsd:string property_value: BEMO:3100022 "297" xsd:string property_value: BEMO:3100023 "8f2dfbddd616818e03a89990f48f31b1db69460f1919bb65cc71ee0d68b7b4f6" xsd:string [Term] id: BEMO:2000291 name: Operator Variability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of operator variability." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses operator variability using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in operator variability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating operator variability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000291" xsd:string property_value: BEMO:3100022 "298" xsd:string property_value: BEMO:3100023 "ae9e50b8f8857543ecb1eb315c23fc88dd3a028cfd40ee4377e1039431544ca0" xsd:string [Term] id: BEMO:2000292 name: Postanalytical Integrity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of postanalytical integrity." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses postanalytical integrity using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in postanalytical integrity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating postanalytical integrity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000292" xsd:string property_value: BEMO:3100022 "299" xsd:string property_value: BEMO:3100023 "b1cf2cbf0a36602510f89d4d570874b9d2148d8bd132ef3b47e7be72655f9ff3" xsd:string [Term] id: BEMO:2000293 name: Preanalytical Robustness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of preanalytical robustness." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses preanalytical robustness using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in preanalytical robustness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating preanalytical robustness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000293" xsd:string property_value: BEMO:3100022 "300" xsd:string property_value: BEMO:3100023 "b76350bac6098346689193598ba9a67fbdcf0cc16c9a9abb5e49d8238a97798b" xsd:string [Term] id: BEMO:2000294 name: Reagent Lot Consistency def: "The degree of agreement in reagent lot across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses reagent lot consistency using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in reagent lot consistency can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating reagent lot consistency as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000294" xsd:string property_value: BEMO:3100022 "301" xsd:string property_value: BEMO:3100023 "66143063e8139ffa9de4cc6fb03a0eb1778bd92be05c901387fc7af071b0e433" xsd:string [Term] id: BEMO:2000295 name: Recovery def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of recovery." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses recovery using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in recovery can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Replicate dilution series; blank and spiked samples; reference materials; method-comparison studies; predefined CLSI/ISO acceptance criteria." xsd:string property_value: BEMO:3200006 "Treating recovery as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000295" xsd:string property_value: BEMO:3100022 "302" xsd:string property_value: BEMO:3100023 "5e396bd1803ce209b22910e5705b5bf0dc26bd235bba5ac5c904b2514e3f7ea8" xsd:string [Term] id: BEMO:2000296 name: Reference Interval Validity def: "The degree to which reference interval supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses reference interval validity using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in reference interval validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating reference interval validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000296" xsd:string property_value: BEMO:3100022 "303" xsd:string property_value: BEMO:3100023 "3706e41c2a6c519ccdfb2643facf47ec1d2a45cc4b5b902e54040a5a53624b7e" xsd:string [Term] id: BEMO:2000297 name: Repeatability def: "The degree to which repeatability yields concordant results under the specified repeated-analysis or repeated-measurement conditions." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses repeatability using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in repeatability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating repeatability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000297" xsd:string property_value: BEMO:3100022 "304" xsd:string property_value: BEMO:3100023 "289ee6101d32dc64bb4644380815480f0d1de4b3d0512c355bf6d1bb8e30c7f2" xsd:string [Term] id: BEMO:2000298 name: Reportable Range def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of reportable range." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses reportable range using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in reportable range can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating reportable range as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000298" xsd:string property_value: BEMO:3100022 "305" xsd:string property_value: BEMO:3100023 "1958a10669f076f26b0e434840fd948f2a615d7e3a768038db89230b0e148857" xsd:string [Term] id: BEMO:2000299 name: Reproducibility of Measurement def: "The degree to which reproducibility of measurement yields concordant results under the specified repeated-analysis or repeated-measurement conditions." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses reproducibility of measurement using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in reproducibility of measurement can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating reproducibility of measurement as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000299" xsd:string property_value: BEMO:3100022 "306" xsd:string property_value: BEMO:3100023 "83e10528c5f3255388bb807d6bfc99c4e2c93d4f418421fcd184c242521982d5" xsd:string [Term] id: BEMO:2000300 name: Sample Stability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of sample stability." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses sample stability using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in sample stability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating sample stability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000300" xsd:string property_value: BEMO:3100022 "307" xsd:string property_value: BEMO:3100023 "42f10127b0bb2f21e12bfaaba11ee2a6c8335cd39935669d6733741eadfc7015" xsd:string [Term] id: BEMO:2000301 name: Site-to-Site Assay Portability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of site-to-site assay portability." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses site-to-site assay portability using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in site-to-site assay portability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating site-to-site assay portability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000301" xsd:string property_value: BEMO:3100022 "308" xsd:string property_value: BEMO:3100023 "c0e7317023f6c1fc290d021e4b38163503a72ee411cc671fe6aae25ee84d1ee5" xsd:string [Term] id: BEMO:2000302 name: Trueness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of trueness." [BEMO:source] is_a: BEMO:1100011 subset: bemo_measurement_assay_and_biospecimen_quality xref: https://www.fda.gov/media/119271/download xref: https://clsi.org/standards/products/method-evaluation/ xref: https://www.iso.org/standard/76677.html xref: https://pubmed.ncbi.nlm.nih.gov/19246619/ property_value: BEMO:3200002 "Assesses trueness using evidence appropriate to measurement and assay analytical validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in trueness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating trueness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Specimen / assay / run / laboratory / study" xsd:string property_value: BEMO:3200009 "Laboratory-developed tests, molecular assays, imaging, pathology, biomarker studies" xsd:string property_value: BEMO:3200010 "FDA Biomarker; CLSI; ISO 15189; MIQE" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000302" xsd:string property_value: BEMO:3100022 "309" xsd:string property_value: BEMO:3100023 "9094cf98fb975c34384185560acacc946dab62ebd8f1815100dcaac099d9df1b" xsd:string [Term] id: BEMO:2000303 name: Cross-Layer Directional Concordance def: "The degree of agreement in cross-layer directional across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses cross-layer directional concordance using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in cross-layer directional concordance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating cross-layer directional concordance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000303" xsd:string property_value: BEMO:3100022 "310" xsd:string property_value: BEMO:3100023 "89f675805a18a02e8214d03853d6a7cdcea2d29079ee839babae7605cea7a581" xsd:string [Term] id: BEMO:2000304 name: Cross-Omics Integration Coherence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of cross-omics integration coherence." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses cross-omics integration coherence using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in cross-omics integration coherence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating cross-omics integration coherence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000304" xsd:string property_value: BEMO:3100022 "311" xsd:string property_value: BEMO:3100023 "c10b406fc4ce6db5663280fc4b358cc062cc17f0ce7a593af68a762307815cdc" xsd:string [Term] id: BEMO:2000305 name: Cross-Omics Replication def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of cross-omics replication." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses cross-omics replication using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in cross-omics replication can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating cross-omics replication as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000305" xsd:string property_value: BEMO:3100022 "312" xsd:string property_value: BEMO:3100023 "5b9be25d7af680eef194d1d2e393dbdeaaf607f62c516cb41c75f5dfd1ba50b9" xsd:string [Term] id: BEMO:2000306 name: Dynamical Stability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of dynamical stability." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses dynamical stability using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in dynamical stability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating dynamical stability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000306" xsd:string property_value: BEMO:3100022 "313" xsd:string property_value: BEMO:3100023 "d58852cf510c70b8fcfa12f792791c36728adc16d59c5b9bb4b7a9b129c39f52" xsd:string [Term] id: BEMO:2000307 name: Emergent-Property Reproducibility def: "The degree to which emergent-property reproducibility yields concordant results under the specified repeated-analysis or repeated-measurement conditions." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses emergent-property reproducibility using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in emergent-property reproducibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating emergent-property reproducibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000307" xsd:string property_value: BEMO:3100022 "314" xsd:string property_value: BEMO:3100023 "e554ab3ba02f294f767076d372c3967762b850eccc356bf4d7c243480641cd98" xsd:string [Term] id: BEMO:2000308 name: Entity Resolution Accuracy def: "The closeness of entity resolution to the accepted reference or true value." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses entity resolution accuracy using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in entity resolution accuracy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating entity resolution accuracy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000308" xsd:string property_value: BEMO:3100022 "315" xsd:string property_value: BEMO:3100023 "81ae3d3ac205c8d1258be22f4b5818a5c36df354b19605060eb458cfdfef682e" xsd:string [Term] id: BEMO:2000309 name: Flux-Balance Consistency def: "The degree of agreement in flux-balance across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses flux-balance consistency using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in flux-balance consistency can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating flux-balance consistency as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000309" xsd:string property_value: BEMO:3100022 "316" xsd:string property_value: BEMO:3100023 "f8d3b19efd68e0150e437c71bac90ab2bb80f33877b4a0e74bc52542a0fd3c26" xsd:string [Term] id: BEMO:2000310 name: Knowledge-Graph Evidence Completeness def: "The extent to which all scientifically necessary components of knowledge-graph evidence are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses knowledge-graph evidence completeness using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in knowledge-graph evidence completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating knowledge-graph evidence completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000310" xsd:string property_value: BEMO:3100022 "317" xsd:string property_value: BEMO:3100023 "082de1cac908d5d8b791ddee2974743d0e0eae71997e72080a5d978e931f8b6c" xsd:string [Term] id: BEMO:2000311 name: Knowledge-Graph Provenance Quality def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of knowledge-graph provenance quality." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses knowledge-graph provenance quality using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in knowledge-graph provenance quality can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating knowledge-graph provenance quality as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000311" xsd:string property_value: BEMO:3100022 "318" xsd:string property_value: BEMO:3100023 "50aaf6749314a5ad4694891f48d60c74feaa99da022b5cc91c17f4221f0696a2" xsd:string [Term] id: BEMO:2000312 name: Latent-Factor Stability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of latent-factor stability." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses latent-factor stability using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in latent-factor stability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating latent-factor stability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000312" xsd:string property_value: BEMO:3100022 "319" xsd:string property_value: BEMO:3100023 "be1e726b2fd3735d5492ec8f375d473b36cbff860abc6d682d2065974c115c50" xsd:string [Term] id: BEMO:2000313 name: Model–Experiment Concordance def: "The degree of agreement in model–experiment across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses model–experiment concordance using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in model–experiment concordance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating model–experiment concordance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000313" xsd:string property_value: BEMO:3100022 "320" xsd:string property_value: BEMO:3100023 "433f97851837c60d123f8a332258d7d5b3872aa7c5564c19691b4c4c00871a8b" xsd:string [Term] id: BEMO:2000314 name: Module Stability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of module stability." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses module stability using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in module stability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating module stability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000314" xsd:string property_value: BEMO:3100022 "321" xsd:string property_value: BEMO:3100023 "191acd0c1abb112365dc2e82b9a1c639642c0798eb52983d078ac92e3f0fbeec" xsd:string [Term] id: BEMO:2000315 name: Network Edge Confidence def: "The justified degree of certainty assigned to network edge given the quantity, quality, consistency, and limitations of supporting evidence." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses network edge confidence using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in network edge confidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating network edge confidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000315" xsd:string property_value: BEMO:3100022 "322" xsd:string property_value: BEMO:3100023 "6118b228a2af4e149e82150fb026ef08cdd6d05b9748a0128d6e8c14f147784c" xsd:string [Term] id: BEMO:2000316 name: Network Node Confidence def: "The justified degree of certainty assigned to network node given the quantity, quality, consistency, and limitations of supporting evidence." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses network node confidence using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in network node confidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating network node confidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000316" xsd:string property_value: BEMO:3100022 "323" xsd:string property_value: BEMO:3100023 "79eaf0a8e6c6fc3012d48e379c545c17d89aecf6de033d40ae6399ec89441a3b" xsd:string [Term] id: BEMO:2000317 name: Network Reconstruction Robustness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of network reconstruction robustness." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses network reconstruction robustness using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in network reconstruction robustness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating network reconstruction robustness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000317" xsd:string property_value: BEMO:3100022 "324" xsd:string property_value: BEMO:3100023 "0b4f2bdfa3ccc3b3abdb67b1f3be15b6d8479743942152580ad3f1929db67d5f" xsd:string [Term] id: BEMO:2000318 name: Ontology Annotation Completeness def: "The extent to which all scientifically necessary components of ontology annotation are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses ontology annotation completeness using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in ontology annotation completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating ontology annotation completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000318" xsd:string property_value: BEMO:3100022 "325" xsd:string property_value: BEMO:3100023 "b8714924720c209e415f9bf2c9aaf707f6bf0edbbbf6ca8da11d2546f9da563d" xsd:string [Term] id: BEMO:2000319 name: Ontology Evidence-Code Strength def: "The magnitude and credibility of independent evidence supporting ontology evidence-code." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses ontology evidence-code strength using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in ontology evidence-code strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating ontology evidence-code strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000319" xsd:string property_value: BEMO:3100022 "326" xsd:string property_value: BEMO:3100023 "98cc3b5d977b0d0bd7a309c477d2653f05eeb7554078021a2d0b2bf21036d891" xsd:string [Term] id: BEMO:2000320 name: Parameter Identifiability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of parameter identifiability." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses parameter identifiability using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in parameter identifiability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating parameter identifiability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000320" xsd:string property_value: BEMO:3100022 "327" xsd:string property_value: BEMO:3100023 "e1eaab072c302dca725ea1fb92e565c0aead2c5a6ddd49490dbfa43ad163dd03" xsd:string [Term] id: BEMO:2000321 name: Parameter Sensitivity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of parameter sensitivity." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses parameter sensitivity using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in parameter sensitivity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating parameter sensitivity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000321" xsd:string property_value: BEMO:3100022 "328" xsd:string property_value: BEMO:3100023 "9735c06335e80bafcbeea74ccb7b405e18e8684330b82448424f6e83ef3974ba" xsd:string [Term] id: BEMO:2000322 name: Pathway Enrichment Consistency def: "The degree of agreement in pathway enrichment across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses pathway enrichment consistency using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in pathway enrichment consistency can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating pathway enrichment consistency as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000322" xsd:string property_value: BEMO:3100022 "329" xsd:string property_value: BEMO:3100023 "d7e323b8eddcaff29fe662695a2fa9bae2a0f04120cfdf422fa3e2d1cd3b117e" xsd:string [Term] id: BEMO:2000323 name: Pathway Topology Support def: "The magnitude and credibility of independent evidence supporting pathway topology." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses pathway topology support using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in pathway topology support can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating pathway topology support as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000323" xsd:string property_value: BEMO:3100022 "330" xsd:string property_value: BEMO:3100023 "f408d8b817c9e3179698dad395d8e94ea187b92ae192e0ab52e026106d82f40a" xsd:string [Term] id: BEMO:2000324 name: Perturbation Prediction Accuracy def: "The closeness of perturbation prediction to the accepted reference or true value." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses perturbation prediction accuracy using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in perturbation prediction accuracy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating perturbation prediction accuracy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000324" xsd:string property_value: BEMO:3100022 "331" xsd:string property_value: BEMO:3100023 "5cc466b3de703eb697570667c57a9230690c56d69b5cf6ec528e42740ec621e9" xsd:string [Term] id: BEMO:2000325 name: Practical Identifiability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of practical identifiability." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses practical identifiability using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in practical identifiability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating practical identifiability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000325" xsd:string property_value: BEMO:3100022 "332" xsd:string property_value: BEMO:3100023 "cb110edeb57b36960477192ea5d1484823905d046fc0f22c33bc8eb340c3c4c3" xsd:string [Term] id: BEMO:2000326 name: Relation Evidence Strength def: "The magnitude and credibility of independent evidence supporting relation evidence." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses relation evidence strength using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in relation evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating relation evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000326" xsd:string property_value: BEMO:3100022 "333" xsd:string property_value: BEMO:3100023 "9009911ac3f6266273d49aa664b528314dd25468ab2969a5c3dfb8593502a99c" xsd:string [Term] id: BEMO:2000327 name: Steady-State Validity def: "The degree to which steady-state supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses steady-state validity using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in steady-state validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating steady-state validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000327" xsd:string property_value: BEMO:3100022 "334" xsd:string property_value: BEMO:3100023 "3a349724361b2712b35c94baaaa135ce8e313533d3edafc463242f1cddef411b" xsd:string [Term] id: BEMO:2000328 name: Structural Identifiability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of structural identifiability." [BEMO:source] is_a: BEMO:1100012 subset: bemo_genetics_omics_and_systems_biology xref: https://geneontology.org/docs/guide-go-evidence-codes/ xref: https://reactome.org/ xref: https://www.uniprot.org/help/evidences xref: https://www.ga4gh.org/ property_value: BEMO:3200002 "Assesses structural identifiability using evidence appropriate to multi-omics and systems biology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in structural identifiability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating structural identifiability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Dataset / model / pathway / network / evidence body" xsd:string property_value: BEMO:3200009 "Integrated omics, networks, pathways, mechanistic and dynamic systems models" xsd:string property_value: BEMO:3200010 "Gene Ontology; Reactome; UniProt; GA4GH" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000328" xsd:string property_value: BEMO:3100022 "335" xsd:string property_value: BEMO:3100023 "36fbdf592582d2c048b53d43d95edfca8afe5d6c7c93d352f32f2a7d7644cfbe" xsd:string [Term] id: BEMO:2000329 name: Adverse Outcome Pathway Support def: "The magnitude and credibility of independent evidence supporting adverse outcome pathway." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses adverse outcome pathway support using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in adverse outcome pathway support can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating adverse outcome pathway support as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000329" xsd:string property_value: BEMO:3100022 "336" xsd:string property_value: BEMO:3100023 "8935703e7b30761e4213b86ddafc1aecae0696f4523a201860d9e64493990a74" xsd:string [Term] id: BEMO:2000330 name: Benchmark Dose Reliability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of benchmark dose reliability." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses benchmark dose reliability using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in benchmark dose reliability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating benchmark dose reliability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000330" xsd:string property_value: BEMO:3100022 "337" xsd:string property_value: BEMO:3100023 "43d4a4ce7127bc52167a879f611c41413072f25e775dbe7c9446cf4028783b10" xsd:string [Term] id: BEMO:2000331 name: Bioavailability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of bioavailability." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses bioavailability using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in bioavailability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating bioavailability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000331" xsd:string property_value: BEMO:3100022 "338" xsd:string property_value: BEMO:3100023 "1dbec5a00f53d17cad5a3a88dd4dfde9ceab9bbbe33a898c76c7086698d1a0a2" xsd:string [Term] id: BEMO:2000332 name: Carcinogenicity Evidence Strength def: "The magnitude and credibility of independent evidence supporting carcinogenicity evidence." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses carcinogenicity evidence strength using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in carcinogenicity evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating carcinogenicity evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000332" xsd:string property_value: BEMO:3100022 "339" xsd:string property_value: BEMO:3100023 "a171459b41fd9ad0436588a80669a48227118c77c3d87194654b56ab6dfa6ad7" xsd:string [Term] id: BEMO:2000333 name: Developmental Toxicity Evidence Strength def: "The magnitude and credibility of independent evidence supporting developmental toxicity evidence." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses developmental toxicity evidence strength using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in developmental toxicity evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating developmental toxicity evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000333" xsd:string property_value: BEMO:3100022 "340" xsd:string property_value: BEMO:3100023 "f5636ed02b8746eb48d98671b027c695a8940399bff60ebeae8ca955d99bae6a" xsd:string [Term] id: BEMO:2000334 name: Dose Proportionality def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of dose proportionality." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses dose proportionality using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in dose proportionality can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating dose proportionality as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000334" xsd:string property_value: BEMO:3100022 "341" xsd:string property_value: BEMO:3100023 "6d7bafb114f62ee059333139662f0dfa2a0fb0aaab829ac8fcdb03ed2fbd0708" xsd:string [Term] id: BEMO:2000335 name: Drug–Drug Interaction Evidence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of drug–drug interaction evidence." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses drug–drug interaction evidence using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in drug–drug interaction evidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating drug–drug interaction evidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000335" xsd:string property_value: BEMO:3100022 "342" xsd:string property_value: BEMO:3100023 "3a82aa8a1751fa8372cd9735fd975781682a359be68aacfb1d0d78e896d96ce5" xsd:string [Term] id: BEMO:2000336 name: Efficacy Reproducibility def: "The degree to which efficacy reproducibility yields concordant results under the specified repeated-analysis or repeated-measurement conditions." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses efficacy reproducibility using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in efficacy reproducibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating efficacy reproducibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000336" xsd:string property_value: BEMO:3100022 "343" xsd:string property_value: BEMO:3100023 "e3d46320b779b7100a656dae6dcb02f7b9eae6762c1680f48b9313843cb64c84" xsd:string [Term] id: BEMO:2000337 name: Exposure–Response Relationship def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of exposure–response relationship." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses exposure–response relationship using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in exposure–response relationship can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating exposure–response relationship as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000337" xsd:string property_value: BEMO:3100022 "344" xsd:string property_value: BEMO:3100023 "882d0346f9d5903a7e9b6a2b5ae992e9e24bd2be9c7e249168f2f9e157dc0354" xsd:string [Term] id: BEMO:2000338 name: Genotoxicity Evidence Strength def: "The magnitude and credibility of independent evidence supporting genotoxicity evidence." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses genotoxicity evidence strength using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in genotoxicity evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating genotoxicity evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000338" xsd:string property_value: BEMO:3100022 "345" xsd:string property_value: BEMO:3100023 "e40592e267890e51ad35407c7dc2af7775fdac9174afe2f08486d28a5e2901b8" xsd:string [Term] id: BEMO:2000339 name: Human-Relevance of Toxicological Evidence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of human-relevance of toxicological evidence." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses human-relevance of toxicological evidence using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in human-relevance of toxicological evidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating human-relevance of toxicological evidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000339" xsd:string property_value: BEMO:3100022 "346" xsd:string property_value: BEMO:3100023 "32b4aadfeeab004a7a018b1fe09f04f0b2283eb92e7749123f8ac828db8cfce6" xsd:string [Term] id: BEMO:2000340 name: Immunotoxicity Evidence Strength def: "The magnitude and credibility of independent evidence supporting immunotoxicity evidence." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses immunotoxicity evidence strength using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in immunotoxicity evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating immunotoxicity evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000340" xsd:string property_value: BEMO:3100022 "347" xsd:string property_value: BEMO:3100023 "577a4370c7a1dc270882fc655889fdc7a0b8ee20d5e6f81f1f733233db939fbd" xsd:string [Term] id: BEMO:2000341 name: Lowest-Observed-Adverse-Effect Level Robustness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of lowest-observed-adverse-effect level robustness." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses lowest-observed-adverse-effect level robustness using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in lowest-observed-adverse-effect level robustness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating lowest-observed-adverse-effect level robustness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000341" xsd:string property_value: BEMO:3100022 "348" xsd:string property_value: BEMO:3100023 "cd00c7765086fbbe65040e649de98f22bdf10298c91d8da0f6e7300a18f0ba9f" xsd:string [Term] id: BEMO:2000342 name: Metabolite Coverage def: "The proportion and representativeness of the relevant metabolite captured by the evidence or measurement process." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses metabolite coverage using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in metabolite coverage can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Target-decoy analysis; spectral scoring; reference standards; replicate injections; retention-time and mass-error monitoring; orthogonal confirmation." xsd:string property_value: BEMO:3200006 "Treating metabolite coverage as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000342" xsd:string property_value: BEMO:3100022 "349" xsd:string property_value: BEMO:3100023 "4bb05358971c228c81cd2238f505b14da043cabfc3f68e3d2dd07884c7f72bc5" xsd:string [Term] id: BEMO:2000343 name: Mixture Interaction Assessment def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of mixture interaction assessment." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses mixture interaction assessment using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in mixture interaction assessment can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating mixture interaction assessment as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000343" xsd:string property_value: BEMO:3100022 "350" xsd:string property_value: BEMO:3100023 "241ffa4364ee9325fbb3832728344d8484375a1aca172f524b6f871b9dc07687" xsd:string [Term] id: BEMO:2000344 name: No-Observed-Adverse-Effect Level Robustness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of no-observed-adverse-effect level robustness." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses no-observed-adverse-effect level robustness using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in no-observed-adverse-effect level robustness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating no-observed-adverse-effect level robustness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000344" xsd:string property_value: BEMO:3100022 "351" xsd:string property_value: BEMO:3100023 "f5f71661574e809d9eb1b7625ffde603665b4c0d25ddbb968f6b8d1a88c38a42" xsd:string [Term] id: BEMO:2000345 name: Organ-Specific Toxicity Evidence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of organ-specific toxicity evidence." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses organ-specific toxicity evidence using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in organ-specific toxicity evidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating organ-specific toxicity evidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000345" xsd:string property_value: BEMO:3100022 "352" xsd:string property_value: BEMO:3100023 "277a918d22b52db9e79eabf5451f64320f342f326be1cc2382f16c69ec72f0a9" xsd:string [Term] id: BEMO:2000346 name: Pharmacodynamic Adequacy def: "The extent to which pharmacodynamic is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses pharmacodynamic adequacy using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in pharmacodynamic adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating pharmacodynamic adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000346" xsd:string property_value: BEMO:3100022 "353" xsd:string property_value: BEMO:3100023 "99eef93672d2993b0ec131c09788c14463fd2a5166870e81b6b8d81c3637506b" xsd:string [Term] id: BEMO:2000347 name: Pharmacokinetic Adequacy def: "The extent to which pharmacokinetic is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses pharmacokinetic adequacy using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in pharmacokinetic adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating pharmacokinetic adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000347" xsd:string property_value: BEMO:3100022 "354" xsd:string property_value: BEMO:3100023 "2b02efdd0f6a774096cee910d90b575b8f28f136a8ee594876642fb213f66330" xsd:string [Term] id: BEMO:2000348 name: Pharmacological Target Validity def: "The degree to which pharmacological target supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses pharmacological target validity using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in pharmacological target validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating pharmacological target validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000348" xsd:string property_value: BEMO:3100022 "355" xsd:string property_value: BEMO:3100023 "2cff4752043ea892788f37639d922b1a249d83c13dfedf581ad1a4ad12ab95b8" xsd:string [Term] id: BEMO:2000349 name: Potency Reproducibility def: "The degree to which potency reproducibility yields concordant results under the specified repeated-analysis or repeated-measurement conditions." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses potency reproducibility using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in potency reproducibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating potency reproducibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000349" xsd:string property_value: BEMO:3100022 "356" xsd:string property_value: BEMO:3100023 "2199b92ac6c23ce1866fa6fdae782c65a478ec51834e2f0193f79d608ea4c3e7" xsd:string [Term] id: BEMO:2000350 name: Receptor Occupancy Evidence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of receptor occupancy evidence." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses receptor occupancy evidence using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in receptor occupancy evidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating receptor occupancy evidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000350" xsd:string property_value: BEMO:3100022 "357" xsd:string property_value: BEMO:3100023 "5025e34702ce03c8ed7e7aa3ed95dd9bde6bac1786183651ce608b34ffcc6a28" xsd:string [Term] id: BEMO:2000351 name: Reproductive Toxicity Evidence Strength def: "The magnitude and credibility of independent evidence supporting reproductive toxicity evidence." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses reproductive toxicity evidence strength using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in reproductive toxicity evidence strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating reproductive toxicity evidence strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000351" xsd:string property_value: BEMO:3100022 "358" xsd:string property_value: BEMO:3100023 "1725f0845040d88689ff2869cde10ea44454b5cfaa1c303d02071f7ff5ccb751" xsd:string [Term] id: BEMO:2000352 name: Safety Margin Evidence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of safety margin evidence." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses safety margin evidence using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in safety margin evidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating safety margin evidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000352" xsd:string property_value: BEMO:3100022 "359" xsd:string property_value: BEMO:3100023 "51ce0324d6952becbbadfd71ba2913a1f56afbcc33aa0148093d10994d18697d" xsd:string [Term] id: BEMO:2000353 name: Selectivity Profile def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of selectivity profile." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses selectivity profile using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in selectivity profile can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating selectivity profile as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000353" xsd:string property_value: BEMO:3100022 "360" xsd:string property_value: BEMO:3100023 "2957579a3d734fc808c8a89eb160fb182b5f5a0f68ba40c4eecc1921dea93153" xsd:string [Term] id: BEMO:2000354 name: Species Extrapolation Validity def: "The degree to which species extrapolation supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses species extrapolation validity using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in species extrapolation validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating species extrapolation validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000354" xsd:string property_value: BEMO:3100022 "361" xsd:string property_value: BEMO:3100023 "f3eb077ab3d21773df18d06eb29c8a11272ed7cbfe8f22da0ffedd8a171bc393" xsd:string [Term] id: BEMO:2000355 name: Therapeutic Window Evidence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of therapeutic window evidence." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses therapeutic window evidence using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in therapeutic window evidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating therapeutic window evidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000355" xsd:string property_value: BEMO:3100022 "362" xsd:string property_value: BEMO:3100023 "34f5d4730ddbb7e269fc6713d96c49c0fba2d2f738ddbfb47d339a6ed5f8cf6e" xsd:string [Term] id: BEMO:2000356 name: Time–Concentration Profile Adequacy def: "The extent to which time–concentration profile is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses time–concentration profile adequacy using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in time–concentration profile adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating time–concentration profile adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000356" xsd:string property_value: BEMO:3100022 "363" xsd:string property_value: BEMO:3100023 "8bfcea065494f7118cb14f95a9459e3f35fa404437872877955c4fdff069147a" xsd:string [Term] id: BEMO:2000357 name: Toxicokinetic Concordance def: "The degree of agreement in toxicokinetic across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses toxicokinetic concordance using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in toxicokinetic concordance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating toxicokinetic concordance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000357" xsd:string property_value: BEMO:3100022 "364" xsd:string property_value: BEMO:3100023 "6cda2f6cb167ccc21d05523345b2fef382432ceed6ebbcbe84fa383cddc4562e" xsd:string [Term] id: BEMO:2000358 name: Toxicological Mode-of-Action Support def: "The magnitude and credibility of independent evidence supporting toxicological mode-of-action." [BEMO:source] is_a: BEMO:1100013 subset: bemo_pharmacology_and_toxicology xref: https://www.oecd.org/chemicalsafety/testing/oecd-guidelines-testing-chemicals-related-documents.htm xref: https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/handbook xref: https://www.fda.gov/media/119271/download xref: https://www.ema.europa.eu/en/ich-e16-genomic-biomarkers-related-drug-response-context-structure-format-qualification-submissions-scientific-guideline property_value: BEMO:3200002 "Assesses toxicological mode-of-action support using evidence appropriate to pharmacology and toxicology, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in toxicological mode-of-action support can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating toxicological mode-of-action support as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Pharmacology, pharmacokinetics, toxicology, safety and mode-of-action studies" xsd:string property_value: BEMO:3200010 "OECD; OHAT; FDA Biomarker; EMA E16" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000358" xsd:string property_value: BEMO:3100022 "365" xsd:string property_value: BEMO:3100023 "05b74bda1c6ce0d8b99d4d0ffdc239f28a207c0631f25d1605f8d1438c74148a" xsd:string [Term] id: BEMO:2000359 name: Cross-Omics Concordance def: "The degree of agreement in cross-omics across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses cross-omics concordance using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in cross-omics concordance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating cross-omics concordance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000359" xsd:string property_value: BEMO:3100022 "366" xsd:string property_value: BEMO:3100023 "447ad3207c1d5333015f6a5189727d810a3a517e4d6a4351f8dc28acbe93a5f0" xsd:string [Term] id: BEMO:2000360 name: Derivatization Efficiency def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of derivatization efficiency." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses derivatization efficiency using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in derivatization efficiency can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating derivatization efficiency as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000360" xsd:string property_value: BEMO:3100022 "367" xsd:string property_value: BEMO:3100023 "d83b78fc8beda508a5c18da8dbb9e284c948a9741d4fb8d070f9f30bc9267827" xsd:string [Term] id: BEMO:2000361 name: Dynamic Range Coverage def: "The proportion and representativeness of the relevant dynamic range captured by the evidence or measurement process." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses dynamic range coverage using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in dynamic range coverage can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating dynamic range coverage as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000361" xsd:string property_value: BEMO:3100022 "368" xsd:string property_value: BEMO:3100023 "57e4c77ea2a48565f0758aadf8529c7db52bab9beb67f6e9c8366f0f3232e753" xsd:string [Term] id: BEMO:2000362 name: Extraction Recovery def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of extraction recovery." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses extraction recovery using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in extraction recovery can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Replicate dilution series; blank and spiked samples; reference materials; method-comparison studies; predefined CLSI/ISO acceptance criteria." xsd:string property_value: BEMO:3200006 "Treating extraction recovery as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000362" xsd:string property_value: BEMO:3100022 "369" xsd:string property_value: BEMO:3100023 "5024c9034e231e8bc296cf1d9092cc063fe94890f4856d8bf70ac077514b55f9" xsd:string [Term] id: BEMO:2000363 name: False Discovery Rate Control def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of false discovery rate control." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses false discovery rate control using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in false discovery rate control can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating false discovery rate control as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000363" xsd:string property_value: BEMO:3100022 "370" xsd:string property_value: BEMO:3100023 "4059adb92dbe8fea43e57c309bf3c42531450ae52d814c6f79932af37f2f97a2" xsd:string [Term] id: BEMO:2000364 name: Fragmentation Spectrum Quality def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of fragmentation spectrum quality." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses fragmentation spectrum quality using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in fragmentation spectrum quality can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Target-decoy analysis; spectral scoring; reference standards; replicate injections; retention-time and mass-error monitoring; orthogonal confirmation." xsd:string property_value: BEMO:3200006 "Treating fragmentation spectrum quality as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000364" xsd:string property_value: BEMO:3100022 "371" xsd:string property_value: BEMO:3100023 "4295f539b87882bc52461f7bd190419d6afdf7864927b9a24efe1e5f65c9fcd7" xsd:string [Term] id: BEMO:2000365 name: Internal Standard Performance def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of internal standard performance." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses internal standard performance using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in internal standard performance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating internal standard performance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000365" xsd:string property_value: BEMO:3100022 "372" xsd:string property_value: BEMO:3100023 "904dce77d19fcc637d6eae56d2d92b19b7052fd578de120e2a18bb08d00f2f54" xsd:string [Term] id: BEMO:2000366 name: Ion Suppression Assessment def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of ion suppression assessment." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses ion suppression assessment using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in ion suppression assessment can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating ion suppression assessment as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000366" xsd:string property_value: BEMO:3100022 "373" xsd:string property_value: BEMO:3100023 "c108ebf1ca903ed7e96063f24ecaf39723dd5e925f97d641601f89fd859897b9" xsd:string [Term] id: BEMO:2000367 name: Isotope Pattern Fidelity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of isotope pattern fidelity." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses isotope pattern fidelity using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in isotope pattern fidelity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating isotope pattern fidelity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000367" xsd:string property_value: BEMO:3100022 "374" xsd:string property_value: BEMO:3100023 "beec5d62727ea3baba10451d532801205b190af60b03027284c15989d51ba1e4" xsd:string [Term] id: BEMO:2000368 name: Mass Accuracy def: "The closeness of mass to the accepted reference or true value." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses mass accuracy using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in mass accuracy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Target-decoy analysis; spectral scoring; reference standards; replicate injections; retention-time and mass-error monitoring; orthogonal confirmation." xsd:string property_value: BEMO:3200006 "Treating mass accuracy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000368" xsd:string property_value: BEMO:3100022 "375" xsd:string property_value: BEMO:3100023 "ebb0e828e6a056d20bce6788aee10b743cfcc2fc175a82fd693585711880ff73" xsd:string [Term] id: BEMO:2000369 name: Metabolic Feature Reproducibility def: "The degree to which metabolic feature reproducibility yields concordant results under the specified repeated-analysis or repeated-measurement conditions." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses metabolic feature reproducibility using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in metabolic feature reproducibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating metabolic feature reproducibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000369" xsd:string property_value: BEMO:3100022 "376" xsd:string property_value: BEMO:3100023 "521bf8b7c1bbe892685e95c05cc7d63a05c4e26119e9951d705ff460b3bb99d1" xsd:string [Term] id: BEMO:2000370 name: Metabolite Annotation Level def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of metabolite annotation level." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses metabolite annotation level using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in metabolite annotation level can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Target-decoy analysis; spectral scoring; reference standards; replicate injections; retention-time and mass-error monitoring; orthogonal confirmation." xsd:string property_value: BEMO:3200006 "Treating metabolite annotation level as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000370" xsd:string property_value: BEMO:3100022 "377" xsd:string property_value: BEMO:3100023 "883e5fdd2ff9e198b3ddcbafc3e6478eed144bbcc7f46c67f19ec93850e8ec4c" xsd:string [Term] id: BEMO:2000371 name: Metabolite Identification Confidence def: "The justified degree of certainty assigned to metabolite identification given the quantity, quality, consistency, and limitations of supporting evidence." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses metabolite identification confidence using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in metabolite identification confidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Target-decoy analysis; spectral scoring; reference standards; replicate injections; retention-time and mass-error monitoring; orthogonal confirmation." xsd:string property_value: BEMO:3200006 "Treating metabolite identification confidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000371" xsd:string property_value: BEMO:3100022 "378" xsd:string property_value: BEMO:3100023 "dd08774f62d4c8036bc0f7c590a94eca58c7ca0613c38dec0e386cab59cc0dbd" xsd:string [Term] id: BEMO:2000372 name: Missing-Value Burden def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of missing-value burden." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses missing-value burden using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in missing-value burden can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating missing-value burden as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000372" xsd:string property_value: BEMO:3100022 "379" xsd:string property_value: BEMO:3100023 "770bd2fa8c1eedf14831e8e8caca6d53a1ad4a7b7272433891be0eac41a4e30c" xsd:string [Term] id: BEMO:2000373 name: Pathway Enrichment Robustness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of pathway enrichment robustness." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses pathway enrichment robustness using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in pathway enrichment robustness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating pathway enrichment robustness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000373" xsd:string property_value: BEMO:3100022 "380" xsd:string property_value: BEMO:3100023 "1a891a794290e0f5eee9ca88b64bc6b46d5840f63c8709e0e546399158fbb914" xsd:string [Term] id: BEMO:2000374 name: Peptide Identification Confidence def: "The justified degree of certainty assigned to peptide identification given the quantity, quality, consistency, and limitations of supporting evidence." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses peptide identification confidence using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in peptide identification confidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Target-decoy analysis; spectral scoring; reference standards; replicate injections; retention-time and mass-error monitoring; orthogonal confirmation." xsd:string property_value: BEMO:3200006 "Treating peptide identification confidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000374" xsd:string property_value: BEMO:3100022 "381" xsd:string property_value: BEMO:3100023 "7f78eede8aa05781dde3f12d7ea8111e1c0b552f5b722c402b0de5323e65b0ea" xsd:string [Term] id: BEMO:2000375 name: Peptide-Spectrum Match Quality def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of peptide-spectrum match quality." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses peptide-spectrum match quality using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in peptide-spectrum match quality can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Target-decoy analysis; spectral scoring; reference standards; replicate injections; retention-time and mass-error monitoring; orthogonal confirmation." xsd:string property_value: BEMO:3200006 "Treating peptide-spectrum match quality as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000375" xsd:string property_value: BEMO:3100022 "382" xsd:string property_value: BEMO:3100023 "69f7898b8265a7daaa45bd90d4d5387c92da6521721d3c4901a5c208a63f0169" xsd:string [Term] id: BEMO:2000376 name: Post-Translational Modification Localization Confidence def: "The justified degree of certainty assigned to post-translational modification localization given the quantity, quality, consistency, and limitations of supporting evidence." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses post-translational modification localization confidence using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in post-translational modification localization confidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating post-translational modification localization confidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000376" xsd:string property_value: BEMO:3100022 "383" xsd:string property_value: BEMO:3100023 "6761ab89a934b85357a2d58a5e53503065037a8cd658104babdb5536291a3653" xsd:string [Term] id: BEMO:2000377 name: Protein Identification Confidence def: "The justified degree of certainty assigned to protein identification given the quantity, quality, consistency, and limitations of supporting evidence." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses protein identification confidence using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in protein identification confidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Target-decoy analysis; spectral scoring; reference standards; replicate injections; retention-time and mass-error monitoring; orthogonal confirmation." xsd:string property_value: BEMO:3200006 "Treating protein identification confidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000377" xsd:string property_value: BEMO:3100022 "384" xsd:string property_value: BEMO:3100023 "86cf8ad175ebd274f625e908935f946750c2c41a33f40e7a8dc33224d8db7d28" xsd:string [Term] id: BEMO:2000378 name: Protein Inference Reliability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of protein inference reliability." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses protein inference reliability using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in protein inference reliability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Target-decoy analysis; spectral scoring; reference standards; replicate injections; retention-time and mass-error monitoring; orthogonal confirmation." xsd:string property_value: BEMO:3200006 "Treating protein inference reliability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000378" xsd:string property_value: BEMO:3100022 "385" xsd:string property_value: BEMO:3100023 "601ad0978c475da6065d2502b00169f5521ae97cb0543ad15ad88f49903cb27e" xsd:string [Term] id: BEMO:2000379 name: Proteoform Identification Confidence def: "The justified degree of certainty assigned to proteoform identification given the quantity, quality, consistency, and limitations of supporting evidence." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses proteoform identification confidence using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in proteoform identification confidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating proteoform identification confidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000379" xsd:string property_value: BEMO:3100022 "386" xsd:string property_value: BEMO:3100023 "8df86e86625f432ba76b927808300a9cfa4a9b6844cae40ca0c6240f4f899eda" xsd:string [Term] id: BEMO:2000380 name: Proteome Coverage def: "The proportion and representativeness of the relevant proteome captured by the evidence or measurement process." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses proteome coverage using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in proteome coverage can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating proteome coverage as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000380" xsd:string property_value: BEMO:3100022 "387" xsd:string property_value: BEMO:3100023 "5fec1390446b523e8b6072b1babcb11902375d326650ad448b800e258e0a8401" xsd:string [Term] id: BEMO:2000381 name: Quantification Accuracy def: "The closeness of quantification to the accepted reference or true value." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses quantification accuracy using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in quantification accuracy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating quantification accuracy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000381" xsd:string property_value: BEMO:3100022 "388" xsd:string property_value: BEMO:3100023 "5205abd1da59c18e5b7272ce8586c2ec2bee590ad36aa3289ce71f4aa4c17c0b" xsd:string [Term] id: BEMO:2000382 name: Quantification Precision def: "The closeness of repeated estimates or measurements and the narrowness of uncertainty around quantification." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses quantification precision using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in quantification precision can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating quantification precision as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000382" xsd:string property_value: BEMO:3100022 "389" xsd:string property_value: BEMO:3100023 "6e5af7c1fffa7603da0abd7518a670fd09cade5fe3e47c8417886f91e6b4e07a" xsd:string [Term] id: BEMO:2000383 name: Retention-Time Stability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of retention-time stability." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses retention-time stability using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in retention-time stability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Target-decoy analysis; spectral scoring; reference standards; replicate injections; retention-time and mass-error monitoring; orthogonal confirmation." xsd:string property_value: BEMO:3200006 "Treating retention-time stability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000383" xsd:string property_value: BEMO:3100022 "390" xsd:string property_value: BEMO:3100023 "7ed489b83705dc957b891fd6483e7b54ca4c70547f903f7dfa9e53d0ca59fa58" xsd:string [Term] id: BEMO:2000384 name: Sequence Coverage def: "The proportion and representativeness of the relevant sequence captured by the evidence or measurement process." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses sequence coverage using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in sequence coverage can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating sequence coverage as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000384" xsd:string property_value: BEMO:3100022 "391" xsd:string property_value: BEMO:3100023 "f98e41911ad517a10150d0d24373bec15a553a9812e119c2e6a10081e9a89aaf" xsd:string [Term] id: BEMO:2000385 name: Spectral Library Match Quality def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of spectral library match quality." [BEMO:source] is_a: BEMO:1100014 subset: bemo_genetics_omics_and_systems_biology xref: https://www.psidev.info/miape xref: https://www.psidev.info/ xref: https://www.metabolomics-msi.org/ property_value: BEMO:3200002 "Assesses spectral library match quality using evidence appropriate to proteomics and metabolomics, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in spectral library match quality can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating spectral library match quality as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Mass spectrometry, affinity proteomics, metabolomics, lipidomics studies" xsd:string property_value: BEMO:3200010 "MIAPE; HUPO PSI; Metabolomics Standards" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000385" xsd:string property_value: BEMO:3100022 "392" xsd:string property_value: BEMO:3100023 "5f1fa5732761f5ddf9eae216997fca90d2ec95264368ca476160849aac179e9a" xsd:string [Term] id: BEMO:2000386 name: Analytical Reproducibility def: "The degree to which analytical reproducibility yields concordant results under the specified repeated-analysis or repeated-measurement conditions." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses analytical reproducibility using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in analytical reproducibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating analytical reproducibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000386" xsd:string property_value: BEMO:3100022 "393" xsd:string property_value: BEMO:3100023 "8e400bbae5ea25bca3af45f9c956cb2ceeb52ded61247de3b92d5364736bab99" xsd:string [Term] id: BEMO:2000387 name: Code Availability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of code availability." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses code availability using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in code availability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating code availability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000387" xsd:string property_value: BEMO:3100022 "394" xsd:string property_value: BEMO:3100023 "196f2dc58cfb1ea70e003d9904020fcfd1f4feec7308ace2e85d573eb71d3b5e" xsd:string [Term] id: BEMO:2000388 name: Computational Reproducibility def: "The degree to which computational reproducibility yields concordant results under the specified repeated-analysis or repeated-measurement conditions." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses computational reproducibility using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in computational reproducibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating computational reproducibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000388" xsd:string property_value: BEMO:3100022 "395" xsd:string property_value: BEMO:3100023 "c15f070192e578e50deb91384b3e8099e5c4b1a0c28cc84d1ac6a3163d36cd17" xsd:string [Term] id: BEMO:2000389 name: Conceptual Replication Success def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of conceptual replication success." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses conceptual replication success using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in conceptual replication success can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating conceptual replication success as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000389" xsd:string property_value: BEMO:3100022 "396" xsd:string property_value: BEMO:3100023 "45fcdc0cd9da1d73796f886d24683b4f40ead7f7a14a06e84d39631b66a910ad" xsd:string [Term] id: BEMO:2000390 name: Data Availability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of data availability." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses data availability using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in data availability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating data availability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000390" xsd:string property_value: BEMO:3100022 "397" xsd:string property_value: BEMO:3100023 "89d3d59a31fe591c17a3c61f83a55d18326e4b311b8033047e95bfb2a93715fa" xsd:string [Term] id: BEMO:2000391 name: Data Provenance Completeness def: "The extent to which all scientifically necessary components of data provenance are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses data provenance completeness using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in data provenance completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating data provenance completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000391" xsd:string property_value: BEMO:3100022 "398" xsd:string property_value: BEMO:3100023 "da25c768c2ee710f0cf6b50b686a1880c8166dd651b4f062c14e952fc1bdf622" xsd:string [Term] id: BEMO:2000392 name: Direct Replication Success def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of direct replication success." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses direct replication success using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in direct replication success can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating direct replication success as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000392" xsd:string property_value: BEMO:3100022 "399" xsd:string property_value: BEMO:3100023 "e6b0ec1b803bb2c7cb8becab175dbb88ab91c9d8ccd3f713a814c836846ea547" xsd:string [Term] id: BEMO:2000393 name: Experimental Reproducibility def: "The degree to which experimental reproducibility yields concordant results under the specified repeated-analysis or repeated-measurement conditions." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses experimental reproducibility using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in experimental reproducibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating experimental reproducibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000393" xsd:string property_value: BEMO:3100022 "400" xsd:string property_value: BEMO:3100023 "6c9d1f649c85d73c0009300283cb79e817b0ca9b1d53444f1a4aa4b5a2e6d8ae" xsd:string [Term] id: BEMO:2000394 name: Independent Replication Strength def: "The magnitude and credibility of independent evidence supporting independent replication." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses independent replication strength using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in independent replication strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating independent replication strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000394" xsd:string property_value: BEMO:3100022 "401" xsd:string property_value: BEMO:3100023 "3837461a84fca58515b90e02475b1cf195c845c2cf4704aa9d0c7c2b412d9406" xsd:string [Term] id: BEMO:2000395 name: Inferential Reproducibility def: "The degree to which inferential reproducibility yields concordant results under the specified repeated-analysis or repeated-measurement conditions." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses inferential reproducibility using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in inferential reproducibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating inferential reproducibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000395" xsd:string property_value: BEMO:3100022 "402" xsd:string property_value: BEMO:3100023 "b49eb32e7bf118727039f0240b17aee8970c665e4a359a2bcecc87341188ecf1" xsd:string [Term] id: BEMO:2000396 name: Interlaboratory Reproducibility def: "The degree to which interlaboratory reproducibility yields concordant results under the specified repeated-analysis or repeated-measurement conditions." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses interlaboratory reproducibility using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in interlaboratory reproducibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating interlaboratory reproducibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000396" xsd:string property_value: BEMO:3100022 "403" xsd:string property_value: BEMO:3100023 "0977ae8d7278730723c8d024585a95d1125aa9fe6da897fe977a079b172ddb48" xsd:string [Term] id: BEMO:2000397 name: Intralaboratory Repeatability def: "The degree to which intralaboratory repeatability yields concordant results under the specified repeated-analysis or repeated-measurement conditions." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses intralaboratory repeatability using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in intralaboratory repeatability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating intralaboratory repeatability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000397" xsd:string property_value: BEMO:3100022 "404" xsd:string property_value: BEMO:3100023 "44bfb4ae3b82bb963a97cc8f3dfed3bd610b7903405993c8f3031931f746d1ce" xsd:string [Term] id: BEMO:2000398 name: Material Availability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of material availability." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses material availability using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in material availability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating material availability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000398" xsd:string property_value: BEMO:3100022 "405" xsd:string property_value: BEMO:3100023 "ad24de4b8dd0c9ae8c1a3d7d5fcdd166b9bd923967cbf8032882e26fce35feb2" xsd:string [Term] id: BEMO:2000399 name: Method Reproducibility def: "The degree to which method reproducibility yields concordant results under the specified repeated-analysis or repeated-measurement conditions." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses method reproducibility using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in method reproducibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating method reproducibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000399" xsd:string property_value: BEMO:3100022 "406" xsd:string property_value: BEMO:3100023 "b36c4ba0356ae6813b5bb255ebc6934635b0cbf83c44326cfea7019592803c5e" xsd:string [Term] id: BEMO:2000400 name: Multiverse Analysis Robustness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of multiverse analysis robustness." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses multiverse analysis robustness using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in multiverse analysis robustness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating multiverse analysis robustness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000400" xsd:string property_value: BEMO:3100022 "407" xsd:string property_value: BEMO:3100023 "80472d064c943a6566bee4bd605245ecac370ebde0eb5ae577d7687482d47cc8" xsd:string [Term] id: BEMO:2000401 name: Protocol Reproducibility def: "The degree to which protocol reproducibility yields concordant results under the specified repeated-analysis or repeated-measurement conditions." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses protocol reproducibility using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in protocol reproducibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating protocol reproducibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000401" xsd:string property_value: BEMO:3100022 "408" xsd:string property_value: BEMO:3100023 "caa28491bc96ceb6cd2e1c6685b9eb89f21391a6d4502473143986af13cc088b" xsd:string [Term] id: BEMO:2000402 name: Random-Seed Stability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of random-seed stability." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses random-seed stability using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in random-seed stability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating random-seed stability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000402" xsd:string property_value: BEMO:3100022 "409" xsd:string property_value: BEMO:3100023 "c1a5a2e956afa3ff1606fb1893282ee7b8d5d3733fbd04798630fe0746f86074" xsd:string [Term] id: BEMO:2000403 name: Reanalysis Concordance def: "The degree of agreement in reanalysis across measurements, studies, methods, populations, or biological levels." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses reanalysis concordance using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in reanalysis concordance can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating reanalysis concordance as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000403" xsd:string property_value: BEMO:3100022 "410" xsd:string property_value: BEMO:3100023 "07f0b47b85e307e7887d3c938a89cbcad651d37d8bfa888ea4ce710d25410a29" xsd:string [Term] id: BEMO:2000404 name: Researcher-Degrees-of-Freedom Sensitivity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of researcher-degrees-of-freedom sensitivity." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses researcher-degrees-of-freedom sensitivity using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in researcher-degrees-of-freedom sensitivity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating researcher-degrees-of-freedom sensitivity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000404" xsd:string property_value: BEMO:3100022 "411" xsd:string property_value: BEMO:3100023 "c196ee0e5b3c49cffc78d559a15b400e1dec74f4854200e7fbd341eef60a59c4" xsd:string [Term] id: BEMO:2000405 name: Result Reproducibility def: "The degree to which result reproducibility yields concordant results under the specified repeated-analysis or repeated-measurement conditions." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses result reproducibility using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in result reproducibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating result reproducibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000405" xsd:string property_value: BEMO:3100022 "412" xsd:string property_value: BEMO:3100023 "60121a2998efa943018d3ff7dd4130d4332ee279da0e8111b650ea175e9dacce" xsd:string [Term] id: BEMO:2000406 name: Specification-Curve Robustness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of specification-curve robustness." [BEMO:source] is_a: BEMO:1100015 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.fged.org/projects/miame xref: https://www.fged.org/projects/minseqe/ xref: https://www.psidev.info/miape xref: https://arriveguidelines.org/arrive-guidelines property_value: BEMO:3200002 "Assesses specification-curve robustness using evidence appropriate to reproducibility and replication, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in specification-curve robustness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating specification-curve robustness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All experimental, computational, clinical, and omics studies" xsd:string property_value: BEMO:3200010 "PRISMA; CONSORT; MIAME; MINSEQE; MIAPE; ARRIVE 2.0" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000406" xsd:string property_value: BEMO:3100022 "413" xsd:string property_value: BEMO:3100023 "290b2551a20c17c23c05ae84270ce7ac2c9d4a43b9817050cdbe8a353ce743ac" xsd:string [Term] id: BEMO:2000407 name: Code-Sharing Transparency def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of code-sharing transparency." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses code-sharing transparency using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in code-sharing transparency can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating code-sharing transparency as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000407" xsd:string property_value: BEMO:3100022 "414" xsd:string property_value: BEMO:3100023 "d85d4b116984de9e36c9410fc248aae4b536153c50f4651cf7e48c6b558b49eb" xsd:string [Term] id: BEMO:2000408 name: Comparator Description Completeness def: "The extent to which all scientifically necessary components of comparator description are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses comparator description completeness using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in comparator description completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating comparator description completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000408" xsd:string property_value: BEMO:3100022 "415" xsd:string property_value: BEMO:3100023 "a4617b71362b91773383e09e14a13eab2a1f342da234aa0f9bf7cc4400a6ff10" xsd:string [Term] id: BEMO:2000409 name: Conflict-of-Interest Transparency def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of conflict-of-interest transparency." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses conflict-of-interest transparency using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in conflict-of-interest transparency can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating conflict-of-interest transparency as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000409" xsd:string property_value: BEMO:3100022 "416" xsd:string property_value: BEMO:3100023 "e951e1891736a22e6ef317b85f2f1f3032c69473b10d7ac72b1ed8342656df25" xsd:string [Term] id: BEMO:2000410 name: Data-Sharing Transparency def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of data-sharing transparency." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses data-sharing transparency using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in data-sharing transparency can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating data-sharing transparency as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000410" xsd:string property_value: BEMO:3100022 "417" xsd:string property_value: BEMO:3100023 "24a8774755f1b71359ef7a35f4a7813a446670f2da0ccc38d22836e1a84f1453" xsd:string [Term] id: BEMO:2000411 name: Deviations-from-Protocol Transparency def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of deviations-from-protocol transparency." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses deviations-from-protocol transparency using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in deviations-from-protocol transparency can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating deviations-from-protocol transparency as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000411" xsd:string property_value: BEMO:3100022 "418" xsd:string property_value: BEMO:3100023 "6d08df9b94938aa4356ba3bbe963ef6fed2e0e499e09e30936b635d55a24d3c8" xsd:string [Term] id: BEMO:2000412 name: Eligibility Criteria Completeness def: "The extent to which all scientifically necessary components of eligibility criteria are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses eligibility criteria completeness using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in eligibility criteria completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating eligibility criteria completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000412" xsd:string property_value: BEMO:3100022 "419" xsd:string property_value: BEMO:3100023 "02e23f40dd856c6f19f825d6191af4cb70f9ed2e604c47f5cbd7bf406e4d2381" xsd:string [Term] id: BEMO:2000413 name: Funding-Source Transparency def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of funding-source transparency." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses funding-source transparency using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in funding-source transparency can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating funding-source transparency as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000413" xsd:string property_value: BEMO:3100022 "420" xsd:string property_value: BEMO:3100023 "35377c10ba740cabcf147ce4b6ab00e3a9c4087ca2ca810c337f7fe08223e6f9" xsd:string [Term] id: BEMO:2000414 name: Harms Reporting Completeness def: "The extent to which all scientifically necessary components of harms reporting are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses harms reporting completeness using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in harms reporting completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating harms reporting completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000414" xsd:string property_value: BEMO:3100022 "421" xsd:string property_value: BEMO:3100023 "15ffc51fd66113f5e5c480a7127c592104dbff4a2e6faafcfafb509cd725ea07" xsd:string [Term] id: BEMO:2000415 name: Intervention Description Completeness def: "The extent to which all scientifically necessary components of intervention description are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses intervention description completeness using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in intervention description completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating intervention description completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000415" xsd:string property_value: BEMO:3100022 "422" xsd:string property_value: BEMO:3100023 "52ff9263e3651129913da102dae69c16126528e71dde3bf30595ca84301723b5" xsd:string [Term] id: BEMO:2000416 name: Materials-and-Reagents Reporting Completeness def: "The extent to which all scientifically necessary components of materials-and-reagents reporting are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses materials-and-reagents reporting completeness using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in materials-and-reagents reporting completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating materials-and-reagents reporting completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000416" xsd:string property_value: BEMO:3100022 "423" xsd:string property_value: BEMO:3100023 "fc72795f141f7cb81bc8cc86190a0c7cf2a5f2f6065d3b22f9bc88dd2e13080e" xsd:string [Term] id: BEMO:2000417 name: Metadata Completeness def: "The extent to which all scientifically necessary components of metadata are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses metadata completeness using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in metadata completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating metadata completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000417" xsd:string property_value: BEMO:3100022 "424" xsd:string property_value: BEMO:3100023 "cfce2b3ca58f108e1dc5461ad1ef2f5a84b55171c75536d306bf4e1e2b3bc58d" xsd:string [Term] id: BEMO:2000418 name: Missing-Data Reporting Completeness def: "The extent to which all scientifically necessary components of missing-data reporting are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses missing-data reporting completeness using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in missing-data reporting completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating missing-data reporting completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000418" xsd:string property_value: BEMO:3100022 "425" xsd:string property_value: BEMO:3100023 "810e02862dfc4630d6f7a0d7bd830ccd305d847e2d0153cfdb863b68f1c2ece8" xsd:string [Term] id: BEMO:2000419 name: Negative-Result Reporting def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of negative-result reporting." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses negative-result reporting using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in negative-result reporting can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating negative-result reporting as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000419" xsd:string property_value: BEMO:3100022 "426" xsd:string property_value: BEMO:3100023 "f6803e55dc7d7550d62e5bed1f8773c7da7d0266b37145da5354a96ceaf769c2" xsd:string [Term] id: BEMO:2000420 name: Null-Result Interpretability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of null-result interpretability." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses null-result interpretability using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in null-result interpretability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating null-result interpretability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000420" xsd:string property_value: BEMO:3100022 "427" xsd:string property_value: BEMO:3100023 "0e7be34e4db71c86201d878decffa3c8da8ca62a1c8481dc3779d3c4caa454b1" xsd:string [Term] id: BEMO:2000421 name: Outcome Definition Completeness def: "The extent to which all scientifically necessary components of outcome definition are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses outcome definition completeness using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in outcome definition completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating outcome definition completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000421" xsd:string property_value: BEMO:3100022 "428" xsd:string property_value: BEMO:3100023 "129e8fff9350e8d3fb88d0a300e3816f498afcc03cf17b3f6037da094441e4fe" xsd:string [Term] id: BEMO:2000422 name: Participant Flow Completeness def: "The extent to which all scientifically necessary components of participant flow are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses participant flow completeness using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in participant flow completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating participant flow completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000422" xsd:string property_value: BEMO:3100022 "429" xsd:string property_value: BEMO:3100023 "c3caaa14ecea68f7075a25ef235cdae89d1a9b9b86ed2b5a30dab5cb5b8bf20d" xsd:string [Term] id: BEMO:2000423 name: Prespecified Analysis Adherence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of prespecified analysis adherence." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses prespecified analysis adherence using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in prespecified analysis adherence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating prespecified analysis adherence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000423" xsd:string property_value: BEMO:3100022 "430" xsd:string property_value: BEMO:3100023 "fe370510831c4feb18d187a9f8348ee0b93ff3174da9ddceea906467255bbd60" xsd:string [Term] id: BEMO:2000424 name: Processed-Data Availability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of processed-data availability." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses processed-data availability using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in processed-data availability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating processed-data availability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000424" xsd:string property_value: BEMO:3100022 "431" xsd:string property_value: BEMO:3100023 "3d4a65e6d3c66bcaca4ff40b6df33feaedf2f77c58697c32f80c96a00d211e95" xsd:string [Term] id: BEMO:2000425 name: Prospective Registration def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of prospective registration." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses prospective registration using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in prospective registration can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating prospective registration as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000425" xsd:string property_value: BEMO:3100022 "432" xsd:string property_value: BEMO:3100023 "32ae2352b0f17339d30893a08c10c681c7fa3992e6b60a3343dae6e95aa8dda5" xsd:string [Term] id: BEMO:2000426 name: Protocol Availability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of protocol availability." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses protocol availability using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in protocol availability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating protocol availability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000426" xsd:string property_value: BEMO:3100022 "433" xsd:string property_value: BEMO:3100023 "6e6dfc0138818017108063ab02fea9da669c25ffc36ec988048eb058c538f84a" xsd:string [Term] id: BEMO:2000427 name: Quality-Control Reporting Completeness def: "The extent to which all scientifically necessary components of quality-control reporting are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses quality-control reporting completeness using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in quality-control reporting completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating quality-control reporting completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000427" xsd:string property_value: BEMO:3100022 "434" xsd:string property_value: BEMO:3100023 "b53b586f994fd48c27b9acc1c6fff59b966085610e593ec05c03735d90e329b2" xsd:string [Term] id: BEMO:2000428 name: Raw-Data Availability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of raw-data availability." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses raw-data availability using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in raw-data availability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating raw-data availability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000428" xsd:string property_value: BEMO:3100022 "435" xsd:string property_value: BEMO:3100023 "2fcf4f96e7ca202f61d3de161ead38ea506d30ac8f05b66ac8a84b27f3da645e" xsd:string [Term] id: BEMO:2000429 name: Recruitment Reporting Completeness def: "The extent to which all scientifically necessary components of recruitment reporting are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses recruitment reporting completeness using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in recruitment reporting completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating recruitment reporting completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000429" xsd:string property_value: BEMO:3100022 "436" xsd:string property_value: BEMO:3100023 "d9e587b4cd42324cc1668fb835e848ce02fea72bac0af2f37bcc6e0a40cbc327" xsd:string [Term] id: BEMO:2000430 name: Reproducibility Information Completeness def: "The extent to which all scientifically necessary components of reproducibility information are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses reproducibility information completeness using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in reproducibility information completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating reproducibility information completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000430" xsd:string property_value: BEMO:3100022 "437" xsd:string property_value: BEMO:3100023 "3aaeec4ac26a2a3b26b615c686a2f19768e2153bd9e1e676bdcd1f2ba2812fc8" xsd:string [Term] id: BEMO:2000431 name: Statistical Methods Reporting Completeness def: "The extent to which all scientifically necessary components of statistical methods reporting are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100016 subset: bemo_reproducibility_replication_and_research_transparency xref: https://www.equator-network.org/ xref: https://www.prisma-statement.org/prisma-2020-checklist xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.equator-network.org/reporting-guidelines/stard/ xref: https://www.tripod-statement.org/ xref: https://www.care-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/cheers/ property_value: BEMO:3200002 "Assesses statistical methods reporting completeness using evidence appropriate to research transparency and reporting completeness, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in statistical methods reporting completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating statistical methods reporting completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Study report / dataset / evidence package" xsd:string property_value: BEMO:3200009 "All biomedical study reports and data releases" xsd:string property_value: BEMO:3200010 "EQUATOR; PRISMA; CONSORT; STROBE; STARD; TRIPOD; CARE; CHEERS" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000431" xsd:string property_value: BEMO:3100022 "438" xsd:string property_value: BEMO:3100023 "d8af14618f3e80ecff3b617a35c54caa9b3c73184f234fcea88a9ee83c7090ff" xsd:string [Term] id: BEMO:2000432 name: Bayes Factor Evidence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of bayes factor evidence." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses bayes factor evidence using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in bayes factor evidence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating bayes factor evidence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000432" xsd:string property_value: BEMO:3100022 "439" xsd:string property_value: BEMO:3100023 "ea8be0499c9c5441e47cac85f3e884bcc28099d593610c01dc6ad24ba5c3d0f3" xsd:string [Term] id: BEMO:2000433 name: Calibration of Statistical Predictions def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of calibration of statistical predictions." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses calibration of statistical predictions using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in calibration of statistical predictions can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating calibration of statistical predictions as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000433" xsd:string property_value: BEMO:3100022 "440" xsd:string property_value: BEMO:3100023 "1d5cbda1b0dc5b30aa8339e6219d08168170bd684f74bf0679b26dd4ece9ead4" xsd:string [Term] id: BEMO:2000434 name: Clinical Relevance of Effect def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of clinical relevance of effect." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses clinical relevance of effect using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in clinical relevance of effect can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating clinical relevance of effect as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000434" xsd:string property_value: BEMO:3100022 "441" xsd:string property_value: BEMO:3100023 "7e04bf59de003d9389f3d5e5a39c09dbec7b25b54fdd665e24d339ccf148fb17" xsd:string [Term] id: BEMO:2000435 name: Confidence Interval Compatibility def: "The justified degree of certainty assigned to confidence interval compatibility given the quantity, quality, consistency, and limitations of supporting evidence." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses confidence interval compatibility using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in confidence interval compatibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating confidence interval compatibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000435" xsd:string property_value: BEMO:3100022 "442" xsd:string property_value: BEMO:3100023 "4b44e65362db0ef8f1ef0ae6eb87b631fd22642d5790f792ab6c3d6a9a693508" xsd:string [Term] id: BEMO:2000436 name: Decision-Curve Net Benefit def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of decision-curve net benefit." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses decision-curve net benefit using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in decision-curve net benefit can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating decision-curve net benefit as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000436" xsd:string property_value: BEMO:3100022 "443" xsd:string property_value: BEMO:3100023 "7e96f3c494e389efab04f0ca564863ebd840cadeaf424446d3f94ddb483ed76c" xsd:string [Term] id: BEMO:2000437 name: Discrimination of Statistical Predictions def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of discrimination of statistical predictions." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses discrimination of statistical predictions using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in discrimination of statistical predictions can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating discrimination of statistical predictions as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000437" xsd:string property_value: BEMO:3100022 "444" xsd:string property_value: BEMO:3100023 "cf100cd63561a5d7a167b9d561a196b9309ca048456a8705766e76a54a524fce" xsd:string [Term] id: BEMO:2000438 name: Distributional Assumption Adequacy def: "The extent to which distributional assumption is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses distributional assumption adequacy using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in distributional assumption adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating distributional assumption adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000438" xsd:string property_value: BEMO:3100022 "445" xsd:string property_value: BEMO:3100023 "79608c041c0babc1613cca804b9e22a2fcbadbeabfda7d7b0bf2336528db7db1" xsd:string [Term] id: BEMO:2000439 name: Effect Magnitude def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of effect magnitude." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses effect magnitude using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in effect magnitude can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating effect magnitude as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000439" xsd:string property_value: BEMO:3100022 "446" xsd:string property_value: BEMO:3100023 "e21896fd55cc8da1ecb273cc15de195832d87a4d4554d2b68b3a9ce060442d84" xsd:string [Term] id: BEMO:2000440 name: Equivalence Margin Validity def: "The degree to which equivalence margin supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses equivalence margin validity using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in equivalence margin validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating equivalence margin validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000440" xsd:string property_value: BEMO:3100022 "447" xsd:string property_value: BEMO:3100023 "226b21fe561d36c12bfde0bcc47bb1ad6cb02760533a4b768747d6a0ab92184b" xsd:string [Term] id: BEMO:2000441 name: Estimate Precision def: "The closeness of repeated estimates or measurements and the narrowness of uncertainty around estimate." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses estimate precision using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in estimate precision can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating estimate precision as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000441" xsd:string property_value: BEMO:3100022 "448" xsd:string property_value: BEMO:3100023 "9458d6e4371d11a80963339d3a9a6c5dcc187a36080cf18d964ecb5827c41820" xsd:string [Term] id: BEMO:2000442 name: Fragility Index def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of fragility index." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses fragility index using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in fragility index can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating fragility index as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000442" xsd:string property_value: BEMO:3100022 "449" xsd:string property_value: BEMO:3100023 "045c39ed086cc31d598f1fe91547a90170ea8cc0b684f22d5338144e750a0843" xsd:string [Term] id: BEMO:2000443 name: Imputation Validity def: "The degree to which imputation supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses imputation validity using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in imputation validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating imputation validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000443" xsd:string property_value: BEMO:3100022 "450" xsd:string property_value: BEMO:3100023 "451bb1f13aa8cd7feb728a231f72c948355ace1a73de7f1903381352517ceaf5" xsd:string [Term] id: BEMO:2000444 name: Influential Observation Sensitivity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of influential observation sensitivity." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses influential observation sensitivity using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in influential observation sensitivity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating influential observation sensitivity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000444" xsd:string property_value: BEMO:3100022 "451" xsd:string property_value: BEMO:3100023 "0202d30b443e9ba2dd8ad4597c8e7b9fcc240af0f60b19db4a115b1d2866e858" xsd:string [Term] id: BEMO:2000445 name: Interaction Assessment Adequacy def: "The extent to which interaction assessment is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses interaction assessment adequacy using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in interaction assessment adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating interaction assessment adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000445" xsd:string property_value: BEMO:3100022 "452" xsd:string property_value: BEMO:3100023 "7942499ba472159741e9410722d92887d17131b3d661f12b98b8ec8f2d490791" xsd:string [Term] id: BEMO:2000446 name: Measurement Error Correction def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of measurement error correction." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses measurement error correction using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in measurement error correction can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating measurement error correction as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000446" xsd:string property_value: BEMO:3100022 "453" xsd:string property_value: BEMO:3100023 "47dddb5f2dde48130ebfa9464b01b7ed1efb5da34ac2d484caa4259055162e55" xsd:string [Term] id: BEMO:2000447 name: Missing-Data Mechanism Plausibility def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of missing-data mechanism plausibility." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses missing-data mechanism plausibility using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in missing-data mechanism plausibility can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating missing-data mechanism plausibility as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000447" xsd:string property_value: BEMO:3100022 "454" xsd:string property_value: BEMO:3100023 "399e0c1d410c7ca1c5cc767b5afb9291915d1ee3db3b4d7314b2092c6d4765e1" xsd:string [Term] id: BEMO:2000448 name: Missing-Data Sensitivity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of missing-data sensitivity." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses missing-data sensitivity using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in missing-data sensitivity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating missing-data sensitivity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000448" xsd:string property_value: BEMO:3100022 "455" xsd:string property_value: BEMO:3100023 "6708217d617153345c000ff0b34cc96bd34facf9514e5d1a84b3e56623ffb545" xsd:string [Term] id: BEMO:2000449 name: Model Fit def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of model fit." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses model fit using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in model fit can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating model fit as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000449" xsd:string property_value: BEMO:3100022 "456" xsd:string property_value: BEMO:3100023 "bf6f70bdb1883a9c1ba70dc7d37eb1885dd46ed70094a2b12bd2cc41e0f53bad" xsd:string [Term] id: BEMO:2000450 name: Model Specification Adequacy def: "The extent to which model specification is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses model specification adequacy using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in model specification adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating model specification adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000450" xsd:string property_value: BEMO:3100022 "457" xsd:string property_value: BEMO:3100023 "c5d48404d8de034fc4aa45bb9f64638b1d861e61321423aa5f11d4f63cc6783b" xsd:string [Term] id: BEMO:2000451 name: Multiplicity Control def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of multiplicity control." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses multiplicity control using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in multiplicity control can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating multiplicity control as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000451" xsd:string property_value: BEMO:3100022 "458" xsd:string property_value: BEMO:3100023 "282fd29ea793d9f6346d4b34598e7ca30406dad2a72b3f3167d354ca92803ec0" xsd:string [Term] id: BEMO:2000452 name: Noninferiority Margin Validity def: "The degree to which noninferiority margin supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses noninferiority margin validity using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in noninferiority margin validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating noninferiority margin validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000452" xsd:string property_value: BEMO:3100022 "459" xsd:string property_value: BEMO:3100023 "5c494db875d0f3ad6860a3bba83e6ac01d9f571b40aa89617a37a42c1c489cab" xsd:string [Term] id: BEMO:2000453 name: Nonlinearity Assessment def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of nonlinearity assessment." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses nonlinearity assessment using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in nonlinearity assessment can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Replicate dilution series; blank and spiked samples; reference materials; method-comparison studies; predefined CLSI/ISO acceptance criteria." xsd:string property_value: BEMO:3200006 "Treating nonlinearity assessment as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000453" xsd:string property_value: BEMO:3100022 "460" xsd:string property_value: BEMO:3100023 "aec401720de6539460ff9d49f62284a772b28790802eda1b3dc7c5fc2d67af3f" xsd:string [Term] id: BEMO:2000454 name: Outlier Influence Robustness def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of outlier influence robustness." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses outlier influence robustness using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in outlier influence robustness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Independent repeats; between-run/site/analyst variability; concordance of effect direction and magnitude; predefined reproducibility thresholds." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating outlier influence robustness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000454" xsd:string property_value: BEMO:3100022 "461" xsd:string property_value: BEMO:3100023 "3a52b33f3faa79b95100ff084b9c7ca54158523c656fcaf5c298f073960428c9" xsd:string [Term] id: BEMO:2000455 name: Overadjustment Bias Risk def: "The probability or degree that overadjustment bias introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses overadjustment bias risk using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in overadjustment bias risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating overadjustment bias risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000455" xsd:string property_value: BEMO:3100022 "462" xsd:string property_value: BEMO:3100023 "20f394b3ef37b7c0b5d8426ebcce5fe9f9ef841bbb2622101174fbb411ab7957" xsd:string [Term] id: BEMO:2000456 name: Posterior Probability Strength def: "The magnitude and credibility of independent evidence supporting posterior probability." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses posterior probability strength using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in posterior probability strength can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating posterior probability strength as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000456" xsd:string property_value: BEMO:3100022 "463" xsd:string property_value: BEMO:3100023 "8a96194c8b8e65d04df266b282704e480656791b819df12c8c4924c984b02272" xsd:string [Term] id: BEMO:2000457 name: Prior Sensitivity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of prior sensitivity." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses prior sensitivity using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in prior sensitivity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified threshold; valid reference standard; complete 2×2 classification; confidence intervals; spectrum and prevalence assessment." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating prior sensitivity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000457" xsd:string property_value: BEMO:3100022 "464" xsd:string property_value: BEMO:3100023 "ced026349740f092de03ee4146894b4367dab3b43793f3aa048eac1fd782cbda" xsd:string [Term] id: BEMO:2000458 name: Residual Diagnostics Adequacy def: "The extent to which residual diagnostics is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses residual diagnostics adequacy using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in residual diagnostics adequacy can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating residual diagnostics adequacy as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000458" xsd:string property_value: BEMO:3100022 "465" xsd:string property_value: BEMO:3100023 "1193234e513641f836d7ad506af2e69fb2fcba17a604fff5710f7b53f487ad89" xsd:string [Term] id: BEMO:2000459 name: Statistical Power def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of statistical power." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses statistical power using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in statistical power can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating statistical power as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000459" xsd:string property_value: BEMO:3100022 "466" xsd:string property_value: BEMO:3100023 "b5866270dc0b1ae7d14dc9e42f0ff6a1d28896f404d73ddeb44c5f7fdaf6b51a" xsd:string [Term] id: BEMO:2000460 name: Type I Error Control def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of type i error control." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses type i error control using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in type i error control can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating type i error control as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000460" xsd:string property_value: BEMO:3100022 "467" xsd:string property_value: BEMO:3100023 "a3eba05a4613d95dc796e3df689756346c4f78ac2fda1dcb4e8cf4b813a22638" xsd:string [Term] id: BEMO:2000461 name: Type II Error Risk def: "The probability or degree that type ii error introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses type ii error risk using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in type ii error risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating type ii error risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000461" xsd:string property_value: BEMO:3100022 "468" xsd:string property_value: BEMO:3100023 "de4287424d92a6f5a119531d8abefacf3d79beff40059540425ff1afc5f1021d" xsd:string [Term] id: BEMO:2000462 name: Variance Estimation Validity def: "The degree to which variance estimation supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100017 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.tripod-statement.org/ xref: https://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumor-marker-prognostic-studies-remark/ xref: https://database.ich.org/sites/default/files/E9_Guideline.pdf property_value: BEMO:3200002 "Assesses variance estimation validity using evidence appropriate to statistical validity and inference, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in variance estimation validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating variance estimation validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "All quantitative biomedical studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; TRIPOD; REMARK; ICH E9" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000462" xsd:string property_value: BEMO:3100022 "469" xsd:string property_value: BEMO:3100023 "43a84aea1ea6cc79814a3121476a165954a222aece0c751b1ff5414b40efbe28" xsd:string [Term] id: BEMO:2000463 name: Adherence Integrity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of adherence integrity." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses adherence integrity using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in adherence integrity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating adherence integrity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000463" xsd:string property_value: BEMO:3100022 "470" xsd:string property_value: BEMO:3100023 "9a20a1494ccbc46d7bc0acd4d260241ebc29edd15b77d8ccc525c9f0dba8e8de" xsd:string [Term] id: BEMO:2000464 name: Allocation Concealment def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of allocation concealment." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses allocation concealment using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in allocation concealment can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating allocation concealment as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000464" xsd:string property_value: BEMO:3100022 "471" xsd:string property_value: BEMO:3100023 "3367e7e58461dcb460260b263a504d906f8c26af8608d0cf2767790d3843a2e7" xsd:string [Term] id: BEMO:2000465 name: Attrition Bias Risk def: "The probability or degree that attrition bias introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses attrition bias risk using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in attrition bias risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating attrition bias risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000465" xsd:string property_value: BEMO:3100022 "472" xsd:string property_value: BEMO:3100023 "0783cbbb1a7caf7ef448d6830ae564e73010beb87e2e08710ddb494b6b76ccb3" xsd:string [Term] id: BEMO:2000466 name: Baseline Comparability def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of baseline comparability." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses baseline comparability using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in baseline comparability can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating baseline comparability as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000466" xsd:string property_value: BEMO:3100022 "473" xsd:string property_value: BEMO:3100023 "93fad13257c869638e96dc16ab4687d4b955a0d40d8d10736f49f12cebec65eb" xsd:string [Term] id: BEMO:2000467 name: Blinding Integrity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of blinding integrity." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses blinding integrity using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in blinding integrity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating blinding integrity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000467" xsd:string property_value: BEMO:3100022 "474" xsd:string property_value: BEMO:3100023 "4e84b980ded4e833e93013ba317d5857e2211ad9b612e4b77eb9308cf8244573" xsd:string [Term] id: BEMO:2000468 name: Carryover Effect Risk def: "The probability or degree that carryover effect introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses carryover effect risk using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in carryover effect risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Replicate dilution series; blank and spiked samples; reference materials; method-comparison studies; predefined CLSI/ISO acceptance criteria." xsd:string property_value: BEMO:3200006 "Treating carryover effect risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000468" xsd:string property_value: BEMO:3100022 "475" xsd:string property_value: BEMO:3100023 "6dbe1d75153c55efcce7da9af8dda3fe869c2f426eaaad651ee6f91b1670d205" xsd:string [Term] id: BEMO:2000469 name: Cluster Recruitment Bias Risk def: "The probability or degree that cluster recruitment bias introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses cluster recruitment bias risk using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in cluster recruitment bias risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating cluster recruitment bias risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000469" xsd:string property_value: BEMO:3100022 "476" xsd:string property_value: BEMO:3100023 "a9882065e899d9f8a8f701c6291666b702a9ad5b769971c1d3cb596c9e39b960" xsd:string [Term] id: BEMO:2000470 name: Co-intervention Bias Risk def: "The probability or degree that co-intervention bias introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses co-intervention bias risk using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in co-intervention bias risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating co-intervention bias risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000470" xsd:string property_value: BEMO:3100022 "477" xsd:string property_value: BEMO:3100023 "de36d6b209ddc70bf44fd968006b0ba61482bcc4bbe42db3c2a605301631de5e" xsd:string [Term] id: BEMO:2000471 name: Comparator Validity def: "The degree to which comparator supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses comparator validity using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in comparator validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating comparator validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000471" xsd:string property_value: BEMO:3100022 "478" xsd:string property_value: BEMO:3100023 "de06a641ed9f64a7c11259e9a1d1346140c2469d57bbd106c6257d947909a5a3" xsd:string [Term] id: BEMO:2000472 name: Contamination Risk def: "The probability or degree that contamination introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses contamination risk using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in contamination risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating contamination risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000472" xsd:string property_value: BEMO:3100022 "479" xsd:string property_value: BEMO:3100023 "eed78db6e72161c41f0a51c8bc55e5d20b0d6675373ef1a7bf65b4c5b0dc75c0" xsd:string [Term] id: BEMO:2000473 name: Control Group Appropriateness def: "The extent to which control group is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses control group appropriateness using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in control group appropriateness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating control group appropriateness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000473" xsd:string property_value: BEMO:3100022 "480" xsd:string property_value: BEMO:3100023 "47dcb7d2162b3c8496d326c0cd9b9dfbef0e0b4032c2c7d93f31f67139c5990f" xsd:string [Term] id: BEMO:2000474 name: Detection Bias Risk def: "The probability or degree that detection bias introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses detection bias risk using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in detection bias risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating detection bias risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000474" xsd:string property_value: BEMO:3100022 "481" xsd:string property_value: BEMO:3100023 "98c36b49fe475eec66359fae3b2440fc1429c378e2bbe5896e082ec203855535" xsd:string [Term] id: BEMO:2000475 name: Differential Follow-up Risk def: "The probability or degree that differential follow-up introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses differential follow-up risk using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in differential follow-up risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating differential follow-up risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000475" xsd:string property_value: BEMO:3100022 "482" xsd:string property_value: BEMO:3100023 "ccfe7e445aeb97f5f6fbabfec00706b7cd315705f68e05e908e47860b40d8ad4" xsd:string [Term] id: BEMO:2000476 name: Early Stopping Bias Risk def: "The probability or degree that early stopping bias introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses early stopping bias risk using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in early stopping bias risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating early stopping bias risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000476" xsd:string property_value: BEMO:3100022 "483" xsd:string property_value: BEMO:3100023 "8ac86a4a6b6a886dad127939918a466b8c70bd2b6b13b03a987aab048ac4c7c3" xsd:string [Term] id: BEMO:2000477 name: Exposure Classification Validity def: "The degree to which exposure classification supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses exposure classification validity using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in exposure classification validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating exposure classification validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000477" xsd:string property_value: BEMO:3100022 "484" xsd:string property_value: BEMO:3100023 "6d08552ad6c8b3c6d5a3c8ed35293fcfc624984197116fb158f6c3a04698789f" xsd:string [Term] id: BEMO:2000478 name: Follow-up Completeness def: "The extent to which all scientifically necessary components of follow-up are present, documented, and evaluable." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses follow-up completeness using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in follow-up completeness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Required elements present; traceable provenance; unambiguous definitions; accessible underlying data/materials; documented deviations." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating follow-up completeness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000478" xsd:string property_value: BEMO:3100022 "485" xsd:string property_value: BEMO:3100023 "a99fe581309ce29c4e888ffbd9a1cba6c99a6948f2a8e99e23714e0f40920b87" xsd:string [Term] id: BEMO:2000479 name: Intervention Classification Validity def: "The degree to which intervention classification supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses intervention classification validity using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in intervention classification validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating intervention classification validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000479" xsd:string property_value: BEMO:3100022 "486" xsd:string property_value: BEMO:3100023 "283a3544a9dd5cb1a16190c929c82c6db2608db0f4c24860780498cb89bc0ac5" xsd:string [Term] id: BEMO:2000480 name: Outcome Ascertainment Validity def: "The degree to which outcome ascertainment supports the intended scientific interpretation without material systematic error." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses outcome ascertainment validity using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in outcome ascertainment validity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating outcome ascertainment validity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000480" xsd:string property_value: BEMO:3100022 "487" xsd:string property_value: BEMO:3100023 "654f73aad6650cd58d63f5a49ae9e034bfcb22952cbf7a018f652c070e1ba6c1" xsd:string [Term] id: BEMO:2000481 name: Performance Bias Risk def: "The probability or degree that performance bias introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses performance bias risk using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in performance bias risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating performance bias risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000481" xsd:string property_value: BEMO:3100022 "488" xsd:string property_value: BEMO:3100023 "67d1ca80d7087e3cfba7c1c9f64d45d3f4094887ac27aef09ef61bfb6d49d732" xsd:string [Term] id: BEMO:2000482 name: Period Effect Risk def: "The probability or degree that period effect introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses period effect risk using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in period effect risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating period effect risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000482" xsd:string property_value: BEMO:3100022 "489" xsd:string property_value: BEMO:3100023 "78e4475c3f570e4a3e966d2bc7b940517b5d7eaa514d888dc22a6ea5b68d38fb" xsd:string [Term] id: BEMO:2000483 name: Protocol Deviation Risk def: "The probability or degree that protocol deviation introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses protocol deviation risk using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in protocol deviation risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating protocol deviation risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000483" xsd:string property_value: BEMO:3100022 "490" xsd:string property_value: BEMO:3100023 "7632dd2b67a9f407b6c186b3a54ef8714ff7082ed9c885957d4f06c0008e5f26" xsd:string [Term] id: BEMO:2000484 name: Protocol Fidelity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of protocol fidelity." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses protocol fidelity using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in protocol fidelity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating protocol fidelity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000484" xsd:string property_value: BEMO:3100022 "491" xsd:string property_value: BEMO:3100023 "ae404e8a9df9a665347ede4db7ae7370bdc6c77c15da3474e23c516ad81dd25e" xsd:string [Term] id: BEMO:2000485 name: Randomization Integrity def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of randomization integrity." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses randomization integrity using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in randomization integrity can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating randomization integrity as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000485" xsd:string property_value: BEMO:3100022 "492" xsd:string property_value: BEMO:3100023 "8438f239c984919f366a44747e2e32efd683c0e45e3f7af6c269801f1d6694c8" xsd:string [Term] id: BEMO:2000486 name: Selective Outcome Reporting Risk def: "The probability or degree that selective outcome reporting introduces systematic distortion into a biomedical estimate or conclusion." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses selective outcome reporting risk using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in selective outcome reporting risk can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified signaling questions; direction and likely magnitude of distortion; domain-level and overall judgment; sensitivity to plausible bias." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating selective outcome reporting risk as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000486" xsd:string property_value: BEMO:3100022 "493" xsd:string property_value: BEMO:3100023 "bcdaa5f06df0a5ab7941c490a740787093ffc20f433c48125d9c2e174850f7fd" xsd:string [Term] id: BEMO:2000487 name: Study Design Appropriateness def: "The extent to which study design is sufficient and fit for the stated biomedical inference." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses study design appropriateness using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in study design appropriateness can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Clear intended use or estimand; accepted reference or criterion; prespecified acceptance thresholds; independent validation; performance across relevant conditions." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating study design appropriateness as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000487" xsd:string property_value: BEMO:3100022 "494" xsd:string property_value: BEMO:3100023 "7f9fb8e0c1ccb555a18bd7b6b07b3173d661a6707fab17a21ee632e59503b393" xsd:string [Term] id: BEMO:2000488 name: Temporal Precedence def: "A canonical biomedical evidence metric quantifying the scientific credibility, reliability, relevance, or interpretability of temporal precedence." [BEMO:source] is_a: BEMO:1100018 subset: bemo_study_design_statistical_validity_and_causal_inference xref: https://www.consort-spirit.org/ xref: https://www.equator-network.org/reporting-guidelines/strobe/ xref: https://www.riskofbias.info/welcome/rob-2-0-tool xref: https://www.riskofbias.info/welcome/home/current-version-of-robins-i xref: https://www.riskofbias.info/welcome/robins-e-tool xref: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools xref: https://jbi.global/critical-appraisal-tools property_value: BEMO:3200002 "Assesses temporal precedence using evidence appropriate to study design and internal validity, distinguishing random uncertainty from systematic error." xsd:string property_value: BEMO:3200003 "Material weakness in temporal precedence can change the direction, magnitude, certainty, or biological interpretation of the research conclusion." xsd:string property_value: BEMO:3200004 "Prespecified operational definition; appropriate comparator or reference; quantified uncertainty; independent or orthogonal corroboration; sensitivity analyses." xsd:string property_value: BEMO:3200005 "Structured critical appraisal; quantitative estimation with uncertainty; prespecified thresholds; independent replication; sensitivity and subgroup analyses." xsd:string property_value: BEMO:3200006 "Treating temporal precedence as interchangeable with overall study quality, or interpreting a favorable value as proof that all other bias and validity domains are satisfactory." xsd:string property_value: BEMO:3200007 "Depends on context, operational definition, thresholds, data quality, and evaluator judgment; it should not be used as a stand-alone summary score without domain-level evidence." xsd:string property_value: BEMO:3200008 "Result / experiment / study / body of evidence, as applicable" xsd:string property_value: BEMO:3200009 "Randomized trials, nonrandomized intervention studies, cohort, case-control, cross-sectional studies" xsd:string property_value: BEMO:3200010 "CONSORT; STROBE; RoB 2; ROBINS-I; ROBINS-E; NIH Quality Tools; JBI" xsd:string property_value: BEMO:3200012 "https://w3id.org/bemo/profile/BEMO_2000488" xsd:string property_value: BEMO:3100022 "495" xsd:string property_value: BEMO:3100023 "ec85a4abfc9e480fea03dfff5177f17a293899d488f06a679715de258c8591b9" xsd:string